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SUMMARY 
Schizophrenia is a devastating mental disorder with disease mechanisms that are still 
poorly understood. Evidence has emerged that lipid dysregulations and myelination 
abnormalities might contribute to the pathophysiology of schizophrenia. Antipsychotic 
drugs often induce severe metabolic adverse effects, such as weight gain, dyslipidemias, 
and diabetes. However, several studies in chronic patients have indicated that some 
antipsychotic drug-related metabolic changes may be associated with improvements in 
psychotic symptoms. The main aim of this doctoral thesis was to combine clinical, 
biological, and imaging data to increase our current understanding of the relationship 
between serum lipid changes and various outcomes in antipsychotic-treated patients 
earlier in their illness course with emphasis on first-episode psychosis (FEP) patients.  
The clinical samples included FEP patients using antipsychotic drug treatment, 
olanzapine-treated, and unmedicated patients with broad schizophrenia spectrum 
disorders, along with a group of healthy controls from the Thematically Organized 
Psychosis project in Oslo. The participants underwent a thorough clinical evaluation, 
structural imaging, analyses of serum lipids, and physical examination, including 
assessment of body mass index (BMI). The severity of positive and negative symptoms 
and cognitive performances were assessed at inclusion and after a one-year follow-up, 
along with serum lipids. Linear mixed-effects models were used to examine associations 
between changes in serum lipids versus changes in positive, negative, and cognitive 
symptoms. General linear models were used to investigate associations between serum 
lipids and cortical thickness and gray/white matter intensity contrast, which were used as 
proxy measures for intracortical myelin. Our results indicate that an increase in serum 
HDL-C during antipsychotic drug treatment is associated with improvements in negative 
symptoms and verbal learning, independent of changes in BMI. Moreover, OLZ treatment 
was linked to normalized cortical intensity contrast, and a higher serum level of HDL-C 
in OLZ-treated patients was related to thicker cortices suggesting a lipid-mediated effect 
on intracortical myelin. Together, our results may indicate that the therapeutic effect of 
antipsychotic drug treatment could in parts be linked to lipid biosynthesis.      
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First, I will give a general overview of the literature on schizophrenia and related 
psychotic disorders, focusing on patients with first-episode psychosis (FEP). Then I will 
go on to introduce more thesis-specific issues, concentrating on antipsychotics and 
metabolic disturbances, primarily dyslipidemia and changes in weight/body mass index 
(BMI). The literature search for this thesis was completed in May 2019. 
 
1. GENERAL INTRODUCTION  
1.1  Schizophrenia and related psychotic disorders  
1.1.1 A walk down history lane 
Psychosis is defined in the Oxford Dictionaries as: “A severe mental disorder in which 
thought and emotions are so impaired that contact is lost with external reality.” Amongst 
the psychotic disorders, schizophrenia is the severest form. It is a chronic multifactorial 
disorder depicted by several symptom dimensions and impairments in cognition and 
functioning.  
 
It was the Swiss psychiatrist, Eugen Bleuler, who first suggested the term 
“Schizophrenia” for the disorder described by the German psychiatrist Emil Kraepelin in 
the late 19
th
 century as “Dementia Praecox.” Dementia Praecox was characterized by the 
early onset of disease with subsequent cognitive deterioration and poor outcome. Bleuler, 
on the other hand, posited that the symptoms of schizophrenia could be explained as an 
inevitable split in patients’ affect and behavior, hence the term (from Greek skhizein ‘to 
split’ + phrēn ‘mind’). Bleuler further argued that the disease was, in fact, a group of 




Kraepelin, Bleuler also noted that some patients could recover from the disease, which 
was an argument against a “neurodegenerative” disease model.  
 
1.1.2 Epidemiology 
The lifetime prevalence of schizophrenia is estimated to be around 0.7 % 
1
. Evensen et al. 
2
 reported a twelve-month prevalence of 0.17 % in the Norwegian population. According 
to the World Health Organization report on the global burden of disease, schizophrenia is 
classified amongst the most common conditions associated with a high rate of years lived 
with disability 
3




1.1.3 Diagnostic criteria 
Psychosis entails an impaired relationship with reality, including symptoms of delusions 
and hallucinations. Psychosis is a central symptom criterion for the Diagnostic and 
Statistical Manual of Mental Disorders 4
th
 (DSM-IV) and 5
th
 (DSM-V) diagnoses of 
schizophrenia, schizophreniform-, schizoaffective-, delusional-, and brief psychotic 
disorder, and in psychosis not otherwise specified (psychosis NOS). We have focused on 
patients with schizophrenia, schizophreniform-, schizoaffective-, and psychosis NOS, 
which is termed as “broad schizophrenia spectrum disorders” in the following thesis. 
 
In the DSM-IV edition, schizophrenia is defined by having at least two of the following 
symptoms: delusions, hallucinations, disorganized speech, grossly disorganized or 
catatonic behavior or negative symptoms (Criterion A). Having only one of the symptoms 
is sufficient to fulfill the criterion A if delusions are bizarre, or if hallucinations consist of 
a voice keeping up a running commentary on the patient’s thoughts or behaviors, or two 
or more voices communicating with each other (“ Schneiderian first-rank symptoms”). 
There must, additionally, be a marked reduction in work or social function (Criterion B). 
Continuous signs of the disorder must last for six months or more. This period must also 




treated adequately). For the schizophrenia criteria to be fulfilled, schizoaffective disorder 
and mood disorder with psychotic features must have been ruled out. Moreover, the 
disturbance must not be due to the physiological effects of substance abuse or a medical 
condition. Finally, if there is a history of pervasive developmental disorder, the additional 
diagnosis of schizophrenia is made only if protuberant delusions or hallucinations are also 
present for at least a month (or less if successfully treated). Recently, there has been a 
change in the definition of schizophrenia with the publication of the latest diagnostic 
manual, DSM-5. In this latter manual, the presence of Schneiderian first-rank symptoms 
alone is not sufficient to satisfy Criterion A, and patients are required two out of five 




In schizophreniform disorder, signs of the disturbance are present for more than one 
month, but less than six months and functional decline does not have to be present. All 
other criteria described for schizophrenia must otherwise be met. In schizoaffective 
disorder, there is a major depressive episode, manic episode, or mixed episode concurrent 
with the characteristic symptoms in schizophrenia. Furthermore, during the same period 
of illness, there must have been delusions or hallucinations for at least two weeks in the 
absence of protuberant mood symptoms.  
 
While we did not include patients with delusional disorder or brief psychotic disorder in 
our studies; delusional disorder is characterized by non-bizarre delusions for at least one 
month, without meeting criterion A for schizophrenia and function is not markedly 
impaired. In brief psychotic disorder delusions, hallucinations, disorganized speech or 
disorganized/ catatonic behavior has to be present for at least one day but less than one 
month, with eventual full return to premorbid level of functioning.  
 
Finally, the diagnosis “psychosis NOS” is used when psychotic symptoms are present but 
do not meet the full criteria for any of the formal diagnoses for schizophrenia, 





1.1.4 Clinical characteristics  
Schizophrenia and other related psychotic disorders are heterogeneous in terms of 
symptomatology, neurocognitive, and functional outcome 
6
. This heterogeneity is 
clinically displayed in many ways, with afflicted individuals varying in symptom severity 
and treatment response. The different symptoms in psychotic disorder are typically 
grouped into symptom dimensions. Along with positive symptoms and negative 
symptoms, cognitive impairments are often considered as core deficits 
6
. I have thus 
focused on these three core symptoms in the present thesis. 
 
Positive symptoms are denoted as such because they constitute an addition to normal 
experiences, and include delusions and hallucinations. Delusions are beliefs that persevere 
despite evidence that the beliefs are not logical or accurate. Hallucinations are sensory 
experiences in any modality that are perceived without an actual external stimulus. The 
most common type experienced is auditory hallucinations, which can range from simple 
sounds to fully formed voices, which may for example comment on the patient’s thoughts 
and actions. Positive symptoms are the most frequently manifested symptoms of 
schizophrenia 
7
. These symptoms usually fluctuate with time, being most severe in first-
episode patients and during exacerbation of the disorder. While they often respond well to 
antipsychotic drug treatment 
7





Negative symptoms are denoted as such because they constitute an absence or marked 
reduction of normal experiences or behaviors, and include alogia (reduced speech content 
or meaning), anhedonia (loss of pleasure), and avolition (decreased motivation or ability 
to initiate or perform self-directed purposeful activities). Patients with these symptoms 
show decreased initiative, poor self-care, social withdrawal, and reduced expressivity. 






. They are independent of the positive symptoms 
10
, and tend to be stable over 
time in contrast to positive symptoms 
11,12
, although there are also reports of a more fluid 
course 
13
. Furthermore, negative symptoms may persist after positive symptoms have 
been successfully treated, and as such, they are found to have a higher impact on 
functioning and recovery 
12,14,15
. Negative symptoms are often divided into primary and 
secondary symptoms, where primary symptoms are considered to be intrinsic to 
schizophrenia, and secondary symptoms to be a response to positive or affective 
symptoms, medication side effects or to environmental deprivation 
16
. In epidemiological 




While not a formal part of the current diagnostic criteria, acknowledgment of cognitive 
impairments dates back to Kraepelin. It is estimated that approximately 60–80% of 
schizophrenia patients manifest a significant level of cognitive deficit 
18
, reaching 
between 1 and 2 standard deviations below the same aged control groups 
19,20
. These 
impairments are reported across all cognitive domains, but the severity is most significant 
in the domains of processing speed, attention, working memory, verbal learning, and 
problem-solving 
21,22
 with impairment already present at the start of first treatment 
23
. 
People with ultra-high-risk of developing schizophrenia and young people with a family 
history of schizophrenia have reduced cognitive functioning compared to healthy 
controls, adding support to a neurodevelopmental origin 
24
. As with negative symptoms, 
cognitive impairment often precedes the presentation of positive symptoms 
25
, and may 
endure after the positive symptoms have been successfully treated 
1
. The presence of 
cognitive impairments is further associated with a more severe course of illness and a 
higher rate of use of health services 
2,26
. Interestingly, a mild to moderate correlation 
between negative symptoms and cognitive deficits have been found 
21,27
. Moreover, both 
cognitive symptoms and negative symptoms have been associated with structural 
dysfunction in similar brain regions 
27,28
 and evidence indicates that they may have a 







1.1.5 Onset and illness course   
In the majority of all cases, the disorder emerges slowly with so-called prodromal 
symptoms. The term “first psychotic episode” is used when the symptoms succeed a 
given level of symptom severity. The further course of the disorder is heterogeneous 
30
, 
but characteristically relapsing-remitting between psychotic episodes and more stable 




The initial years of the disorder are the most symptomatic and often include considerable 
psychosocial deterioration 
32
. The rate of relapse within the first years after illness onset 
has been estimated to be around 35% 
33
, while the lifetime risk of relapse has been 
estimated to be up to 70% 
34
, irrespective of pharmacological treatment. That said, 
approximately 40 % of individuals with first-episode psychosis (FEP) experience 
relatively long periods with limited or no active phase symptoms as well as a decent level 
of functioning after undergoing their first psychotic episode 
35
. Systematic reviews based 
on meta-analyses of clinical trials have revealed that the risk of relapse in schizophrenia 
decreases with antipsychotic medication use 
36
, and some even argue that the leading risk 




The importance of studying patients with FEP  
In the last decades, researchers have become more interested in patients in the early stages 
of the disorder. Studying patients with an FEP could also uncover risk factors less biased 
by antipsychotic drug treatment, drug side effects, and long-term effects of a detrimental 
lifestyle. Early illness phase and response to treatment during the first years after onset 
are further believed to be important predictors for future progression 
37
. Therefore, 
studying patients with an FEP could provide valuable information about the illness course 





1.1.6 Etiology and pathophysiology 
Although fastidious efforts have been made to identify the precise etiology and 
pathophysiological mechanisms of schizophrenia, it still remains an unresolved puzzle 
25
. 
Schizophrenia is currently believed to be multifactorial with complex gene-environment 
interactions 
38
. The heritable component has been estimated to be between 60-80% 
39,40
. 
While genetic research has exploded over the years, and international collaborations have 
aided in large sample Genome-Wide Association Studies (GWAS) with identification of a 
vast number of susceptibility genes for schizophrenia 
41
, genetic findings so far have only 
explained a small fraction of the heritability 
6
. In addition to these genetic risk factors, 
environmental factors such as high paternal age, obstetric complications, childhood 
trauma, infectious agents, urbanization, migration, and use of cannabis increase the risk of 




Abnormalities in brain structure have repeatedly been found in post-mortem 
43,44
, and in 
vivo magnetic resonance imaging (MRI) studies 
45–47
. Based on such findings, 
schizophrenia is currently regarded to be a neurodevelopmental disorder, in which the 
normal brain development is altered due to genetic and environmental factors during 
gestation and early life with the onset of clinical symptoms later in life 
48
. Structural 
neuroimaging studies have frequently reported brain volume changes in schizophrenia 
patients compared to healthy controls 
45–47
. These include enlargement of the ventricles 
and smaller total brain volume, reduced cortical gray matter volume (particularly in 
frontal and temporal regions), and reduced hippocampal volume. A reduction in thickness 
has also been demonstrated in schizophrenia and related psychoses in comparison to 
healthy controls 
45,49
; most consistently in frontal and temporal regions.  Several diffusion 
tensor imaging (DTI) studies have, moreover, reported of various white matter aberrations 
(i.e., lowered white matter integrity) typically assessed by fractional anisotropy (FA) 
reductions (for a review see 
50–53
). These white matter abnormalities have been associated 
with positive symptoms (hallucinations) 
54
, negative symptoms 
55–57
, as well as cognitive 







In addition to the aforementioned brain structural pathologies, disturbances in 
neurotransmission have also been implicated in the pathophysiology of schizophrenia (see 
review 
59
). Neurochemical imaging studies have indicated that in the active phases of the 
illness, an increase in dopamine synthesis and release in specific brain areas (striatum), as 
well as a higher concentration of synaptic dopamine compared to steady-state 
concentrations, could be found 
60
. These changes in dopamine transmission have further 




As the underlying pathophysiology of schizophrenia is still not clear, we do not have 
medication or other treatment options that as of today target the cause of the disorder. 
Treatment is primarily symptomatic and aimed at reducing psychotic symptoms, where 
treatment options include medication and psychosocial interventions such as cognitive 
therapy and community-based psychosocial interventions.  
 
2.  SPECIFIC INTRODUCTION TO THE THESIS  
2.1 Antipsychotic drugs    
2.1.1 A brief history of antipsychotic drug development  
During the first half of the 20
th
-century patients with schizophrenia were confined to 
specially designed psychiatric hospitals: “mental asylums.” The “cures” of the pre-
neuroleptic era included lobotomy, cold baths, and insulin comas, causing many 
unnecessary deaths. With the introduction of antipsychotics, the care of schizophrenia 
was revolutionized, allowing a significant number of institutionalized patients to be 
discharged and successfully reintegrated into the community. Antipsychotics are now a 





Chlorpromazine is considered the prototype antipsychotic agent, and the first of the “first-
generation antipsychotics” (FGAs) introduced as a treatment for psychiatric disorders 
more than 60 years ago. The serious adverse effects associated with FGA, including 
motor symptoms from the extrapyramidal system and hyperprolactinemia, however, 
encouraged the search for new antipsychotics. Clozapine (CLZ), the first “second-
generation antipsychotic” (SGA) agent, was synthesized in the late 1950s and introduced 
clinically in Europe in the early 1970s 
61
. While the ability of antipsychotic drugs to block 
dopamine D2-receptors is considered pivotal for symptom relief, there are general 
differences in the receptor binding profiles of FGAs and SGAs (Figure 1). SGAs, in 
general, have lower affinity for dopamine D2-receptors and a higher affinity for 




Figure 1: A simplified receptor binding profile of first-generation antipsychotics (FGAs) 
and second-generation antipsychotics (SGAs), along with their therapeutic and adverse 











2.1.2 Antipsychotics and effects on psychotic symptoms 
With antipsychotic treatment, symptomatic remission is achieved by as many as 80% of 
patients affected by an FEP 
63
. In the acute setting, the early introduction of an SGA at the 




While both FGA and SGA have proven to be able to treat positive symptoms leading to 
symptom reduction effectively, and even recovery in some patients 
6,65
, cognitive deficits 
and negative symptoms that better predict long-term outcome do not seem to show a 
similar response rate 
6,66,67
. In a meta-analysis by Leucht and colleagues 
68
, some SGAs 
(amisulpride, CLZ, olanzapine (OLZ), and risperidone) were found to be more efficient 
than FGAs for treatment of negative symptoms. Conversely, other SGAs (quetiapine, 
aripiprazole, sertindole, ziprasidone, and zotepine) were only as effective as FGAs.  
With that said, few of the studies included in this meta-analysis had explicitly examined 
the effect of SGAs on primary negative symptoms. Some SGAs may be useful for 
Receptors 
 
Therapeutic and Adverse Effects 
Dopaminergic (D2) 
 





5-HT2A Modulation of nigrostriatal dopamine binding (decreased 
extrapyramidal symptoms) 
 5-HT2C Metabolic complications and weight gain 
 
*Other receptors Histaminergic 
 














secondary negative symptoms since they show greater effects on symptoms such as 
depression and anxiety and because they have a lower risk of extrapyramidal symptoms 
(EPS) 
69
. Nevertheless, a relatively recent study examining FGAs and SGAs found that 
OLZ was more effective in treating schizophrenia patients with predominantly negative 
symptoms compared to the other antipsychotic agents 
70
. The latter is also supported by a 
recent systematic review 
71
, that found some SGAs (including amisulpride and OLZ) to be 
more effective in treating patients with predominantly negative symptoms.  
 
Despite a large number of studies that have evaluated the effects of antipsychotic 
medications on cognition, this relationship remains somewhat controversial 
72
.  While 
there are studies that have shown that SGAs in comparison to FGAs may improve specific 
cognitive domains (see review 
73
), there has also been work that has challenged such 
findings. Perhaps the most known one is The Clinical Antipsychotic Trials of Intervention 
Effectiveness (CATIE) study 
74
, which indicated that regardless of the grouping (FGA or 
SGA), the antipsychotics had similar effects on cognition. The authors further argued that 
the effect size for cognitive improvements was small 
74





With that said, other studies have reported a beneficial effect of certain SGAs in relations 
to specific cognitive domains. For example, OLZ treatment has been found to 
significantly improve several cognitive domains, including vigilance, attention, verbal 
learning and memory, verbal fluency, as well as executive functioning 
76,77
. CLZ has 
likewise shown a large to moderate positive effect on verbal fluency, attention, and 
executive functioning 
76
. Still, as with the debate on the possible superiority of SGAs, 
there are also those who have not found a specific SGA agent having a uniform positive 
effect on cognitive functioning (for a review see 
78
). It is further unclear whether the 
improvement observed with SGAs in the studies mentioned above epitomize actual 




related cognitive effects 
79
. It is also possible that the improvements may, at least in part, 




Lastly, it is estimated that up to 30% of patients with schizophrenia do not respond to 




2.1.3 Antipsychotics and effects on brain structures 
The majority of studies in patients with FEP as well as in patients with chronic 
schizophrenia have linked antipsychotic drug exposure to decreases in prefrontal and 
parietal lobe volumes, gray matter loss, and increases in basal ganglia volumes 
82–86
. 
However, there are also authors who report no significant association between 
antipsychotic drug treatment and brain structures, both in adolescents 
87
 as well as in 
chronic patients 
88–90
. DTI studies examining treatment-related changes in white matter in 
patients with schizophrenia have likewise been inconsistent. Some report reduced white 
matter integrity during antipsychotic treatment 
91,92
; whiles others report an increase in FA 




Several studies that have examined subgroups of antipsychotics have found a differential 
effect of FGAs and SGAs on brain volume changes in schizophrenia. SGAs have for 
example been putatively associated with a lesser decrease in cross-sectional and 
longitudinal gray matter volume studies than has been found for FGAs 
85,95–99
. In a five-
year MRI study of schizophrenia patients, Van Haren et al. 
85
 examined cortical thickness 
and change in cortical thickness. They reported significant correlations between 
antipsychotic medication and cortical thickness change although with difference in the 
nature of these associations: for FGAs, correlations were negative (i.e., higher intake was 
associated with more pronounced decreases in cortical thickness), whereas correlations 
with SGAs were positive (i.e., higher intake was related to less decrease in cortical 
thickness). In another study, Lieberman et al. 
96
, examined the differential effects of OLZ 




associated with significant reductions in gray matter volume after 12 and 52 weeks in 
comparison to healthy controls, whereas OLZ treatment was not. In compliance with 
these studies, a relatively recent meta-analysis concluded that the instrumental role of 
antipsychotic treatment in decreasing cortical gray matter volume cannot be generalized, 




The biology underlying such differential effect of antipsychotics is yet to be understood, 
but Liebermann et al. 
100
 postulated that some SGAs might be able to reverse the 
morphological brain changes observed in patients with schizophrenia, including gray 
matter volume reductions, and decrease in dendritic spine density observed within the 
prefrontal cortex. Others have hypothesized that SGAs might have a neuroprotective 
effect, either increasing the expression of neurotrophic factors 
101
 or by stimulating 
neurogenesis 
102
. A cumulative number of studies, by Bartzokis and colleagues, have 
further indicated that some SGA might promote and/or improve myelination of the cortex 
103,104
, possibly through stimulating lipid pathways 
105–107
.  Such a notion is further 




2.2  Lipid disturbances in patients with a psychotic disorder  
2.2.1 Evidence of lipid disturbances in schizophrenia  
Metabolic disturbances such as weight gain, dyslipidemia, and abnormal glucose 
metabolism are widely found in patients with schizophrenia, but also amongst other 
psychotic disorders. These disturbances increase the risk for diabetes, metabolic 
syndrome and cardiovascular diseases, and have been found to contribute to increased 




As reviewed in the preceding sections, substantial efforts have been made in the search 
for etiological and pathophysiological factors. Interestingly, several clinical observations, 




schizophrenia. First, the genes encoding the Sterol Regulatory Element Binding Proteins, 
SREBP1 and SREBP2, transcription factors involved in lipid biosynthesis, have been 
associated with schizophrenia 
115,116
.  Secondly, Andreassen et al. 
117
 demonstrated 
overlap in genetic susceptibility factors between schizophrenia and various cardiovascular 
risk factors, including BMI, triglycerides (TG),  low-density lipoprotein cholesterol 




Considering that schizophrenia is a neurodevelopmental brain disorder, and lipids 
(especially cholesterols) are crucial for proper brain development and neuron cell 
communication 
118,119
, other genetic and non-genetic studies have likewise indicated an 
abnormality in lipid biosynthesis and metabolism in the pathophysiology of schizophrenia 
120–126
. For example, the onset of schizophrenia in late adolescence or early adulthood 
127
 
coincides with a period of neuronal development when significant changes in fatty acid 




Lipids are also essential for myelin formation and functioning 
129
, which has been found 
to be deficient in patients with schizophrenia 
130
. Indeed, a meta-analysis of DTI studies in 
schizophrenia found decreased FA in white matter tracts interconnecting the prefrontal 
cortex and hippocampus 
131
. Such white matter disruption and other myelin abnormalities, 
hampering efficient communication between distinct brain regions, are known to play a 
crucial role in cognition and negative symptoms 
132
. Recently, researchers have started to 
focus more on the cerebral cortex as it is highly myelinated and such cortical myelin 
abnormalities are demonstrated in several neuropsychiatric disorders including 
schizophrenia 
133,134
. The degree of intracortical myelination is also considered to be 
critical for the optimization of brain function 
135
, and it is found to be highly associated 




Other lipid abnormalities, such as lower levels of membrane lipids, have also been 






There are, for example, studies showing alterations in the levels of polyunsaturated fatty 
acids (PUFAs), phospholipids and TGs in prefrontal and frontal cortex of schizophrenia 
patients 
124,125
. PUFA disturbances have, in particular, been related to negative symptoms 
139,140
 and, to a lesser degree, to cognitive symptoms 
141
. Having in mind that negative 
symptoms and cognitive symptoms may have a common neurodevelopmental origin and 
be related to more structural brain changes, studies show that higher membrane PUFA 
concentrations may be associated with better brain white matter integrity 
51,140
. 
Intriguingly, the membrane lipid abnormalities are not only observed within the central 




Finally, disturbances related to serum lipids have been exhibited in the early phases of the 
disorder 
120,143,144
. According to two recent meta-analyses, FEP patients with minimal or 
no exposure to antipsychotics show differences in serum lipid profiles compared to 
healthy controls 
120,145
. These serum lipid differences include lower levels of total 
cholesterol and LDL-C and higher TG levels in FEP. The meta-analysis by Misiak et al. 
120
 also found lower levels of HDL-C in their FEP patients. Correspondingly, studies in 





2.2.2 Metabolic effects following antipsychotic drug treatment: focusing on lipids and 
weight measures 
Patients with schizophrenia, in comparison with the general population, have a 4-fold 
higher prevalence of metabolic syndrome, a constellation of features: abdominal obesity, 
dyslipidemia, abnormal glucose metabolism, and hypertension 
146
. Whereas a sedentary 
lifestyle and lack of physical activity may be partially at fault 
147
; antipsychotic drug 
treatment is considered the leading cause 
148–150
. A meta-analysis determined that patients 




substantially higher risk of metabolic syndrome than antipsychotic-naïve individuals 
151
. 
The risk was far greater with OLZ and CLZ than with other antipsychotics such as 
aripiprazole, and much larger in patients on polypharmacotherapy than in those on 
monotherapy 
151
. Our focus has been on serum lipid changes as, along with weight gain; 
these are considered by many to be the most frequent metabolic changes following 
antipsychotic drug treatment 
113,152
. As serum lipids and BMI may be correlated 
153
; I will 
also review the literature on antipsychotic-related weight changes.  
 
Most antipsychotics have an increased risk of causing weight gain and disturbances in 
lipid metabolism 
154
. However, there are reported differences in the extent of these 
disturbances. Meta-analyses have repeatedly shown CLZ and OLZ to induce more weight 
gain than other antipsychotic agents 
155,156
. Weight gain, mainly caused by enhanced 
appetite and food intake, may indirectly increase lipid levels, but it has also been shown 
that dyslipidemia can occur independently of weight gain in antipsychotic-treated patients 
157–159
. A specific concern was raised by a recent meta-analysis 
160
, which revealed that 
about 40% of patients with schizophrenia and related disorders treated with an 
antipsychotic had lipid disturbances and that dyslipidemia (i.e., high levels of TG and 
lower levels of HDL-C) might be the most prevalent cardiovascular risk factor in 




 and young schizophrenic patients 
150,161
 are more prone to adverse 
metabolic effects with increases in TG levels, weight gain and metabolic syndrome 
following antipsychotic treatment, addressing metabolic concerns in patients earlier in 
their disease course may be imperative. Correll et al. 
150
 in their baseline data from 
Recovery After an Initial Schizophrenia Episode–Early Treatment Program (RAISE-ETP) 
study uncovered dyslipidemia in about half of their FEP patients with limited prior drug 
exposure, which is comparable to adults averaging 20 years older in the general US 
population 
162
. Several studies also report that the adverse metabolic effects seem to 
prevail in as short as three months after initiation of pharmacotherapy 
163,164








In previously drug-naïve patients and patients with limited prior antipsychotic drug 
exposure, the weight gain and lipid disturbances have been even more pronounced 
166,167
.  
For example, Perez-Iglesias 
167
  found that after only 12 weeks of antipsychotic drug 
treatment (haloperidol, risperidone or OLZ), previously drug-naive FEP patients 
experienced a marked weight gain (mean = 5.7 kg) leading to overweight in about 40 % 
and a worsening in lipid profile (increase in total cholesterol, LDL-C, and TG). 
Additionally, in drug-naïve patients contra more chronic patients, all antipsychotics (i.e., 





, although with some differences in magnitude as demonstrated in the 
European First Episode Schizophrenia Trial (EUFEST) 
148,170
 and in the “Evaluation of 




2.2.3 Possible therapeutic implications of the metabolic adverse effects  
While the metabolic side effects may impose a serious burden on the somatic health, it 
has also sparked some debate as two of the most metabolically potent drugs, CLZ and 
OLZ, 
171
 are also the most efficacious drugs 
69,172
. This issue gets further complicated as 
there is a growing body of studies reporting an association between antipsychotic-related 
weight gain and clinical improvement (to name a few: 
173–179
) and remission status 
180
, 
especially during OLZ and CLZ drug treatment. In relation to these studies, Sharma et al. 
179
  raised some key questions: “are metabolic side effects a necessary evil with the use of 
antipsychotic medication?” and “‘is there a metabolic threshold for antipsychotics?”. 
 
The answer appears to be complicated, as amisulpride, which has a lesser propensity for 
weight gain, has in some studies shown better long-term efficacy compared with more 
conventional serotonin-, dopamine- or multireceptor-SGAs 
69,179




indicating a general link between weight gain and clinical improvement independent of 
the type of antipsychotic drug used 
181
. These issues raise the question that perhaps other 
metabolic pathways, e.g., lipid-related pathways, might be mediating the previously 
observed link between antipsychotic-related weight gain and therapeutic efficiency. 





Studies have found an association between elevated TG and treatment response (mostly 
reduction in overall and positive symptoms) in patients receiving antipsychotic drug 
treatment 
159,181–183
. For example, Procyshyn et al. 
159
 reported that risperidone-treated 
patients who improved in total and negative symptom PANSS scores had increased TG 
and total cholesterol levels when controlling for weight gain. In another study with 372 
chronic schizophrenia patients treated with antipsychotics for more than two years, Chen 
et al. 
184
 established a link between the increase in TG levels and improvements in 
negative symptoms. There are also studies reporting a link between higher levels or 
increases in total cholesterol, HDL-C, and LDL-C levels, and improvement in cognitive 
symptoms 
185,186
. Lancon et al. 
185
 examined 168 schizophrenia outpatients and found an 
association between metabolic syndrome and memory impairment on measures of verbal 
learning, and short- and long-term memory. When examining the different components of 
metabolic syndrome, they discovered that low HDL cholesterol was associated with 
memory impairment (along with hypertriglyceridemia and abdominal obesity).  
 
However, in the post-hoc analysis of the CATIE trial, Hermes et al. 
181
 could not find an 
association between serum lipids and improvement in psychosis, even when each 
antipsychotic drug was analyzed separately. Likewise, a link between serum lipids and 
cognition during antipsychotic usage has not consistently been observed 
187,188
. One cause 
for the discrepancies between these studies may be sample differences, with the latter 
three studies including mostly chronic patients, where illness- and lifestyle-related factors 




during antipsychotic drug treatment is hard to study in an in vivo setting, but there may be 
some indications for studying serum lipids as a proxy for the lipid availability in the CNS.  
 
2.2.4 Lipids in the brain and the peripheral system 
2.2.4.1 From a general perspective   
Lipids constitute a large group of molecules involved in numerous essential processes and 
structures in the human organism 
189
. TGs are the primary storage form of lipids in the 
body, composed of a glycerol backbone and three esterified fatty acids. Fatty acids, TG, 
cholesterol may be absorbed from the diet or synthesized de novo.  
De novo synthesis of cholesterol is a complex pathway where cholesterol is synthesized 
via the isoprenoid biosynthetic pathway (for details see 
190
). Altogether, a minimum of 20 
enzymes is involved for manufacturing cholesterol, where the hydroxymethyl glutaryl-
Coenzyme A reductase is the rate-limiting enzyme 
190
. For transport and storage, 
cholesterol is usually esterified, i.e., linked to fatty acids through an ester binding. 
 
The brain is the most cholesterol-rich organ, containing about 20% of the whole body’s 
cholesterol pool 
191
. Nearly 80% of the cholesterol in the adult brain is in myelin sheaths 
formed by oligodendrocytes to insulate the axons; the rest is made up by plasma 





Cholesterols, as well as the receptors for cholesterol-containing molecules, are pivotal 
signaling molecules for brain morphology during embryonic development 
129
. Sufficient 
availability of cholesterol is crucial for the physicochemical properties of cells within the 
CNS and an absolute requirement for synapse development, synapse formation, dendritic 
differentiation, axonal guidance, and long-term potentiation 
192–194
. The highest rate of 
cholesterol synthesis in humans occurs during the first postnatal weeks 
195




of time corresponds with the peak of the myelination process, where deficiencies in 




During the maturation of neurons, the endogenous synthesis of cholesterol is impaired, 
and the neurons depend on cholesterol provided by astrocytes 
197
. Sufficient availability of 
cholesterol is necessary for all normal neuronal function and morphology, but there are 
marked differences in the cholesterol content in different brain regions as indicated by the 
differences in the expression of cholesterol-synthesizing enzymes and lipoprotein 




Most of the CNS cholesterol is recycled. However, for adequately maintaining 
homeostasis, mechanisms to export cholesterol into the circulation are mandatory. CNS 
cells, in particular astrocytes, can shed HDL-like lipoproteins composed of cholesterol 
and phospholipids and apolipoprotein E into the cerebrospinal fluid 
129
. Another pathway 
for cholesterol excretion, which is quantitatively more important, is the export of 
cholesterol as 24(S)-hydroxycholesterol and 27-hydroxycholesterol 
129
. Oxysterols, with 
hydroxylated side chains, can cross the lipophilic membrane of the blood-brain barrier 




In plasma, the above-mentioned oxysterols are transferred on lipoproteins such as LDL 
and HDL 
129
. The proportion of 24(S)-hydroxycholesterol to cholesterol in plasma is 
relatively constant, and patients with hypercholesterolemia also show higher plasma 
concentration of 24(S)-hydroxycholesterol 
200
. Interestingly, 27-hydroxycholesterol can 
pass the BBB, and the daily influx of this oxysterol into the brain has been estimated to be 
around 5 mg, depending on the concentration in the circulation and on the integrity of the 
BBB 
201
. On the latter matter of the integrity of BBB: there is growing clinical and 
experimental evidence that vascular endothelial dysfunction and BBB hyperpermeability 
occur in a subset of individuals with schizophrenia 
202




least in parts support peripheral (i.e., serum) lipids to be used as a proxy for cholesterol 
metabolism in the CNS.  
 
2.2.4.2 From an antipsychotic drug perspective  
Studies by our research group were the first to demonstrate that weight-inducing 
antipsychotic drugs also up-regulate the expression of genes involved in the biosynthesis 
of cholesterol and fatty acids 
203
. These genes are controlled by the SREBP transcription 
factors, SREBP1 and SREBP2 (for a review, see 
204
). These transcription factors bind to a 
specific DNA sequence called the sterol regulatory element and increase the transcription 
of enzymes involved in cholesterol and fatty acid biosynthesis 
205
. Examinations of 
various antipsychotics in cultured CNS-cells have further revealed that CLZ is one of the 
most potent SREBP activators 
107
, and experiments in cultured liver cells have shown that 




As previously mentioned, CLZ and OLZ have the highest disadvantage regarding adverse 
metabolic effects (including dyslipidemia and weight gain); however, these drugs are also 
the most effective ones 
68,207
. Fernø et al., hence proposed that the SREBP-mediated 
activation of cellular lipid biosynthesis may represent a new mechanism of antipsychotic 
drug action, involved in both therapeutic efficacies 
107,203
 (through the enhanced synthesis 
of lipids in CNS) and metabolic side effects 
203,208
 (through increased production of lipids 
in peripheral tissues such as the liver).  Indeed, there seems to be some correspondence 
between SREBP activation in the in vitro experiments mentioned above and their 
association to weight gain reported in the clinical setting.  
 
Remembering that myelin deficits are repeatedly found in schizophrenia, and that myelin 
is constituted of mainly lipids, there are several studies using MRI and DTI showing a 
beneficial effect (e.g., increasing FA) of antipsychotics on myelin and other brain 




subcortical myelin has been studied extensively, in recent years focus has shifted to 
intracortical myelin. Some authors even argue that deficits in intracortical contra 
subcortical myelin may be more pronounced in patients with schizophrenia 
209
.  
Following this train of thoughts, studying peripheral (i.e., serum) lipids as a proxy 
measure for central lipid synthesis during antipsychotic drug treatment and relating it to 
intracortical myelin, may aid in investigating possible in vivo lipid effects of 
antipsychotics on brain structures and perhaps increase our understanding of the link 
between serum lipids and psychosis as outlined in section 2.2.3. 
 
2.3  Knowledge Gaps  
Summarizing the literature hitherto, there are some essential knowledge gaps in our 
understanding of antipsychotic-related lipid disturbances and their link to outcomes, thus 
compiling the rationale for the current PhD thesis.  
There is evidence supporting an association between BMI, TG, and positive symptoms, 
but few have studied such associations to the other psychotic symptoms, herein negative 
symptoms and cognitive symptoms. Prior studies have focused mostly on chronic patients 
where long illness duration, multi-pharmacy, and lifestyle are harder to control for. 
Moreover, studies assessing the cognitive changes during antipsychotic drug treatment in 
relation to metabolic changes have in general lacked a healthy control group to control for 
practice effects and also for addressing the impact of current obesity trends in the society. 
While DTI studies have been widely used to study antipsychotic-related subcortical 
myelin changes; the intracortical myelin has just recently gained interest. Additionally, 
most imaging studies have not included an unmedicated patient group, which may be 
important to differentiate the subtle changes related to illness versus the potential effects 





3. AIMS OF THE STUDY  
The overall objective of this thesis was to combine clinical, biological and brain imaging 
data to increase our current understanding of the relationship between serum lipids and 
clinical, cognitive, and brain structural outcomes in antipsychotic-treated patients with 
broad schizophrenia spectrum disorders, emphasizing on patients with FEP.  
 
The following questions were raised:  
1) Is there an association between antipsychotic-related change in serum lipids and 
clinical outcome defined in terms of reduction in positive or negative symptoms? If so, 
are these associations independent of concomitant changes in BMI? 
2) Is there an association between change in serum lipids and improvement in cognitive 
function? If so, are these associations independent of concomitant changes in BMI? 
3) Does treatment with a metabolically potent antipsychotic agent (i.e., OLZ) influence 
intracortical myelin, assessed indirectly via cortical thickness and gray/white matter 
intensity contrast in patients with a broad schizophrenia spectrum disorder?  Moreover, is 
there an association between such structural changes, if any, and changes in serum lipid 
levels? 
 
4. MATERIALS AND METHODS  
The patient sample and corresponding data that were used in this PhD project had been 
collected by others as part of the Thematically Organized Psychosis (TOP) Study in Oslo 
(see below). 
 
4.1 Ethical aspects 
Thorough information about the study was given, and the participants’ ability to give 




was voluntary and that they could withdraw at any point, and request all their collected 
data to be deleted. All participants gave written informed consent prior to their inclusion 
in the study. The Regional Ethics Committee and The Norwegian Data Inspectorate 
approved the study.  
 
4.2 Clinical samples 
The three articles in this thesis include results from two one-year cohort studies (with the 
same FEP sample: Study 1 and Study 2) as well as a cross-sectional MRI study (Study 3). 
For sociodemographic and clinical characteristics of the samples, see Table 1 and Table 2. 
 
Participants in the three studies were recruited consecutively during 2003-2014 from in- 
and out-patient psychiatric units in the catchment areas of the four major hospitals within 
the South-Eastern health region in Norway, as part of the TOP Study.  
 
General inclusion criteria for the TOP Study: Being in a stable psychosis phase and 
having a DSM-IV diagnosis of broad schizophrenia spectrum disorder or bipolar 
spectrum disorder. Age between 18 – 65 years old, speaking and understanding a 
Scandinavian language well enough to complete the assessments, and being able and 
willing to give informed consent.  
 
General exclusion criteria: Presence of a pronounced cognitive deficit (IQ below 70), or 
severe brain damage. Patients were also excluded if their diagnosis was considered to be 
alcohol- or substance-induced disorder instead of a primary psychiatric disorder. Presence 
of alcohol- or substance-related disorders was not in itself an exclusion criterion for the 
patients.  
 
FEP patients (Study 1 and Study 2)  
In addition to the general criteria of TOP, in Study 1 and 2 we had some additional 




87 (66%) with a diagnosis of schizophrenia, N = 5 (4%) schizophreniform disorder, N = 
16 (12%) schizoaffective disorder and N = 24 (18%) psychosis NOS. The rationale for 
including wider diagnoses was that the diagnoses in the early phases are less stable than 
later on 
210
. FEP was defined as the onset of first-episode positive psychotic symptoms 
(i.e., PANSS score of 4 or higher on positive scale items P1-delusions, P3-hallucinatory 
behavior, P5-grandiosity, P6-suspiciousness, or General scale item G9-unusual thought 
content), and not having received adequate prior treatment for psychosis. Adequate 
treatment was defined as antipsychotic medication in doses over 1 Defined Daily Dosage 
(DDD) for > 12 weeks or briefer if this treatment was followed by symptomatic 
remission. DDD is the anticipated average maintenance dose per day for a drug used for 
its primary purpose in adults 
(https://www.whocc.no/ddd/definition_and_general_considera/). In general, the patients 
were recruited in the early phases of treatment but were most often not treatment-naïve.  
 
OLZ-treated and unmedicated patients with broad schizophrenia spectrum 
disorders (Study 3) 
For study 3, we selected a subsample of patients with broad schizophrenia spectrum 
disorders (from the TOP main study) who were either on stable OLZ monotherapy (n=33) 
or were unmedicated (n=19). Stable monotherapy was defined as using a constant daily 
dose of OLZ (minimum 5 mg) at the time of blood sampling and on the day of MRI. 
Being unmedicated was defined as the absence of any antipsychotic drug at the time of 
blood sampling and at the time of MRI scanning. Patients were excluded if the time 
interval between MRI scan and blood sample surpassed 90 days (mean interval= 38.8 
days, SD= 28.6).  
 
The distribution of DSM-IV diagnoses was for the OLZ group: schizophrenia, N = 12 
(36%); schizophreniform disorder, N = 5 (15%); schizoaffective, N = 4 (12 %); and 




schizophrenia, N = 9 (47%); schizophreniform disorder N = 1 (5 %); psychosis NOS, 
N = 9 (48 %). 
 
Of the 19 unmedicated patients, six were antipsychotic-naïve, whereas ten patients had 
used antipsychotics previously. Data on previous medication were missing for three 
participants. Among the ten patients who had received antipsychotics earlier, the average 
time since treatment with an antipsychotic agent was 18 months (SD: 16 months, range 3-
47 months, data was missing for one patient). Six of these patients had previously used 
OLZ (mean dosage 10 mg, SD: 6.1 mg, data missing for one patient). For more details, 
we refer to the Methodological section in Study 3.  
 
Healthy controls in the TOP study 
Healthy controls from the TOP database were used in Study 2 (N=83 subjects) and Study 
3 (N=76 subjects). These individuals were aged 18-45 years and invited to participate 
based on a random selection from the National Registry in Norway. The controls were 
interviewed with Primary Care Evaluation of Mental Disorders (PRIME-MD) 
211
 to 
ensure no history of a severe psychiatric disorder in controls or any of their first degree 
relatives. Controls with somatic conditions interfering with brain functioning or history of 
drug abuse/dependency (or use of cannabis within the last three months), head trauma, 
neurological disorders, or pathological neuroradiological findings were excluded. For 
study 2, we matched for age and gender. For Study 3, we did not match for age or gender; 
however, there were no significant differences between the OLZ and unmedicated group 










Table 1: Sociodemographic and clinical characteristics of the first-episode psychosis 





























t p-value  
Age (years) 132 83 26.7 (7.6) 29.0 (6.8) -2.6 0.01 
Education (years) 132 83 12.9 (2.8) 14.2 (2.0) -4.43 <0.001 
Alcohol use (AUDIT scores) 120 71 7.3 (7.4) 5.9 (3.0) 1.89 0.06 
       
DUP (weeks), median (range) 132  40.0 (1-1040)    
Total PANSS scores 132  63.2 (13.9)    
PANSS positive subscores 132  2.6 (1.0)    
PANSS negative subscores 132  2.2 (1.0)    
Depressive symptoms (CDSS scores)  128  6.2 (4.5)    
       














Gender (male) 132 83 85 (64.4) 80 (59.7) 0.62 0.45 
Ethnicity (Caucasian) 132 83 87 (65.9) 132 (98.3) 52.32 <0.001 
Smoking (daily) 132 86 60 (45.5) 17 (19.8) 15.04 <0.001 
Hospitalization at inclusion 132  30 (22.7)    
       
Change in diet ("better diet") 
†
 132  20 (15.2)    
Change in exercise ("increased exercise ") 
‡
 129  21 (15.9)    
       
Continuous antipsychotic drug use 
§
 132  100 (76)    
Intermittent antipsychotic drug use 
¶
 132  32 (24)    
Antipsychotic monotherapy 132            91 (69)    
Antipsychotic polypharmacy  132  41 (31)    
 
FEP= first episode psychosis, HC= healthy controls, SD= standard deviation, n= number of subjects,  %=                   
percentage,. AUDIT=Alcohol Use Disorder Identification Test, DUP= duration of untreated psychosis, PANSS=            
Positive and  Negative Syndrome Scale, CDSS= Calgary Depression Scale for Schizophrenia.  
P-values are obtained from T-tests and Chi-square test. 
† 
Diet was divided into “similar or poorer” and “ better " compared to diet habits at baseline.   
‡ 
Exercise was divided into “similar or reduced ” and “increased" compared to exercise habits at baseline. 
§  








Table 2: Sociodemographic and clinical characteristics among olanzapine-treated (1) 















p-values Post-hoc tests 
Age (years), mean (SD) 31.0 (11.2) 33.1 (11.1)  31.9 (9.6) NS  
Gender (male), n (%) 18 (55) 14 (74) 45 (59) NS  
Ethnicity (Caucasian), n (%) 28 (85) 14 (74) 74 (97) X2 (8, N = 128) = 18.09,  p=0.02 2 vs. 3 
Education (years), mean (SD) 13.2 (3.2) 12.2 (2.4) 14.2 (2.4) F (2,115) = 3.54, p = 0.03 2 vs. 3 
Handedness (right),  n  (%) 25 (96) 13 (81) 65 (86) NS  
Smoking (daily),  n  (%) 20 (62.5) 8 (47.1) 12 (22) NS  




H: 23 (71.9) 
MH: 8 (25.0) 
UH: 1 (3.1) 
H: 10 (58.8) 






Exercise, n  (%) L: 21 (70) L: 6 (46.2) NA NS  
 M: 7 (23.3) 
F: 2 (6.7) 
M: 5 (38.5) 




      
Alcohol use (AUDIT), mean (SD) 8.0 (8.9) 9.8 (8.4) NA NS  
Substance use (DUDIT), mean (SD) 5.7 (10.3) 6.5 (8.1) NA NS  
      
Diagnosis, n  (%) SZ=12 (36),  
SF=5 (15),  
SA= 4 (12),  
NOS=12 (36) 
SZ=9 (47),        
SF=1 (5),          
SA= 0 (0),     
NOS=9 (48) 
NA NS  
 








U= 104.5, Z=-2.64, p =0.01 
 
1 vs. 2 
Duration of illness (years), mean (SD) 2.9 (4.0) 7.6 (7.2) NA t(34)=-2.53, p=0.02  
Currently hospitalized,  n  (%)  6 (18.2) 1 (5.3) NA NS  
Previous admissions due to psychosis, mean (SD) 
 
OLZ dosage (mg/day), mean (SD) 
1.3 (1.0) 
 











OLZ treatment duration (months), mean (SD) 19.2(33.3) NA NA NA  
      
Total PANSS, mean (SD)  54.6 (15.0) 57.1 (10.2)  NA NS  
Positive PANSS subscores, mean (SD)  11.9 (4.1) 15.3 (4.7) NA t(50)=-2.67,  p =0.01 1 vs. 2 
Negative PANSS subscores, mean (SD)  14.5 (7.4) 11.2 (3.3) NA NS  
Global functioning, function (GAF-F), mean (SD)  47 .4 (12.1)  47.5 (12.6)  NA NS  
Global functioning, symptoms (GAF-S), mean (SD)  47.8 (12.2) 44.0 (11.6)  NA NS  
Groups: 1=Olanzapine-treated patients (OLZ), 2=unmedicated patients, 3=healthy controls. Diet was classified as H= healthy, 
MH= moderately healthy, and UH=unhealthy.  Exercise was classified as L=little, M=moderate, and F=frequent. 
AUDIT=Alcohol Use Disorder Identification Test, DUDIT= Drug Use Disorder Identification Test, DUP= duration of 
untreated psychosis, was defined as the number of weeks from the first occurrence of a psychotic symptom above clinical 
threshold to the first adequate treatment. PANSS=Positive and Negative Syndrome Scale, GAF-F= Global Assessment of 
Functioning- functions, GAF-S= Global Assessment of Functioning-symptoms, SZ= schizophrenia, SF= schizophreniform, 
SA= schizoaffective, NOS= psychosis not otherwise specified, N= number of subjects, NA= not applicable, NS= non 
significant, SD = standard deviation, F= F-test,  T=t-test. P-values are obtained from one-way ANOVA, T-tests, Chi-square 
test and Mann-Whitney U test. Post-hoc tests (t-tests) were performed for the F-tests that were significant and we only report 




4.3 Clinical assessments  
Information about demographic variables (age, gender, ethnicity, education), clinical 
variables (age at onset, history of psychosis, hospitalizations, symptom severity and 
functioning), and lifestyle-related variables (smoking, alcohol, drug use) was collected 
as part of a clinical interview and by using standardized structured interviews and 
rating scales. For healthy controls in the TOP study, demographical information (age, 
gender, ethnicity, education) and lifestyle variables (smoking, alcohol, drug use) were 
obtained.  
 
A clinical assessment team of clinical psychologists, psychiatrists, and medical doctors 
performed the diagnostic and clinical assessments. A satisfactory inter-reliability was 
achieved with an overall agreement of 82%, κ = 0.77 (95% Cl: 0.60-0.94) for DSM-IV 
diagnostics. Senior psychiatrists and specialists in clinical psychology continuously 
supervised the clinical assessment.  
 
The Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-
PANSS) 
212
 assessed current symptomatology. This interview assesses the patient’s 
symptom burden over the last week. The original PANSS scale is divided into three 
sections, positive symptoms (7 items), negative symptoms (7 items), and general 
pathology (16 items). Likert scale ranging between 1-7; where each item is defined 
and scored according to it being absent or present in the following way: 1=absent, 
2=minimal, 3=mild, 4=moderate, 5= moderately severe, 6=severe, 7=extreme.  
 
Since a variety of factor analyses have revealed other factor structures to have better 
clinical validity in different cultural background 
213
 and for assessment of FEP 
214
, we 
used the five-factor model proposed by Wallwork et al. 
213
 in Studies 1 and 2. Here the 
positive and negative symptom factors are reported, as these two symptom factors are 
considered to be most relevant in testing our hypotheses. The positive symptom factor 
includes item P1 (delusions), P3 (hallucinations), P5 (grandiosity), and G9 (unusual 
thought). The negative symptom factor includes item N1 (blunted affect), N2 




N6 (lack of spontaneity and flow of conversation) and G7 (motor retardation). Because 
each five-factor subscale includes a different number of items, and to avoid confusion 
with the original three-scale PANSS, Studies 1 and 2 report mean item scores for the 
five-factor PANSS positive and negative subscales.  
 
Duration of untreated psychosis (DUP) was defined as the number of weeks from the 
first occurrence of a psychotic symptom above the clinical threshold to the first 
adequate treatment (for details see 
215
). Remission was defined as at least one week 
with no score of ≥4 on any of the following five PANSS items: P1, P3, P5, P6, or G9. 
Depressive symptoms were assessed with the Calgary Depression Scale for 
Schizophrenia (CDSS) 
216
, as it has been found to differentiate well between 
depression and negative symptoms. Global functioning was assessed with the Global 
Assessment of Functioning (GAF) split version (with separate scales for symptoms 
(GAF-S) and functioning (GAF-F)) 
217.  
 
Smoking was coded based on the self-report of the participants as current smokers and 
non-smokers. Alcohol and substance use was measured with the Alcohol Use 
Disorders Identification Test (AUDIT) 
218
 and the Drug Use Disorders Identification 
Test (DUDIT) 
219
. In patients’ interviews, information regarding diet (classified as 
healthy, moderately healthy or unhealthy) and exercise habits (classified as light, 
moderate or frequent) was obtained at baseline and 12 months. In Studies 1 and 2, diet 
was divided into “similar or poorer diet” (including patients who did not change their 
diet habits from inclusion to 12 months, as well as patients who reported a poorer diet 
at 12 months) and “better diet” (consisting of patients who reported a beneficial 
change in diet). Exercise was, likewise, divided into “similar or reduced exercise” and 
“increased exercise” at 12 months. 
 
4.4 Cognitive assessments  
Current IQ was measured with the Wechsler Adult Intelligence Scale (WAIS) 
subscales similarities and block design 
220
. The cognitive test battery comprised of five 




fluency, and inhibition) on the basis of previous findings related to cognitive 
dysfunction in FEP 
221
. To minimize the number of statistical tests, one subtest within 
each test was selected. All participants showed satisfactory neuropsychological test 
effort marked by two errors or less on the forced recognition trial of the California 
Verbal Learning Task (CVLT-II) 
222
. Higher scores indicated better performance on all 
tests apart from the inhibition subtest, where higher scores indicated a poorer 
functioning. Raw scores were reported for all tests in order to be able to calibrate the 
cognitive performance of the FEP patients as compared to a representative age- and 
gender-matched healthy control group from the same catchment area as the patients. 
 
Verbal learning was measured with the California Verbal Learning Test (CVLT-II) 
222
, 
verbal learning subscore. Participants were asked to repeat a list of 16 words that were 
read a total of five times. The key score used was the total number of words 
immediately recalled (sum of trials 1-5). 
 
Processing speed was measured with the Digit Symbol Test (WAIS) 
220
. Numbers 
paired with symbols comprises the test, and the task is to fill in blank spaces with 
correct symbols within the time limit of 90 seconds. The total number of correct 
symbols was used as a measure of processing speed.  
 
Working memory was measured with the Letter-number Sequence Test (WAIS) 
220
. 
The participant is presented orally to a list of digits and letters. The task is to sort the 
digits in ascending order and the letters in alphabetical order. The key score represents 
the total number of correctly arranged trials.  
 
Verbal fluency was measured with the Verbal Fluency Test, phonetic subscore from 
the D-KEFS 
223
. The subtest consists of three trials, requiring the production of as 
many words as possible beginning with the letters ‘F’, ‘A,’ and ‘S’ within the time 
frame of 60 seconds each. The number of words generated in each of the trials was 





Inhibition was measured with the Color-Word Interference Test from the Delis Kaplan 
Executive Function Scale (D-KEFS) 
223
, inhibition subscore. The key score for 
inhibition represents the time used to name the color of the ink of written words of 
incongruent colors. 
 
4.5 Antipsychotic drug treatment and use of other medication 
A detailed record of the patient’s current medication was obtained through medical 
records and self-reports (see Appendix Tables 1- 2 for details). None of the patients 
used lipid-lowering prescription or antidiabetic drugs. Due to the extent of switching 
between different antipsychotic agents, current antipsychotic drug treatment was 
defined as continuous antipsychotic use and intermittent antipsychotic use in Studies 1 
and 2. Continuous use was delineated as using any antipsychotic agent at baseline and 
12 months (not necessarily the same antipsychotic drug at both time points), while 
intermittent use was delineated as using whichever antipsychotic agent at either 
baseline or 12 months. All patients who used FGAs also used SGAs. Due to 
insufficient data on switches and duration of antipsychotic treatments during the 
follow-up period, it was not feasible to calculate cumulative drug exposure.  
In Study 3, medication information from the day of MRI was used.  
 
4.6 Somatic examination 
The patients were asked about comorbid somatic diseases. Heart, lungs, and the 
abdomen were evaluated by clinical examination, and a short neurological status was 
conducted. Digital weights were used to weight all the participants, and BMI 





Blood was drawn from the antecubital vein in the morning after overnight fasting at 
baseline and 12 months, on the day the neuropsychological testing took place. The 
Department of Clinical Chemistry at Oslo University Hospital, using standard 




cholesterols (total, HDL-C, LDL-C) and TG. All blood samples were sent immediately 
after gathering and analyzed unremittingly as routine samples.  
 
4.7 Brain imaging data 
The MRI is a non-invasive technique for in vivo brain visualization without the use of 
ionizing radiation. This technique takes advantage of the magnetic assets of hydrogen. 
In short, the patient is placed in a magnet tunnel, which uses radio waves in pulses to 
polarize and excite hydrogen protons in the tissue. Termination of the pulse returns the 
protons to their original spin (relax) and emit radiofrequency waves, which are used to 
reconstruct images of the tissue. The relaxation process can be divided into different 
aspects, such as the T1 and T2 relaxation time constants. Simplified, the T1 tells more 
about the tissue properties, while the T2 tells more about the internal factors of the 
magnetic spin of the protons. The tissue contrast is dependent on T1 and T2 relaxation 
times, the number of affected protons, flow, and temperature. In T1 weighted imaging, 
fat has a high signal (appears white on the image) and water a low signal (appears 
black on the image). In T2 weighted images, tissues with high fat content show weak 
signals (appears black on the image), while tissues with high water content show high 
signals (appears white on the image).  
 
In the present thesis, structural T1 weighted MR images were obtained to investigate 
quantitative measures (morphometry) of brain structures as our focus was on cortical 
structures and because a significant determinant of this intensity signal is the 
cholesterol in myelin 
224,225
. Moreover, strong correlations are reported between T1 




4.7.1 MR scan acquisition and data processing 
Patients and healthy controls in Study 3 were scanned consecutively at the Department 
of Neuroradiology, Ullevål University Hospital in Oslo, on the same 1.5 T Siemens 
Magnetom Sonata scanner equipped with a standard eight-channel head coil. A 




studies. During the study period, there was no major scanner up-grade or change of 
hardware. Before undergoing post-processing, scans were visually inspected, and poor 
quality scans were excluded. T1-weighted data from all subject samples were 
processed using FreeSurfer version 5.3.0 (freely available from the website 
http://surfer.nmr.mgh.harvard.edu/). All surfaces were inspected, and manual editing 
was performed according to standard FreeSurfer quality control procedures. From the 
reconstructed surfaces, cortical thickness was measured as the shortest distance from 
the white area to the pial surface at each vertex. For the primary analyses, we extracted 
average cortical thickness for each label in the Desikan-Killiany atlas (34 regions) 
228
 
and merged 33 of these labels (all except the insular cortex) into eight bilateral lobar 
areas, as shown in Figure 2. Average cortical thickness across the cortical surface was 
also extracted. 
 
Figure 2. The eight bilateral lobar 










4.7.2 Calculation of the gray/white matter contrast 
FreeSurfer was used to sample intensity values at each vertex along the gray/white 
boundary. Sampling distances were set at 0-60% into the cortical ribbon and 0-1.5 mm 
into subjacent white matter (see Figure 3). Values from gray matter were averaged to 
form a single gray matter intensity value for each vertex; similarly, values from white 
matter were averaged to form a single white matter value. The difference between 
these values (i.e., averaged gray and white matter intensity values at each vertex) was 




values at each vertex. For more details, we refer to the Methodology section in Study 
3. 
 
Figure 3. Illustration of 
gray/white matter intensity 
contrast. The yellow line 
represents the gray/white 
matter boundary. The blue 
lines represent different 
sampling distances used to 
obtain gray/white matter 
intensity values.  
 
4.8 Statistical analyses  
All data were analyzed using the Statistical Package for the Social Sciences (SPSS 
Inc., Chicago, IL, USA). Analyses were performed with a significance level < 0.05, 
two-tailed (confidence interval of 95%). All variables were checked for deviations 
from a normal distribution and logarithmically transformed if necessary, before being 
entered into the analyses.  
 
The main analyses consisted of the following: To examine which outcome variables 
were associated with longitudinal changes in serum lipids and BMI, mixed-effects 
regression modeling was used in Studies 1 and 2. In these mixed models, we 
controlled for age, gender, and antipsychotic usage. Of note, antipsychotic usage was 
controlled for in the main analyses in Study 1 and in the post-hoc analyses in Study 2. 
In Study 3, we employed a general linear model (GLM) controlling for age, gender, 
and group (OLZ, unmedicated, and healthy controls).  
 
Missing variables were treated pairwise. Preliminary analyses (Little's Missing 




randomly distributed. For more details on the statistical approaches and details on 
missing variables, we refer to the Statistical sections of the individual studies. 
 
5. SUMMARY OF RESULTS 
Study 1: Increase in serum HDL-C level is associated with less negative symptoms 
after one year of antipsychotic treatment in FEP. 
 
In Study 1, we aimed to examine whether changes in serum lipids are associated with 
improvement of psychosis symptoms following one year of antipsychotic drug 
treatment in a cohort of 132 FEP patients included through the TOP project. Data on 
antipsychotic usage, serum lipids (total cholesterol, HDL-C, LDL-C, and TG), BMI 
and clinical state using PANSS were obtained at baseline and after 12 months. Mixed-
effects models were used to examine the relationship between serum lipids and 
psychotic symptoms while controlling for potential confounders, including BMI.   
 
Our results indicate that during the one-year follow up, the FEP patients experienced a 
significant reduction in PANSS positive and negative subscores, (B = − 0.48, p 
<0.001) and (B = − 0.17, p =0.03), respectively.  
 
Concerning the serum lipids, there was a significant decrease of 0.07 mmol/L (SD = 
0.27) in mean HDL from baseline (1.39 mmol/L; SD = 0.38) to 12 months (1.32 
mmol/L; SD = 0.37) at the group level (p = 0.02), but on an individual level 49 
subjects (54%) experienced a decrease and 41 subjects (46%) an increase in their 
HDL-C levels. Group comparison between patients with an increase in HDL levels 
versus those with a decrease during the follow-up period displayed no significant 
differences in sociodemographic or illness-related factors except that the HDL 
increase group had higher mean PANSS negative subscore at baseline, 2.5 (SD = 1.1) 
vs. 2.0 (SD = 1.0) (p = 0.04) and a higher mean AUDIT score at 12 months, 8.8 (SD = 




serum total cholesterol, LDL-C, or ln TG. Also, there was no significant difference in 
the direction of lipid change between continuous versus intermittent antipsychotic use. 
 
At baseline, regression analyses showed a negative association between HDL level 
and PANSS negative subscores when controlling for age, gender, and antipsychotic 
use (B = − 0.67, p = 0.02). After one year of antipsychotic treatment, the mixed-effects 
model demonstrated a significant association between an increase in HDL-C and a 
decrease in PANSS negative subscores (B = − 0.48, p = 0.03). Moreover, the 
association between change in HDL-C and change in negative symptoms remained 
significant after controlling for BMI change (B = − 0.54, p = 0.02). No significant 
associations were found between changes in total cholesterol, LDL-C, ln TG, BMI, 
and changes PANSS positive and negative subscores.  
 
Post-hoc mixed model analyses further showed that neither illness (including 
diagnosis subgroup, DUP, hospitalization, concurrent changes in PANSS positive 
subscores and CDSS scores) nor lifestyle-related factors (including smoking, alcohol 
use, changes in diet and exercise) significantly influenced the relationship between 
HDL-C and PANSS negative subscores. 
 
In conclusion, we found that an increase in HDL-C level during antipsychotic 
treatment was related to improvement in negative symptoms, independent of BMI 
changes. 
 
Study 2: Improvement in verbal learning over the first year of antipsychotic 
treatment is associated with serum HDL-C levels in a cohort of FEP patients. 
 
As a follow-up to Study 1, we investigated in Study 2 whether changes in serum lipids 
are associated with cognitive performance in FEP patients during the first year of 
antipsychotic drug treatment. The same antipsychotic-treated FEP sample was used 
along with 83 age- and gender-matched healthy individuals to control for practice 




population. Information regarding cognitive performance, psychotic symptoms, 
lifestyle, BMI, serum lipids, and antipsychotic treatment, were obtained at baseline 
and after one-year follow-up. The cognitive test battery comprised assessments for 
verbal learning, processing speed, working memory, verbal fluency, and inhibition. 
Mixed-effects models were employed to examine the relationship between changes 
over time in serum lipids and cognitive domains, controlling for potential confounders.  
 
For group differences in demographic-related variables we refer to Table 1. Regarding 
the cognitive measures, our results indicate that the FEP patients exhibited marked 
impairments in cognitive functioning for all domains at baseline (p < 0.001). During 
the one-year follow-up, there was a group by time interaction for verbal learning 
(F = 6.86, p = 0.01), with a steeper change in FEP than in the control subjects 
(B = 3.54, p = 0.01), signifying that practice effects alone cannot explain the relatively 
more marked improvement in patients compared to healthy controls. The mixed-
effects model analyses also revealed a group by time interaction for verbal fluency 
(F = 6.38, p = 0.01); here, the FEP group displayed a negative change in comparison 
with the healthy control group, (B = − 3.15, p = 0.01), respectively. 
 
Regarding the serum lipids, the FEP patients had significantly higher levels of total 
cholesterol and LDL-C compared to the healthy controls at baseline, 
(F = 8.94, p = 0.003) and (F = 11.54, p = 0.001), respectively. At the one-year follow-
up, there was no significant change in mean levels of serum lipids among the FEP 
patients when compared to the healthy controls at the group level. Still, at the 
individual level, FEP patients displayed the following changes in their serum lipids: 47 
patients (47%) experienced a decrease and 52 (53%) an increase in their total 
cholesterol levels; 49 patients (54%) experienced a decrease and 41 (46%) an increase 
in their HDL-C levels; 43 patients (50%) experienced a decrease and 43 (50%) an 
increase in their LDL-C levels; 40 patients (45%) experienced a decrease and 49 





When investigating the two cognitive domains that showed a group by time interaction 
(verbal learning and verbal fluency) for associations with serum lipid levels, we 
discovered that there was a significant group by HDL-C interaction effect for verbal 
learning (F = 11.12, p = 0.001): an increase in HDL-C level was related to 
improvement in verbal learning among FEP patients compared to the healthy controls 
(B = 10.32, p = 0.001). Verbal fluency, in contrast, did not evidence any significant 
group by lipid interactions.  
 
The post-hoc mixed models adjusting for antipsychotic usage (i.e., continuous use 
versus intermittent use), and positive and negative symptoms demonstrated that the 
group (i.e., FEP) specific link of HDL-C to verbal learning remained highly significant 
(F = 7.45, p = 0.007). Similarly, adjusting for remission status did not considerably 
impact the observed link between serum HDL-C and verbal learning in the FEP group 
(B = 8.42, p = 0.002). Moreover, while there was a main effect of BMI on verbal 
learning (F = 4.88, p = 0.03), the group by HDL-C interaction remained significant 
(F = 9.86, p = 0.002) indicating that the link between HDL-C and verbal learning was 
independent of BMI. Lastly, ethnicity, hospitalization, depressive symptoms, smoking 
habits, diet, exercise, and alcohol use demonstrated no attenuation of results for the 
observed link between HDL-C and verbal learning.  
 
In conclusion, the current study of antipsychotic-treated FEP patients revealed that 
during the first year of follow-up, an increment in serum HDL-C was associated with 
better cognitive performance in verbal learning, independent of BMI changes. 
 
Study 3: Association between OLZ treatment and brain cortical thickness and 
gray/white matter intensity contrast is moderated by cholesterol in psychotic 
disorders. 
 
In a sample of patients with broad schizophrenia spectrum disorders, we investigated 
the relationship between treatment with OLZ and cortical thickness and gray/white 




levels. A total of 33 OLZ users, 19 currently unmedicated psychotic patients, and 76 
healthy controls were included. Data on serum lipids (total cholesterol, HDL-C, LDL-
C, and TG), BMI, clinical state and functioning were acquired through clinical 
assessments and interviews. Cortical measures were obtained by MR brain images. 
GLMs analyses were, thereafter, used to asses any group differences, as well as to 
investigate possible associations between serum lipids and cortical measures.  
 
For group differences in demographic- and illness-related variables we refer to Table 
2. Regarding the cortical measures, our results indicate that the OLZ users had similar 
cortical gray/white matter intensity contrast measures as the healthy controls (p < 0.05, 
corrected). Although the unmedicated patients had higher nominal intensity contrast 
compared to the healthy controls (frontal, cingulate, lateral temporal, and medial 
temporal regions) (p < 0.05, uncorrected), they did not remain significant after 
correction for multiple comparisons.  
 
OLZ users also displayed significantly thinner cortices compared to the healthy 
controls in frontal, orbitofrontal, and medial temporal regions (p < 0.05, corrected), 
while there were no significant differences in cortical thickness between unmedicated 
patients and the healthy controls. Of note, the cortical thickness and intensity contrast 
were correlated in all regions except for cingulate and pericentral cortex. 
 
Regarding the serum lipids, there was a group difference in mean serum HDL-C levels 
and LDL-C levels, (F = 3.28, p = 0.04) and (F = 3.51, p = 0.03), respectively. The post-
hoc tests revealed that the OLZ-group exhibited a lower mean HDL-C value and a 
higher LDL-C value compared to the healthy controls.  
 
Examining any group-specific interactions between serum lipids and cortical 
measures, we found that OLZ-treated patients with higher HDL-C levels had thicker 
cortices in frontal, orbitofrontal, cingulate, occipital, and pericentral regions, as well as 
a thicker mean cortex (p < 0.05, uncorrected). However, only the pericentral region 





For the gray/white matter intensity contrast, a group-specific interaction with LDL-C 
for occipital lobe contrast was observed, where higher LDL-C levels were associated 
with higher intensity contrast in OLZ users specifically (p < 0.05, uncorrected). 
However, this interaction did not remain significant after corrections for multiple 
comparisons were applied (p > 0.05, corrected). 
 
The group effects, concerning cortical measures, found in the main analyses remained 
significant when controlling for potential confounders, including ethnicity, education, 
DUP, illness duration, and positive symptoms (p < 0.05, uncorrected). Moreover, the 
HDL-interaction with cortical thickness demonstrated in the main analysis, remained 
significant when controlling for BMI, positive and negative symptoms (p < 0.05, 
uncorrected).  
 
In conclusion, the cortical gray/white matter intensity contrast was found to be similar 
among users of the SGA OLZ and the healthy controls, suggesting comparable cortical 
myelin content. Despite the general thinning of the cortex in the OLZ users, there was 
a moderating effect of HDL-C on cortical thickness, which may indicate a lipid-related 
increment in cortical myelin among the OLZ users. 
 
6. DISCUSSION 
In the following sections, I will first discuss the main findings of each study (6.1), 
followed by a general discussion of our findings (6.2). Lastly, I will discuss 
methodological issues (6.3) and possible clinical and scientific implications of our 





6.1 DISCUSSION OF THE SPECIFIC STUDIES 
6.1.1 Study 1   
The link between HDL-C and negative symptoms 
The central finding from Study 1 was a specific link between HDL-C and negative 
symptoms, both at baseline and also after one year of antipsychotic drug treatment. To 
the best of my knowledge, there are no other comparable studies in FEP patients; there 
are however two studies in chronic schizophrenia populations, which report a link 




In one of these publications, Chen and colleagues 
184
 found that negative symptoms (as 
measured with the Scale for the Assessment of Negative Symptoms (SANS)) were 
positively related to change in HDL-C levels (and negatively related to change in TG 
levels) in antipsychotic-treated patients. These authors reasoned that negative 
symptoms might have a distinct lipid profile. While on the surface the positive 
association between HDL-C and negative symptoms may seem to conflict with our 
results, the sample in Chen’s study was different; the patients were chronic and treated 
for two years with different antipsychotic agents. HDL-C usually decreases with 
continued antipsychotic usage and also with multiple psychotic episodes 
113
, which 
could explain the positive correlation between negative baseline symptoms and 
subsequent change in HDL-C levels. Possible differences in the percentage of CLZ 
users between the studies, differences in ethnicity (Caucasian versus Asian) and other 
demographic variables (e.g., outpatients versus inpatients), as well as which negative 
symptoms are measured (e.g., PANSS negative subscores versus SANS scores) may 
additionally have contributed to the apparent differences in the link between HDL-C 
and negative symptoms.  
 
In our study, both serum HDL-C and negative symptoms decreased during the study 
period. As already outlined, several studies report of a decrease in serum HDL-C 
levels during antipsychotic drug treatment with an SGA drug 
150,160,229
, and SGAs are 






Still, in our study we found a significant inverse association between serum HDL-C 
and negative symptoms. At first glance, this may seem counterintuitive, but one 
possible reason for the disparity may be the differences between examining something 
at a group level contra an individual level. 
 
 We found that while on a group level the mean HDL-C decreased amongst the FEP 
patients, on an individual level, 46% experienced an increase in HDL-C levels after 
antipsychotic treatment. This indicates that both increases and decreases may occur at 
the individual level, being “hidden” within the mean levels of the group. Indeed, there 
may be a subgroup of individuals who experience an increase in HDL-C even during 
treatment with an SGA. For example, Wirshing et al. 
230
 found that treatment with 
risperidone resulted in an increase in mean HDL-C levels by 5% and minimum HDL-
C levels by 11%. In our FEP sample, the patients whose HDL-C levels increased did 
not differ from those who experienced a decrease concerning sociodemographic, 
lifestyle- or illness-related factors, except for reporting higher alcohol consumption at 
12 months. It is, however, unlikely that the increase in HDL-C levels may be solely 
due to higher alcohol consumption as there was no significant increase in alcohol use 
during the follow-up period.  
 
While we did not assess medication side effects in details, which could be linked to 
secondary negative symptoms as previously delineated, we used the five-factorial 
PANSS (instead of PANSS three-scale), which is more specific to the various 
symptom dimensions in psychosis, differentiating better between general symptoms 
and more secondary negative symptoms due to antipsychotic drug treatment. 
Additionally, we controlled for antipsychotic usage (continuously versus intermittent 
use) to see if the symptom trajectory differed, as using medication continuously is 
more likely to cause adverse side effects than intermittent use. Our results indicated 
that whether one uses antipsychotics continuously or intermittently had a limited effect 





As studies indicate that concomitant positive symptoms may lead to periods of 
hospitalization and social isolation – both of which are circumstances that might evoke 
secondary negative symptoms 
11
 – we controlled for positive symptoms in the post-hoc 
analyses, obtaining similar results as in our main analyses. Moreover, as depressive 
symptoms may sometimes disguise themselves as negative symptoms (i.e., secondary 
negative symptoms), we also controlled for this in the post-hoc analyses, again 
obtaining similar results as in our main analyses. These additional analyses may 
denote that the link between HDL-C and negative symptom improvement could reflect 
an improvement not only in secondary symptoms but perhaps also to some extent in 
primary negative symptoms. Remembering that negative symptoms may be related to 
impairment in myelin 
55–57
 and that myelin primarily consists of lipids 
129
, it may be 
possible that increasing availability of HDL-C could be beneficial in improving 
negative symptoms by addressing the myelin deficits. The possible link between HDL-
C, myelin, and psychosis is further discussed under “General discussion” (see below). 
 
While a link between HDL-C levels and reduction in negative symptoms conveyed via 
myelination may be intriguing, the observed link between HDL-C and PANSS 
negative subscores could also represent an indirect effect of successful treatment that 
reduces the negative symptoms, leading to subsequent changes in lifestyle and diet, 
and improving HDL-C levels. A recent study by Jakobsen et al. 
231
 may support such 
an interpretation; they found that negative symptoms at baseline were associated with 
worse metabolic outcomes including higher BMI values and lower HDL-C levels in 
their two-year follow-up study of antipsychotic-treated patients with schizophrenia. 
The authors argued that negative symptoms, with apathy and avolition, might have led 
to inadequate diet and cardiorespiratory fitness and consequently to higher BMI and 
lower levels of HDL-C.  
 
In our study, patients who experienced an increase in HDL-C had more pronounced 
negative symptoms at baseline. Moreover, there was a link between higher HDL-C 
levels and lower negative symptoms at baseline, implying that having a higher HDL-C 




our studies were also receiving standard treatment according to recent guidelines. The 
clinical changes were thus not due to a different quality of treatment. In addition, as 
the Norwegian outpatient clinics and the hospitals are mostly government-sponsored 
and catchment area based, the socioeconomic difference is unlikely to explain the 
displayed changes in serum HDL-C levels and negative symptoms. 
 
As mentioned in the Introduction section 2.2.3, most prior studies have found an 
association between an increase in serum TG levels and a reduction in positive 
symptoms during treatment with antipsychotics 
159,183,232
. It is therefore relevant to 
discuss why we did not find a similar link to positive symptoms in our FEP sample. 
One possible explanation is that most prior studies were performed on chronic patients 
treated with CLZ, an antipsychotic agent with known TG increasing potential. In our 
relatively young sample, there were only three CLZ users (Studies 1 and 2 see 
Appendix Table 1). Differences in the number of patients using antidepressants may 
also have affected the results, as antidepressants can also increase TG levels 
233
, 
although their effect on positive symptoms is disputed. None of our patients were 
using medications for dyslipidemia (nor diabetes); hence, the lack of significant 
increase in TG was not due to such medications. Lastly, it is essential to acknowledge 
the differences in the PANSS three-scale versus the five-factorial PANSS that we 
used. The five-factorial PANSS has shown to be more specific to the various symptom 
dimensions in psychosis.  
 
6.1.2 Study 2 
A link between HDL-C and verbal learning 
The main finding of Study 2 was the positive association between serum HDL-C and 
verbal learning, which is in line with two prior studies in chronic patients 
185,234
. 
Lancon et al. 
185
 established a link between HDL and verbal learning and memory in a 
cross-sectional sample of chronic schizophrenia patients. Lindenmayer 
234
 and 
colleagues found that HDL-C levels were positively associated with scores on 




schizoaffective disorder. Notably, in the latter study, the authors also reported that 
higher levels of TG were associated with lower scores on attention/vigilance.  
 
Our study, however, is the first to report on an association between HDL-C and 
cognition in a cohort of FEP patients with limited prior antipsychotic drug exposure 
while controlling for practice effect. The young age amongst our patients and the lack 
of long-lasting effects of poor lifestyle choices and multi-pharmacy is a major strength 
of the study as it may be easier to differentiate illness chronicity from treatment 
effects.  
 
That being said, an important follow-up question is why a similar link was not 
demonstrated amongst the healthy controls. One plausible explanation is that there 
may be higher interindividual variability in brain structures, cognitive measures, and 
metabolic measures between patients with schizophrenia than between healthy 
controls, increasing the probability of detecting statistical relationships. In support of 
this, DTI studies have shown that neurocognitive functioning may correlate with 
impaired connectivity in patients with schizophrenia but not in healthy controls 
235
. 
Unfortunately, due to our study design and sample composition, we cannot determine 
whether any differences in interindividual variability between patients and healthy 
controls are due to intrinsic factors or extrinsic factors such as antipsychotic drug 
treatment. 
 
As pointed out in the Result section of Study 2, there was a significant decline in 
verbal fluency in FEP patients compared to the healthy controls, but no links to serum 
lipids were uncovered. It is possible that the relative decline may be partly due to an 
improvement in the control group, whereas patients with schizophrenia may not have 
shown any improvement 
236
. Alternative explanations may include that the subgroup of 
patients who declined, might have struggled with higher symptom load with more 
positive symptoms such as hallucinations, and also experienced more negative 
symptoms with secondary effects on cognitive processes 
237




consider the possibility that verbal fluency is not similarly linked to lipid metabolism 
as verbal learning.  
 
Brain structures such as the hippocampus express high transcript levels of lipid 
biosynthesizing enzymes 
129
, are densely populated by synapses, and play a prominent 
role in verbal learning and memory 
238,239
. Several studies have found a link between 
performance on verbal learning and hippocampal volume 
240,241
. More importantly, 
there is evidence in the normal aging population and patients with neuropsychiatric 
disorders, which points to high serum HDL-C levels, in particular, being protective 
against hippocampal atrophy 
242
. This dependency of the hippocampus on intact 
cholesterol metabolism could at least in parts explain our finding of a distinct link 
between HDL-C and the hippocampus-based task of verbal learning. 
 
As we found in the same FEP population a link between HDL and negative symptoms, 
and existing literature indicates a mild to moderate correlation between negative 
symptoms and cognition 
27
, and more specifically to verbal learning 
29,237
, we adjusted 
for negative symptoms in the post-hoc analyses while arriving at the same conclusion: 
a link between HDL-C and verbal learning.  
 
Some of the inconsistencies in prior studies, pertaining to the nature of the relationship 
between negative symptoms and cognition, may be related to differences in 
methodology. The definitions and instruments used to assess negative and cognitive 
symptom constructs could be a source of significant variability. For example, the 
SANS or the original negative scale of the PANSS 
212
 include items which may be 
closer to cognitive dysfunction than to negative symptoms, thus producing some 
measurement overlap 
243
.  In contrast, factorial analyses carried out in the last decades 
have generally yielded five-factorial constructs for the PANSS, which include a 
“Cognitive/Disorganized factor,” as well as a “Negative PANSS factor” with a more 
restricted composition than the original PANSS negative scale. We employed the five 





Combined, our results may suggest related but partly independent mechanisms behind 
cognitive deficits and negative symptoms in schizophrenia 29. On the latter note, there 
are some newer studies which indicate disturbances in lipid metabolism as a plausible 
denominator for both these disease components 
56,103,244,245
. We found that the effect of 
HDL levels on verbal learning was more than that of negative symptoms on verbal 
learning, as indicated by a larger standardized beta coefficient.  
 
6.1.3 Study 3 
Cortical thinning 
In Study 3, we observed a general cortical thinning (i.e., a reduction in mean cortical 
thickness) in OLZ-treated patients, but with specific regions located in frontal and 
temporal lobes showing more significant thinning 
246
. Prior studies have reported of 
both a general cortical thinning in schizophrenia 
247,248





Contrary to our initial expectations, it was the OLZ-treated patients in our sample, and 
not the unmedicated patients, who exhibited a significant cortical thinning compared 
to the healthy controls. Negative findings have been reported in other studies with 
small sample sizes 
250,251
. Thus, we could have lacked sufficient power in our 
unmedicated sample as it consisted of only 19 patients. Still examining the mean 
values, the unmedicated patients were more or less similar to the healthy controls.  
 
An alternative explanation may, therefore, be that the exhibited cortical thinning in the 
OLZ-treated group and the seemingly "normal" cortical thickness in the unmedicated 
group could be due to the MRI techniques applied in our study, which cannot 
differentiate pathologies in the cellular layers of the cortex. Along this line of thought, 
glial proliferation, a general marker for neuronal loss in neurodegenerative diseases, 
has not been found in the brains of patients with schizophrenia, and neuronal cell 
numbers appear to be similar in patients and healthy controls 
252
, indicating that 





The clinical correlates of the detected brain changes following antipsychotic drug 
treatment are yet to be studied in depth 
253–255
. In our sample, the OLZ group had 
significantly thinner cortices, but it was the unmedicated patients who experienced a 
higher positive symptom load. Perhaps shedding some light on this matter are studies 
that demonstrate thicker cortices in patients in non-remission compared to those who 
are in remission 
256
. One may therefore wonder whether the apparently “normal” 
cortical thicknesses in the unmedicated group could dissimulate illness severity.  
 
Increased anisotropy has, for instance, been reported in patients experiencing 
hallucinations compared to healthy controls and other patients without active 
hallucinations 
257
. This might also open up for the possibility that dynamic changes 
wherein increases in signals from myelin-related structures might reflect reactive 
processes of the disease such as swelling of myelin or remodeling of connections 
associated with psychosis 
258
. Given the foregoing, we found a nominally increased 
gray/white matter intensity contrast (possibly suggesting impaired intracortical 
myelination) along with higher positive symptoms in the unmedicated patient group. 
 
Gray/white matter intensity contrast  
As already mentioned, we found that the OLZ-treated patients had comparable 
gray/white matter intensity contrast to the healthy controls. While the unmedicated 
patients did not differ significantly from the healthy controls, their contrast measures 
were nominally higher than those for OLZ and healthy controls. In a larger sample 
(including our patients) Jørgensen et al.
259
 found increased gray/white matter contrast 
in sensory and motor regions of the cortex in patients with schizophrenia compared to 
healthy controls. The regions showing differences were found to overlap with heavily 
myelinated regions of the cerebral cortex as evidenced by both MRI-based myelin 
maps and post-mortem studies 
260
. Since signal intensity in both gray and white matter 
is closely related to myelin content, the gray/white-matter intensity contrast, although 
not a direct measure of myelin, could, in theory, reflect illness-related alterations of 




could be a result of lower gray matter signal intensity indicative of reduced 
intracortical myelin.   
 
Contrary to our findings, Kong et al. 
261
 reported decreased gray/white matter contrast 
in frontal, temporal, and parietal regions in patients with schizophrenia. One possible 
explanation for the discrepancy in the findings may be that Kong et al. 
261
 recruited 
older inpatients (48 years) with longer duration of illness (25 years), and the sample 
sizes differed considerably. Additionally, they did not include an unmedicated group 
nor examine the specific effects of one antipsychotic agent. In particular, the influence 
of aging is essential to consider, since increasing age correlates with tissue contrast 





It is, furthermore, essential to mention that we cannot exclude the probability that an 
intense regional thinning of the cortex might have impacted the computation of gray 
matter intensity values, as there was a partial correlation (adjusted for age and gender) 
between thickness and contrast. Nonetheless, the strength of these correlations was 
weak, which may suggest some biological independence between the two cortical 
measures.  
 
A link between serum lipids and cortical measures  
Our second aim in Study 3 was to examine if there was a group dependent serum lipid 
interaction effect with cortical measures. The results indicated an OLZ-specific 
interaction with HDL-C for cortical thickness pertaining to pericentral regions, which 
also remained significant after correcting for multiple comparisons and testing for a 
range of other potential confounders. Similar findings were also demonstrated in the 
cortices mean, frontal, orbitofrontal, cingulate, occipital, and pericentral regions (p < 
0.05, uncorrected).  
 
There are some prior studies, which have demonstrated cortical thinning in the 




prefrontal cortex in patients with negative symptoms; proposing that such cortical 
thinning may reflect underlying abnormalities in the cytoarchitecture in schizophrenia 
263,264
. As already stated, in our study it was the OLZ users who displayed a thinning of 
their cortices (including in the areas near auditory cortex and the prefrontal cortex), 
but it was the unmedicated subjects as a group who reported a higher positive 
symptom load while no differences were found in negative symptoms between the two 
patient groups. One could, therefore, wonder as to whether thicker cortices in OLZ 
users with higher levels of HDL-C could represent a subgroup with less psychotic 
symptoms (hallucinations) possibly related to improved myelination; unfortunately, 
we lacked sufficient statistical power to perform such subgroup analyses.  
 
As outlined in the Introduction sections 2.2.2 and 2.2.4.2, a growing body of evidence 
points to OLZ (and other antipsychotics) inducing lipid biosynthesis 
107,203,265
 and also 
up-regulation of cholesterol transport proteins 
265
. It is further established that 
cholesterol is crucial for developing and maintaining lipid-rich brain structures, such 
as the myelin and for proper neuronal cell communication 
118,119
. Thus, one 
interpretation of our results may be that the specific link between serum HDL-C and 
increased cortical thickness during OLZ treatment reflects increased intracortical 
myelin related to the increased availability of specific lipid fractions 
266
. In further 
support of such an idea, certain SGAs have been found to ameliorate the loss of gray 
matter in patients in the early stages of schizophrenia 
96,98
, and several studies from 
Bartizokis’ research group have provided evidence of increased myelin (including 
intracortical myelin) during treatment with SGAs (risperidone) 
104,135,267
. Changes in 
body cholesterol balances have, likewise, been shown to alter myelin integrity 
268
. Last 
but not least, a similar HDL-C x cortical thickness interaction was not observed 
amongst the healthy controls (indicating that it was not an overall improvement in 
myelin by some other means) or in the unmedicated group (indicating that the 
improvement was not solely related to patient status) giving additional support to an 





6.2 GENERAL DISCUSSION 
6.2.1 Is it the body weight or serum lipids that are related to clinical outcomes? 
Several studies have pointed towards a link between antipsychotic-related adverse 
metabolic effects, such as weight gain, and improvement in positive and overall 
psychotic symptoms 
174,176,177,269
. Even though almost two-thirds of our patients 
experienced an increase in BMI, there were no significant associations between weight 
gain and improvement in positive or negative symptoms of schizophrenia. A similar 
lack of association has also been reported elsewhere in the literature for some SGAs 
270,271
, including in patients treated with a metabolically potent drug such as CLZ 
272
. 
Hence, our results do call into question the view that weight gain is a “necessary evil” 




Also, other parts of the literature indicate that weight gain is not a “necessary evil”. 
For example, obesity and metabolic syndrome in the general population, as well as in 
schizophrenia, is related to impaired cognition and functioning 
234,273
. Moreover, 
lifestyle modification with weight gain prevention in patients treated with an SGA 
drug has not led to detrimental effects on psychopathology 
274
. Also, switching 
strategies from high-risk metabolically potent antipsychotic to a low-risk agent has not 
unequivocally demonstrated an increased risk of clinical deterioration 
275,276
. Finally, 
those who spontaneously recover have not shown a consistent link between recovery 
and weight gain 
159,175
. One possible reason for the inconsistency in the literature may 
be due to a third variable effect. In our studies, we observed a BMI-independent link 
between serum HDL-C and outcome measures.  
 
6.2.2 What does the link between serum HDL-C and symptom change imply?  
In our two FEP cohorts, we found a link between an increase in serum HDL-C and 
clinical improvement, with a reduction in negative symptoms and an improvement in 
verbal learning. In Study 3, moreover, we found a link between HDL-C and thicker 
cortices possibly indicating increased intracortical myelination. While the causality 








Figure 4. A link between HDL-C and improvement in psychotic symptoms.  
 
 
Examining the above relationship (Figure 4), one way of looking at it may be that 
having higher HDL-C levels per se is associated with a lesser symptom load. In 
support of this, higher levels of HDL-C have been linked to less transitioning to 
psychosis in high-risk patients 
277
, and a worsening of HDL-C levels has been 




Figure 4 could also be interpreted this way: increasing HDL-C levels by any means 
might be beneficial for psychotic symptom relief. Supporting such a notion, studies are 
reporting that improving diet, by for instance regular intake of fish oil or other 
substrates that may improve lipid profile, could be related to better cognitive 
performance 
278
 and to a reduction in psychotic symptoms in general 
279
. Nonetheless, 





Along with an improvement in diet, exercise is often recommended for patients with 
dyslipidemia. Exercise therapy as an add-on to other treatment options in patients with 
psychotic disorders has demonstrated beneficial effects on brain structures, 
improvement in cognitive performance, and overall psychotic symptoms (for a review 
see 
282,283




improvements in our studies may be related to such lifestyle improvements, we did 
control for diet and exercise in the post-hoc analyses. Our results indicate that the 
association between HDL-C and clinical improvements were independent of such 
factors. 
 
Also, less favorable lifestyle choices such as increased alcohol consumption have by 
some been found to increase serum HDL-C levels 
284
, and there are even studies that 
report a reduction in negative symptoms with alcohol intake 
285
. While the latter 
possibility may seem intriguing to some, it is most likely linked to a reduction in 
secondary negative symptoms such as anxiety. It is also important to remember that 
increased alcohol consumption has not been related to improved cognitive 
performances; on the contrary, it has often been associated with poorer performances 
on cognitive tasks 
286,287
. As a final note, in regards to alcohol, we controlled for 
alcohol use in Studies 1 and 2 without finding any significant effect on the observed 
link between HDL-C and outcome measures. 
 
Other important aspects to consider is the possible bi-directionality of the HDL-C 
association witnessed in our studies as our results are based on regression analyses 
where directionality cannot be determined (Figure 5).  
 





For example, the observed links between HDL-C and negative symptoms and verbal 




psychotic symptoms, leading to subsequent changes in lifestyle and diet while 
improving HDL-C levels (Figure 5). The study by Jakobsen 
231
 mentioned in section 
6.1.1 may support such an interpretation. Still, if clinical improvements were to be 
significant determinants of the HDL-C increase, than patients in remission or recovery 
would be expected to have higher HDL-C levels. In our studies, there were no 
significant differences between the patients who were in remission versus those in 
non-remission with regards to their HDL-C levels. Besides, when controlling for 
remission status in the post-hoc analyses, we could not find any significant impact on 
the observed link between HDL-C and our outcome measures. 
 
How does antipsychotic drug treatment fi t into the puzzle? 
 
Possibility 1:  
As described in the Introduction section 2.2.2, most studies report an increase in LDL-
C and TG levels during antipsychotic drug treatment, but the effects on HDL-C have 
been less uniform. Additionally, in the majority of psychotic patients and especially in 
patients with limited prior drug exposure (e.g., FEP), antipsychotics have been found 
to be highly effective 
63
. Hence, one possible explanation for the observed link 
between HDL-C and clinical improvement during antipsychotic drug treatment may be 
that antipsychotic drugs could cause both lipid changes and therapeutic benefits by 
independent pathways (Figure 6).  
 
Figure 6. Antipsychotic (AP)-related effects on psychotic symptoms and serum HDL-







A possible independency between the pathways could also imply that the therapeutic 
efficiency of antipsychotics might be due to mechanisms not necessarily related to 
lipid pathways. There have, for example, been some studies related to other lipid 
moieties, which have demonstrated a reduction of LDL-C, and/or TG levels during 
lipid-lowering medications without deterioration in psychotic symptoms. The effects 
of lipid-lowering medications on HDL-C are, however, poorly understood 
288
, but in 
clinical practice there seems to be little effect of these medications on serum HDL-C 
levels.  
 
Possibility 2:  
As reviewed in the Introduction sections 1.1.6 and 2.2.1, compelling evidence from 
different lines of research has implicated dysfunctional myelin and oligodendrocytes 
(i.e., the cells responsible for wrapping myelin around neuronal axons in the brain) in 
the pathology of schizophrenia and related psychotic disorders 
103,130
. Myelin is 
essential for controlling and regulating conduction velocities along axons and thus the 





The effect of antipsychotics on myelin structures has been increasingly studied in 
recent times. In a DTI study of schizophrenia patients in exacerbation, Garver et al. 
258
 
found increased diffusibility consistent with decreased myelin integrity during acute 
psychosis. After four weeks of treatment with the SGAs risperidone or ziprasidone, or 
the FGA haloperidol, they observed a partial restoration of myelin integrity in the 
subgroup that responded to treatment. Others, such as Bartzokis et al. 
267
, have 
demonstrated higher volumes of intracortical myelin in schizophrenia patients treated 
with oral risperidone than in those treated with the FGA fluphenazine decanoate.  
 
A recent study by Tishler et al. 
290
 examined 93 patients with schizophrenia treated 




control subjects. They found that the relationship between the length of exposure to 
SGAs and intracortical myelin was positive during the first year of treatment, but was 
subsequently negative. The authors hypothesized that such intracortical myelin 
trajectory might agree with the “clinically observed antipsychotic response trajectory 
with high rates of remission in the first year followed by progressively lower response 
rates.” They further argued that as postmortem evidence implicates intracortical 
myelin deficits in schizophrenia pathophysiology, “correcting these deficits may be an 
important mechanism of action for antipsychotics.”  
 
As noted earlier, myelin consists primarily of lipids (particularly cholesterol), 
synthesized mainly de novo in the brain. Interestingly, several studies (both in vitro 
cell studies, in vivo animal and human studies) indicate that antipsychotics drugs could 
induce lipogenesis directly through activation of SREBP (for an overview see 
123
) and 





Revisiting the result from Study 1, we observed a significant link between the increase 
in HDL-C levels and improvement in negative symptoms during antipsychotic drug 
treatment. Additionally, though a comparable number of healthy controls and FEP 
patients experienced an increase in serum HDL-C levels, it was only amongst the FEP 
patients that an association between HDL-C levels and verbal learning was exhibited 
(Study 2). Moreover, in Study 3, we found an OLZ-specific link between higher serum 
HDL-C levels and thicker cortices, possibly related to increased intracortical myelin, 
which was not evidenced in the unmedicated patients or the healthy controls. Hence, 
an interesting (though speculative) way of interpreting our results is that antipsychotic 
drugs by inducing lipid pathways that increase the availability of certain lipid fractions 
in the brain, 
107,230
 may aid in “correcting” the defective myelin in schizophrenia, 
facilitating symptom relief (Figure 7).  
 
The latter view could also imply that antipsychotic drugs cause lipid changes and 




may be necessary for the therapeutic efficacy. Indeed, animal studies depict myelin-
protecting and also oligodendrocyte- stimulating properties as therapeutically relevant 
mechanisms of antipsychotic drug action 
291,292
. Moreover, studies in schizophrenia 
patients have repeatedly demonstrated a correlation between the increase in serum 
lipid levels during antipsychotic drug treatment and clinical improvements 
69,159,183
, 
with differences in the effectiveness of antipsychotic drugs being reliant on their 
ability to induce metabolic changes.  
 
Lastly, as mentioned in the Introduction, cholesterols are key components of lipid rafts 
in the cell membrane. These lipid rafts are essential for proper signal transduction and 
cell communication 
293
. While there are several studies that have indicated a 
dysfunctional cell membrane in patients with schizophrenia (section 2.2.1), there are 
also some authors who describe a "normalizing" effect of antipsychotics on the 




Seen together, these findings may point to a shared lipid-related mechanism by which 
antipsychotics achieve their therapeutic properties 
107,203,295
 (Figure 7). Further 
substantiating such a view is the fact that increased availability of cholesterols, 
especially HDL-C, has been related to improved synaptic plasticity and vesicle 
formation 
296,297
 (crucial for neuronal communication) and also to increment of 
hippocampal structures (important in memory and learning tasks). 
 
 
Figure 7.  Hypothesized mechanism for antipsychotic (AP) therapeutic effect. An 
antipsychotic drug-induced activation of lipid biosynthesis in glial cells may increase 











6.2.4 Representativeness of the FEP sample in light of the observed changes in 
lipids and clinical symptoms 
 
Changes in serum lipids during follow-up 
As reviewed in the Introduction, section 2.2.2, previous literature has often reported an 
increase in TG and LDL-C levels especially during treatment with an SGA 
298,299
, and 
more so in FEP patients with limited prior drug exposure 
165,300
. In our sample, there 
were no significant changes at a group level in serum total cholesterol or LDL-C, but 
there was a trend-wise increase in TG levels. While the lack of significant changes in 
serum TG, LDL-C, and total cholesterol during the one year on antipsychotic 
medication may question the representativeness of our FEP sample, there are similar 
studies in FEP patients which report non-significant changes in serum lipids during 
antipsychotic drug treatment 
301




One may be that we had only two time-points, but TG and other serum lipids are likely 
to fluctuate during the one-year follow-up. Added to the fact that our patients had 
considerable antipsychotic switching during the follow-up period, this may have 
“neutralized” some of the initial serum lipid changes. 
 
Changes in positive and negative symptoms during follow-up 
In accordance with previous literature (Introduction section 2.1.2), there was a 
reduction in positive and negative symptoms over the first year of antipsychotic drug 
treatment 
302,303
 where the decline in negative symptoms was quantitatively less than 
for positive symptoms 
302,303
. While the general view has been that negative symptoms 
are “stable” in the non-acute phase of the disorder 
11
, a recent meta-analysis found that 
negative symptoms may improve over time in outpatients with schizophrenia 
304
. One 
possible reason for the different results in the clinical course of negative symptoms 
may be due to methodological issues. For instance, there are differences in the 
assessment tool concerning which negative symptoms that are measured. Also, the 
timeline may be different: the PANSS assesses the symptoms of the previous week; 
while the SANS assesses symptoms of the last month. Still, the improvements in 
negative symptoms found in our study and in the aforementioned meta-analysis 
304
 
may imply a greater potential for treatment responsiveness than previously anticipated. 
 
Baseline cognitive deficits and changes during follow-up 
Following previous literature on patients with an FEP, our patients showed generalized 
cognitive deficits 
305,306
. While the majority of prior studies have found a stable course 
for the cognitive impairments 
23,24
, we found that verbal learning improved amongst 
the FEP in comparison to the healthy controls. Also, other studies of patients early in 
their illness course have reported cognitive changes during the study periods; both 




One possible reason for the conflicting results is that different cognitive domains are 
perhaps measured or summarized to composite scores, which may, in theory, give rise 
to different trajectories. For instance, Barder et al. 
309




impulsivity, and working memory did not change over the study period (up to five 
years), suggesting “stability,” while motor speed and verbal learning displayed trends 
towards significant decline. This introduces some nuance to the picture of cognitive 
stability. Also, in support of distinguishable cognitive trajectories, pharmacological 
interventions studies have reported specific effects on different cognitive domains (see 
Introduction section 2.1.2) designating a pharmacological dissociation of certain 
groups of cognitive processes. In our study, none of the patients were using 
medications for diabetes or dyslipidemia, nor did they have any known heart diseases 
or diabetes, which in theory could have affected the brain circulation and functioning, 
including cognitive performance.  
 
6.3 METHODOLOGICAL ASPECTS: STRENGTHS AND LIMITATIONS  
6.3.1 Study design and clinical sample 
6.3.1.1 Naturalistic study design 
The three studies encompassing this doctoral thesis are of naturalistic study design, 
permitting us to gather information on a representative sample of individuals receiving 
“treatment as usual.” A significant limitation with naturalistic designs, in general, is 
that we cannot rule out that confounding factors not taken into account might influence 
the associations presented.  
 
6.3.1.2 Sample size and subgroups 
We chose to include a broader diagnostic spectrum, i.e., patients with FEP not limited 
to first-episode schizophrenia. One benefit of such broader inclusion is that it increases 
the number of participants and thereby the statistical power. Nevertheless, there are 
some disadvantages also: when patient subgroups with more severe or less severe 
disease are included in the same sample; pronounced variation may blur important 
associations. We tried to address this issue by focusing on symptom-specific outcomes 




part of a longitudinal study, information on diagnosis from the one-year follow-up 
visits was used to ensure some temporal stability. 
 
For study 3, there were some additional concerns regarding the sample sizes within 
each group, and we cannot exclude that the analyses may have been underpowered to 
detect all real group differences. Still, the post-hoc-power analyses using G*Power 
showed that there were enough subjects within the different groups to find moderate to 
strong associations, but perhaps not to find weaker associations. 
 
6.3.1.3 Possible selection biases  
Participation in the project required the ability to give informed consent and to co-
operate during clinical interviews and MRI scanning. Thus, the most severely ill 
patients would likely decline participation, or they may not be capable of completing 
the inclusion procedures. As the main bulk of inclusion took place in outpatient 
clinics, this could also bias the sample towards subjects with more factors promoting 
treatment adherence (e.g., having positive attitudes towards the treatment and its 
necessity). On the other hand, it is a well-known fact that a proportion of patients 
referred to further treatment in outpatient clinics from in-patient wards may fail to 
follow treatment and are therefore not recruited in the studies.  
 
It is also likely that severely ill patients may be on more extensive antipsychotic 
regimes (which is more likely to increase TG and LDL-C levels) but due to the clinical 
situation, they may be non-compliant to a blood test and therefore not be included in 
the lipid analyses. This may have resulted in us “missing” possible associations 
between TG and LDL-C and clinical outcomes. 
 
A particular concern with the patient samples in Study 3 was that the unmedicated 
group might have consisted of psychiatrically stable outpatients who either refused to 
take medication or were off medication for unknown reasons, thereby denoting that the 




Future studies should, therefore, seek to better control for factors behind being 
unmedicated, including psychosocial determinants.  
 
Finally, healthy controls were recruited by sending letters of invitation to a randomly 
drawn sample from the National Registry in Norway. There is likely to be some bias 
among the individuals who decided to participate (e.g., having higher education), 
resulting in a control sample not fully representative of the general population. Even 
so, we had age and gender-matched healthy controls in Study 2, and all healthy 
controls (in Study 2 and 3) were recruited from the general population of the same 
geographical and socio-cultural area and within a limited time-span. This procedure 
should limit falsely enlarged differences between patients and controls due to temporal 
trends, such as more overweight and metabolic disturbances in the overall population. 
 
6.3.2 Issues related to antipsychotic drug treatment 
6.3.2.1 Drug naïve patients 
The studies included in this thesis (Studies 1 and 2) involved patients with limited 
prior drug exposure. Still, some antipsychotic-induced metabolic changes, especially 
weight gain could, in theory, have occurred before inclusion by the way we defined 
our FEP sample as not previously having received adequate treatment for psychosis. 
Adequate treatment was demarcated as antipsychotic medication in doses over 1 DDD 
for < 12 weeks or shorter if this treatment was followed by symptomatic remission.  
 
6.3.2.2 Antipsychotic switching  
There was a considerable amount of switching of antipsychotic medication in the two 
cohort studies (see Appendix Table 1). Thus, it is possible that patients who 
experienced weight gain or dyslipidemias switched to more metabolically neutral 
agents during the study period, reducing or reversing the initial metabolic effects. 
Having several time points between baseline and the one-year follow-up could have 
provided a better overview of these effects. Likewise, the remaining FEP patients at 12 




metabolic side effects, in particular weight gain, which is a known cause for 
discontinuation of treatment 
310
. Having said that, it is reassuring that the FEP 
(independent of the specific antipsychotic agent), were not statistically different from 
the age and gender-matched healthy controls at baseline; yet, they experienced a 
significant increase in BMI compared to the controls (Study 2), and that a considerable 
proportion (39%) experienced a clinically significant increase in BMI, i.e., ≥ 7% of 




In order to tackle some of the issues concerning antipsychotic drug switches, we 
merged the exposure to different antipsychotic drug types into a dichotomized variable 
(continuous use versus intermittent use). While it may be suboptimal, all naturalistic 
studies face this dilemma and to achieve sufficient statistical power; instrumental 
groupings are often needed. We did not group the treatment variable in the general 
matter of FGA versus SGA since all patients using FGA also used SGA. Grouping 
patients according to whether they used a metabolically potent drug (e.g., OLZ) or 
more metabolically neutral drugs also proved to be difficult due to vast switching 
between the drugs, and to insufficient subject numbers in each group. Also, in our 
cohort studies we were primarily interested in the serum lipid changes per se with 
relations to outcome measures, and not necessarily in relations to a specific 
antipsychotic agent. Nonetheless, as there may be differences in the serum lipid levels 
between monotherapy and polypharmacy, we did adjust for this in the post-hoc 
analyses. The latter analyses, showed that whether one was receiving monotherapy or 
polypharmacy did not significantly impact the observed relationships between serum 
HDL-C levels and clinical outcomes, corroborating findings from other studies of 
which antipsychotic polypharmacy was not independently associated with the 







6.3.3 Issues related to clinical assessments 
6.3.3.1 Clinical data 
In the present thesis, we used standardized and widely accepted measures with good 
psychometric properties to study the phenomena at hand. Still, some aspects of 
assessment should be addressed. Assessments at baseline were not done before 
symptoms had stabilized. The consequence of this may be that the difference between 
the two assessment points on symptom level will be less, since patients may already be 
“stabilized” at the baseline assessment. On the other hand, it may also be considered as 
an advantage as it eliminates some of the acute phase changes, which is often “noise” 
in the statistical analyses. Furthermore, it is a well-known predicament that higher 
baseline psychopathology score may be associated with more significant improvement 
over time due to regression to the mean. In our sample, the initial PANSS scores were 
moderate, and we also adjusted for initial PANSS values by looking at the within-
subject changes from baseline.  
 
As indicated previously, negative symptoms are not a unitary construct but are made 
up of different symptoms. Different symptom scales, like the PANSS and SANS, 
differ on how they define the individual negative symptoms and what negative 
symptoms that are focused on and measured. This should be kept in mind when 
interpreting the results from Study 1, but also to some degree when interpreting the 
results in Study 2, as we adjusted for negative symptoms (i.e., PANSS negative 
subscores) in the post-hoc analyses.  
 
An additional issue, which researchers may encounter, is that it is hard to differentiate 
the primary negative symptoms, which are part of the disease process itself, from the 
secondary negative symptoms that arise as a result of e.g., depression, side effects of 
antipsychotic medication, or psychotic withdrawal 
16
. Being diagnosed with 
schizophrenia may in itself be an adverse life event causing stigma and functional 
impairments. Hence, the improvement in negative symptoms over the one-year follow-





6.3.3.2 Cognitive data 
Assessment of each cognitive domain was based on one neuropsychological subtest to 
restrict the number of statistical tests. Thus, we might have overlooked associations 
with other potentially relevant cognitive functions. It is, however, debatable whether 
the differences between the individual subtests are clinically meaningful as it is likely 
to be smaller differences between subtests than differences between tests developed 
entirely separate from each other (due to their co-norming on a single patient sample). 
In order to reduce the number of tests and outcome measures, some researches may 
choose to use summary scores. A contentious issue with such summary scores is that 
they may “hide” variations in the contributions of each test. We believe that by using 
single tests from widely used neuropsychological tests, it is easier to reproduce our 
findings and for comparing them across studies. 
 
We did not use the standardized Measurement and Treatment Research to Improve 
Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery due to the fact 
that it had not been translated to the Norwegian language when the TOP-study started. 
Nonetheless, the domains chosen to be tested were based on a previous study in an 
FEP population by our colleagues 
221
 and overlap with many of the domains measured 
by the MATRICS test battery 
313
. Still, it is essential to recognize that different 
cognitive tests, while testing the same domain, may give rise to different results.  
Also, natural variations, e.g., the mood that day, the medication used may have 
affected our results. Moreover, we cannot exclude the possibility that other biological 
parameters and subclinical disease may have confounded the observed associations. 
We did nevertheless try to reduce the influence of the factors mentioned above by 
controlling for concomitant changes in positive, negative and depressive symptoms, 
and also for BMI in our studies; obtaining comparable results as in our main finding 
(i.e., a link between serum HDL-C and verbal learning).  
 
An additional issue with Study 2 is that the controls were healthy, and could, in theory, 




to differences in the learning potential in the FEP and the healthy control group. While 
an untreated control group may have been ideal for addressing this matter, this is not 
always ethically advisable.  
 
6.3.3.3 Biological data  
All subjects were fasting on the day of blood sampling, which took place on the same 
day as the cognitive testing. Still, the serum lipid measures are “screenshots,” and it is 
possible that the patients during the 12-month period could have fluctuated in their 
serum lipids (Studies 1 and 2). It is also necessary to highlight that using blood as a 
proxy for the brain has limitations, and should be considered when drawing 
conclusions 
314
. Moreover, for the MRI study (Study 3) we set a limit of 3 months 
between blood sampling and brain scanning; still, we cannot be sure that the serum 
lipid levels are representative of the values measured on the day of brain scanning. In 
general, it is the serum TG levels that fluctuate the most, even on a day-to-day basis 
depending on the food intake and the composition of dietary intake. While the 
mechanism explaining the biological variation in serum lipid concentrations are not 
fully elucidated, they are most likely caused by intrinsic factors related to their 
biosynthesis and tissue use, as regulated by genetic factors, and their interactions with 
extrinsic factors. Tackling all of these problems in a naturalistic setting is, however, 
difficult.  
 
6.3.3.4 Subjective measuring of diet and exercise  
The assessment of self-rated diet and exercise (Studies 1 and 2) is associated with 
some challenges. For example, cognitive impairment may influence the ability to both 
remember and reflect on the statements regarding diet and exercise. On the other hand, 
social stigma and wanting to be perceived as healthy individuals may cause the 
participants to report a better diet and exercise than what may be the actual case. 
While it may not be feasible outside the confinement of an institution, more detailed 





6.3.4 Issues related to brain imaging  
Motion of the head is a potential confounder that could influence our findings in Study 
3, mainly because patient populations tend to have more head motion than healthy 
controls 
315
. While we did not measure motion during scan acquisition, all scans were 
visually inspected, and poor quality scans were removed. Future studies should, 
nonetheless, consider prospective motion corrections during scan acquisitions 
316
  
together with physical interventions (e.g., improved padding) to reduce actual motion.  
 
Patients and healthy control subjects were scanned concurrently, which limits the 
possibility of scanner drift over time, affecting the results. Also, there were no scanner 
hardware upgrades during the inclusion period. Nevertheless, there may be variability 
in how cortical structures are measured, leading to difficulties in the interpretation of 
findings across studies. In the present thesis, the commonly used FreeSurfer software 
was used to define the cortical region boundaries. This method sections brain regions 
into cortical regions delineated by reliable anatomical landmarks (gyri and sulci) and 
is considered anatomically valid 
247
. Employing a standardized procedure to retrieve 
brain regions of interest enables replication in future studies. 
 
Another issue pertaining more to the selected cortical measures is that while the 
reliability of regional cortical volumes and thickness measures as well as subcortical 
volumes has been examined in several studies; the reliability of the gray/white tissue 
intensity contrast has not been equally documented. Additionally, although the 
gray/white tissue intensity contrast may be sensitive to changes in myelin, it is 
important to bear in mind that they are not direct measures of myelination. Prior 
studies have, in general, employed DTI techniques to study myelin. However, DTI has 
limitations in identifying the exact nature of myelin changes as the FA may reflect 
different processes like myelination, axonal swelling, or atrophy, and is also sensitive 
to confounding effects of fiber crossings 
317
. To tackle some of these issues, 
Palaniyappan and colleagues 
318
   suggested combining DTI with myelin volume to 





Also, the effect of antipsychotic medication contra symptom fluctuation has to be 
studied in a well-characterized population before any firm conclusions can be made. 
Employing multimodal MRI could aid in this pursuit, e.g., by describing structural 
findings in terms of their relationship with other tissue properties, including diffusion 
properties. More reliable studies from non-medicated patients may also aid in this 
process. For future studies, we also suggest focusing on longitudinal designs for 
investigation of medication effects as such studies has the advantage of within-subject 
analyses.  
 
6.3.5 Statistical issues  
Attrition in longitudinal studies is common and hard to avoid altogether. If the final 
group no longer reflects the original sample, such attritions could endanger the validity 
of the study results. In order to check for variables missing at random, we used Little’s 
Missing Completely at Random (MCAR) test, which showed that variables were 
indeed missing at random - see the statistical sections in Studies 1 and 2. We also 
checked whether subjects lacking data differed in a significant manner from the ones 
with a full dataset concerning demography, the severity of symptoms, lifestyle or 
medication use, determining that there were no significant differences.  
 
The choice of statistical approaches used to minimize the effect of missing variables is 
equally important and could alter any findings markedly. We used linear mixed-effects 
models, which “tackles” data with a different number of repeated measurements for 
each subject 
319
. Other advantages of mixed-effects models in studies with repeated 
measures include: accounting for the correlation of repeated measures observations 
and any variability in the time between assessments for each subject. Moreover, time-




Another important aspect of statistical testing is the correction for multiple 
comparisons. This is necessary to avoid type I errors, i.e., detecting a group difference 
that is not present (false positive) as increasing the number of tests increases the 




The studies in this doctoral thesis were mostly hypothesis-driven, decreasing, in 
general, the number of statistical tests performed when investigating specific 
associations. For Study 3, however, we had three groups and multiple cortical regions, 
each with a possible link to a lipid; thus, correction for multiple comparisons was 
prudent. While the most common way of dealing with multiple testing is a Bonferroni-
correction where the critical p-value 0.05 is divided by the total number of tests, 
setting a new threshold for significance, such corrections are also known to be too 
stringent for many clinical settings. We, therefore, employed a repeated Benjamini-
Hochberg procedure, which also takes into consideration the dependency of the 
measures used (details are described in the Statistical section of Study 3). 
 
6.4 POSSIBLE CLINICAL AND SCIENTIFIC IMPLICATIONS 
Studies so far have identified negative symptoms and cognitive dysfunctions as unmet 
challenges in the treatment of schizophrenia, which should be prioritized, especially as 
they play a critical role in the functional decline observed in many individuals with 
schizophrenia. We, therefore, believe that the findings in this thesis are clinically 
relevant and that they may argue for using changes in serum HDL-C for monitoring 
treatment response in the first year of antipsychotic drug treatment, mainly as 
measuring serum lipids could easily be implemented in the daily clinical practice. 
Moreover, our findings of a specific HDL-C-related link to negative and cognitive 
symptoms advocates for exploiting specific lipid pathways with overlap to treatment 
response in developing more effective treatments in the future. The HDL-C 
association could also indicate a disease mechanism that may be amenable to other 
intervention by, e.g., increasing HDL-C levels as an add-on treatment for cognitive 
remediation. Exploring these possibilities in the right setting is highly warranted. 
Guidance and support in making healthy lifestyle modifications should also be an 
integral part of the treatment of psychiatric disorders as we found the HDL-C link to 
clinical improvement being independent of changes in BMI. As roughly one-fourth of 
the patients show only mild functional impairment after the first-episode of psychosis, 
identifying factors that may help to understand better outcomes may also improve 




relevant as the different contributing factors that are in play during the transition from 
normality to pathology will be present, and the danger of misinterpreting research 
findings due to chronicity, recall bias or the effects of long-term medication is 
reduced. The studies included in this thesis, further, indicate a need for more research 
on patients with similar longitudinal symptom courses above and beyond constricts of 
diagnostic categories. 
 
7. CONCLUSION AND FUTURE PERSPECTIVES 
7.1 Conclusion  
Prior to the current study, several papers in chronic patients with schizophrenia had 
already indicated a correlation between clinical improvement and adverse metabolic 
effects (weight gain and serum TG levels) during antipsychotic drug treatment. The 
present doctoral thesis is the first to uncover an antipsychotic-related HDL-C link to 
clinical improvement (negative symptoms and verbal learning) in patients with an 
FEP, and also supports the notion of an antipsychotic (OLZ)-related effect on cortical 
intensity contrast and a more specific HDL-C effect on cortical thickness suggestive of 
increased intracortical myelin. Our findings need to be replicated in future studies, and 
in particular, the impact of antipsychotic medication use on brain structure alterations 
needs to be clarified.  
 
7.2 Future perspectives 
While our understanding of the relationship between lipids and psychiatric disorders is 
increasing, there are still many unanswered questions that require further investigation: 
 
 One question is whether the association between serum lipid levels and clinical 
outcomes during antipsychotic drug treatment is a general feature of all 
antipsychotics used in the first year of treatment, or whether it is related to 




mediators that may be involved in the relationship between dyslipidemia and 
psychiatric disorders is also essential, and an RCT study design may aid in this 
request. 
 As studies show that there may be different facets and trajectories within the 
group of “negative symptoms” with potentially different origin, it may be 
interesting to investigate the individual symptom components and to examine 
any relations with changes in serum HDL-C (and other lipids) during 
antipsychotic drug treatment. 
 The question regarding the unique consequence of antipsychotic medications 
(including the potentially different role of FGAs and SGAs) in the progression 
of structural abnormalities should also be in focus in future neuroimaging 
studies. Here a longitudinal study design with multiple time points and a 
multimodal MRI approach may help in better understanding of the timing and 
progression as well as the meaning of changes in brain structures; making it 
possible to infer causality. 
 Additional studies, including other antipsychotic agents and more direct 
measures of intracortical myelin, are also needed before any firm conclusions 
can be made. Given the complex and capricious clinical features and cognitive 
impairments associated with psychotic disorders, it seems likely that numerous 
brain systems are involved to varying extents in different individuals. This 
could imply that different features of the disorder mirrors underlying 
disturbances of distinctive brain functions and moreover that these may cross 
current diagnostic boundaries. These considerations also entail that we could 
anticipate that novel treatments would target particular symptoms or groups of 
symptoms sharing common underlying mechanisms and that they will be 
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This table shows the psychotropic drugs used at baseline by the FEP patients.                   
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Background:A potential link between increase in total cholesterol and triglycerides and clinical improvement has
been observed during antipsychotic drug treatment in chronic schizophrenia patients, possibly due to drug re-
lated effects on lipid biosynthesis. We examinedwhether changes in serum lipids are associatedwith alleviation
of psychosis symptoms after one year of antipsychotic drug treatment in a cohort offirst-episode psychosis (FEP)
patients.
Methods: A total of 132 non-affective antipsychotic-treated FEP patients were included through the Norwegian
Thematically Organized Psychosis (TOP) project. Data on antipsychotic usage, serum lipids (total cholesterol,
high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides (TG)),
body mass index (BMI) and clinical state were obtained at baseline and after 12 months. The Positive and Neg-
ative Syndrome Scale (PANSS) was used to assess psychotic symptoms. Mixed-effects models were employed
to examine the relationship between serum lipids and psychotic symptoms while controlling for potential con-
founders including BMI.
Results: An increase in HDL during one year of antipsychotic treatment was associated with reduction in PANSS
negative subscores (B=−0.48, p= 0.03). This relationship was not affected by concurrent change in BMI (ad-
justed HDL: B=−0.54, p=0.02). No significant associationswere found between serum lipids, BMI and PANSS
positive subscores.
Conclusion:We found that an increase in HDL level during antipsychotic treatment is associated with improve-
ment in negative symptoms in FEP. These findings warrant further investigation to clarify the interaction be-
tween lipid pathways and psychosis.










Metabolic disturbances such as obesity and dyslipidemia are com-
mon in schizophrenia (Allison et al., 1999; Mitchell et al., 2013;
Vancampfort et al., 2013). Thesemetabolic abnormalitiesmay be caused
by environmental factors, but can also be intrinsic to the illness itself
(Mitchell et al., 2013; Vancampfort et al., 2013). Indeed, dyslipidemia
has been observed in antipsychotic-naive and in first-episode psychosis
(FEP) patients (Chen et al., 2013; De Hert et al., 2006; Enez Darcin et al.,
2014; Fleischhacker et al., 2013; Kaddurah-Daouk et al., 2012; Misiak et
al., 2016; Saari et al., 2004; Thakore, 2004; Verma et al., 2009;Wu et al.,
2013; Zhai et al., 2017). In linewith thesefindings, there is also evidence
of overlapping genetic markers between disturbed lipid metabolism
and schizophrenia (Andreassen et al., 2013). Additional findings of
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white matter abnormalities and reduced myelination in schizophrenia
(Bernstein et al., 2015; Davis et al., 2016; Mighdoll et al., 2015) also in-
dicate an involvement of lipids, as cholesterol is crucial for myelin for-
mation and functioning (Dietschy and Turley, 2004; Saher et al., 2005;
Verheijen et al., 2003).
Themetabolic effects ofmany antipsychotic drugs further illuminate
the possible link between lipid factors and schizophrenia. It is well
known that treatment with antipsychotics may lead to weight gain
and dyslipidemia (Goncalves et al., 2015; Musil et al., 2015; Young et
al., 2015). Weight gain, mainly caused by enhanced appetite and food
intake, may indirectly increase lipid levels, but it has also been shown
that dyslipidemia can occur independently of weight gain in antipsy-
chotic treated patients (Birkenaes et al., 2008; Lally et al., 2013;
Procyshyn et al., 2007). Although antipsychotic-related metabolic
changes have been associated with negative health consequences (De
Hert et al., 2011; Mitchell et al., 2013; Nasrallah et al., 2015;
Newcomer, 2005), there are also several studies that report a positive
link between treatment-related weight gain and improvement in psy-
chosis (Bai et al., 2006; Czobor et al., 2002; Gupta et al., 1999; Hermes
et al., 2011; Lamberti et al., 1992; Lane et al., 2003; Leadbetter et al.,
1992; Meltzer et al., 2003; Sharma et al., 2014). Similarly, treatment-re-
lated increases in serum triglycerides (TG) have been associated with
improvement in overall psychotic symptoms, and with a reduction in
positive symptoms (Atmaca et al., 2003; Lally et al., 2013; Pande et al.,
2002). There are also reports of an association between an increase in
TG and/or total cholesterol, and improvement in negative symptoms
(Chen et al., 2014; Procyshyn et al., 2007) and in cognitive symptoms
(Krakowski and Czobor, 2011). Recent advances in lipidomics research,
moreover, have linked changes in cell membrane lipid profiles to treat-
ment response, signifying the multifaceted role of lipids in psychosis
(Kaddurah-Daouk et al., 2012; Tessier et al., 2016). Nevertheless, thena-
ture of these associations is not fully clarified, as prior studies have
mainly involved chronic patients in whom the long-term effect of
poor lifestyle and multiple drug exposures may be difficult to
disentangle.
The main objective of the present study was to explore the relation-
ship between serum lipids and symptom relief in FEP patients during
their first year of antipsychotic treatment. Our main hypothesis was
that an increase in serum lipids during antipsychotic treatment would
be associated with improvement of psychosis-related symptoms, even
after controlling for potential confounders including changes in body
mass index (BMI). To test our hypothesis, we used data from a longitu-
dinal sample of FEP patientswhere data regarding serum lipids, BMI and
clinical state (i.e. positive and negative symptoms) at baseline and after
12 months of treatment were obtained.
2. Materials and methods
2.1. Study design
The present study is a prospective longitudinal study with a natural-
istic design, with patients recruited at their first treatment for a psy-
chotic disorder from inpatient and outpatient psychiatric units in the
catchment areas of the major hospitals in Oslo, Norway, as part of the
larger Thematically Organized Psychosis (TOP) study (http://www.
med.uio.no/norment/english/). The Regional Ethics Committee and
The Norwegian Data Inspectorate approved the study.
2.2. Patients
One hundred and thirty-two FEP patients were included in the pres-
ent study (see Fig. 1). The inclusion criteria followed the general inclu-
sion criteria for the TOP study: (1) age 18 to 65 years, (2) meeting the
diagnostic criteria for a broad schizophrenia spectrumpsychosis accord-
ing to Diagnostic and StructuralManual ofMental Disorders, fourth ver-
sion (DSM-IV, American Psychiatric Association, 2000), (3) no head
trauma, neurological or other medical disorder that could influence
CNS functioning, and (4) IQ over 70. The specific inclusion criteria for
this longitudinal study was that the patient had not previously received
adequate treatment for their psychotic disorder. Adequate treatment
was defined as antipsychotic medication in doses over 1 Defined Daily
Dosage (DDD) for N12 weeks or shorter if this treatment was followed
by symptomatic remission; “first episode psychosis”. DDD is the as-
sumed average maintenance dose per day for a drug used for its main
indication in adults (https://www.whocc.no/ddd/definition_and_
general_considera/). In general, the patients were recruited in the
early phases of treatment. However, some individuals were too psy-
chotic to give informed consent at an early stage and patients could
thus give consent to enter the study up to 52 weeks after start of first
treatment (for details see Simonsen et al., 2017). For the purposes of
the analyses in the current paper we did not include patients who (1)
were not using any antipsychotics at baseline as well as at follow-up,
and (2) participants treated with cholesterol-lowering medications
(statins and fibrates).
The distribution of diagnoseswas as follows:N=87 (66%)with a di-
agnosis of schizophrenia,N=5(4%) schizophreniformdisorder,N=16
(12%) schizoaffective disorder andN=24 (18%) psychotic disorder not
otherwise specified (psychosis NOS).
2.3. Clinical assessments
Sociodemographic history (including age, gender, ethnicity, edu-
cation), smoking, alcohol consumption, diet, exercise habits, dura-
tion of untreated psychosis (DUP), hospitalization, antipsychotic
medication, and use of cholesterol-lowering medication were ob-
tained through structured interviews. The ethnicity of patients was
categorized as Caucasian or non-Caucasian. All patients were diag-
nosed with the Structural Clinical Interview for DSM-IV (SCID)
(First et al., 1996). Inter-rater reliability was good, with an overall
kappa score of 0.77 (95% CI: 0.60–0.94). Psychotic and other related
symptoms were assessed using The Positive and Negative Syndrome
Scale (PANSS) (Kay et al., 1987), we report the means for a five-fac-
tor model (Wallwork et al., 2012). Depression was assessed with the
Calgary Depression Scale for Schizophrenia (CDSS) (Addington et al.,
1992). The extent of alcohol use was measured with The Alcohol Use
Disorders Identification Test (AUDIT) (Saunders et al., 1993). Diet
and exercise habits were assessed at inclusion and at 12 months by
interviews. The patients were asked to describe their eating habits
as healthy, moderately healthy or unhealthy. This variable was
then dichotomized into “similar or poorer diet” (including patients
who did not change their diet habits from inclusion to 12 months,
as well as patients who reported a poorer diet at 12 months) and
“better diet” (consisting of patients who reported a beneficial change
in diet). Exercise was also initially assessed as light, moderate or
hard, and then dichotomized into “similar or reduced exercise” and
“increased exercise” at 12 months. Our rationale for dichotomizing
diet and exercise was that we were primarily interested in the
change in these variables, as they would reflect improvement or de-
cline in lifestyle.
2.4. Use of antipsychotic medication
Information about current and previous use of antipsychotics was
obtained through interviewswith the patients combinedwith prescrip-
tion data from themedical charts. All participants used one or more an-
tipsychotics at least once during the study period (see Supplementary
Tables 1–4, for information concerning antipsychotic and non-psycho-
tropic drug use). For the purpose of this study, where our main goal
was to investigate if serum lipid changes during antipsychotic drug
therapy were related to improvement in psychosis, we defined treat-
ment with any type of antipsychotic agent throughout the study period
as continuous antipsychotic use (n = 100; 76%). In contrast, treatment
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with any type of antipsychotic agent, either at baseline or at 12 months
(n=32; 24%), was defined as intermittent antipsychotic use, see Table
1 for details. Since the number of patients using the same antipsychotic
agent asmonotherapy at both time pointswas low (Table 1), we did not
have the statistical power to perform subgroup analyses for the differ-
ent drugs.
Compliance was checked by measuring antipsychotic drug
levels in serum samples analyzed by standard therapeutic drug
monitoring methods at Diakonhjemmet Hospital, Oslo, Norway
(Solberg et al., 2016). Since antipsychotic drug levels give informa-
tion on the drug treatment at one particular point in time, which in
the present study did not necessarily reflect the drug treatment for
the whole study period, the drug levels were not included in the
main analyses, but this information was used to exclude non-
adherent patients.
2.5. Metabolic parameters
2.5.1. Serum lipid measurements
Blood was sampled in the morning after overnight fasting. Choles-
terol (total cholesterol, HDL, LDL) and TG were analyzed at the Depart-
ment of Clinical Chemistry at Oslo University Hospital with standard
enzymatic methods from Roche Diagnostics Norge AS, Oslo, Norway.
Data on serum lipids are reported in Table 2.
2.5.2. BMI measurement
All participants were weighed on calibrated digital weights under
equal conditions and height was measured with standard methods.
Body mass index (BMI) was calculated according to the standard for-
mula: BMI = weight (in kilograms) divided by height (in meters
squared) (kg/m2).
2.6. Statistical analysis
All statistical analyses were performed using SPSS version 22 (SPSS
Inc., Chicago, IL, USA/IBM, NewYork, USA). For the comparison of demo-
graphic and clinical characteristics, chi-squared test and t-tests were
used. Paired t-tests were used to examine the change in serum lipid
levels, BMI and PANSS positive and negative subscores during the fol-
low-up period. Pearson correlation coefficients were used to examine
the correlation between serum lipid levels and BMI.Multivariate regres-
sion analyses controlling for age, gender and continuous vs. intermittent
antipsychotic use were applied to examine the relationship between
metabolic variables and outcome measurements at baseline and after
12 months. Two-sided tests were employed in all analyses, and the sig-
nificance level was set to p ≤ 0.05.
Linear mixed effects models were applied to investigate the associa-
tion between change in PANSS positive and negative subscores and
Fig. 1. Participants flow chart.
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change in metabolic parameters (total cholesterol, HDL, LDL, TG and
BMI) from baseline to one year follow-up. In this procedure, both
PANSS positive and negative subscores were investigated in separate
models along with each metabolic parameter (total cholesterol, HDL,
LDL, TG and BMI). The PANSS subscores were defined as dependent fac-
tors, while time (baseline and 12 months), age, gender, continuous vs.
intermittent antipsychotic use, serum lipid levels (total cholesterol,
HDL, LDL, TG) and BMI were defined as fixed factors (independent var-
iables). Time was considered a repeated factor with compound covari-
ance. The final model was chosen based on the information criteria
(Akaike information criterion). Preliminary analyses were conducted
to ensure assumptions of normality, linearity, multicollinearity and
homoscedasticity. Serum TG values were ln-transformed after inspec-
tion of residuals. Due to issues with multicollinearity, we did not enter
all the lipids in the samemixedmodel analysis. Therewere no problems
with linearity or homoscedasticity.
Missing variables were treated pairwise. Preliminary analyses
showed that the missing variables were randomly distributed (Little's
MCAR test: chi-square = 463.54, df = 440, and p = 0.21) and that
there were no significant differences in sociodemography, illness-re-
lated factors or antipsychotic usage between the patientswith complete
lipid datasets and the oneswithmissing lipid data. To further ensure the
validity of the results we reran themixedmodel analyses including only
subjects with full dataset (total cholesterol n = 99; HDL n = 90; LDL n
= 86; ln TG n = 89; BMI n = 112).
3. Results
One hundred and thirty-two FEP patients participated, of whom 85
(64%) were males and 87 (66%) were Caucasians. Mean age was 26.7
(SD = 7.6) years and median DUP 40.0 (range 1–1040) weeks. See
Table 1.
3.1. Changes in serum lipid levels and BMI
There was a statistically significant decrease of 0.07 mmol/L (SD =
0.27) in mean HDL from baseline (1.39 mmol/L; SD = 0.38) to
12 months (1.32 mmol/L; SD = 0.37) at the group level (p = 0.02);
49 subjects (54%) experienced a decrease and 41 subjects (46%) an in-
crease in their HDL levels (Table 2). There were no significant changes
in serum total cholesterol, LDL or ln TG (Table 2). Also, there were no
significant differences in the direction of lipid change between continu-
ous vs. intermittent antipsychotic use (data not shown).
Paired sample t-test showed that mean BMI increased significantly
from 25.0 (SD = 4.2) to 26.3 (SD = 4.7) during the follow-up period
(p b 0.001) (Table 2). Eighty-three patients (74%) with BMI measure-
ments experienced weight gain. Forty-four (39%) out of these cases ex-
perienced a clinically significant increase in BMI, i.e. ≥7% of BMI at
baseline. Twenty-nine patients (26%) displayed a reduction in BMI, of
whom 20 subjects (69%) were using antipsychotic medication during
the entire study period. There were no significant differences in direc-
tion of weight change between patients with continuous antipsychotic
use vs. patients with intermittent use (chi-square (1, N = 112) =
1.71, p = 0.19).
3.2. Relationship between serum lipids and BMI
Pearson correlation coefficients showed that changes in total choles-
terol levels were correlated with changes in HDL (r = 0.21, p = 0.05),
LDL (r = 0.64, p b 0.001), ln TG (r = 0.22, p = 0.04) and BMI (r =
Table 1
Demographic and treatment characteristics of the FEP sample.
Characteristics
Age (years), mean (SD) 26.7 (7.6)
Gender (male), n (%) 85 (64.4)
Ethnicity (Caucasian), n (%) 87 (65.9)
Education (years), mean (SD) 12.9 (2.8)
Change in diet (“better diet”)a, n (%) 20 (15.2)
Change in exercise (“increased exercise “)b, n (%) 21 (15.9)
Smoking (daily), n (%) 60 (45.5)
Alcohol use (AUDIT), mean (SD) 7.3 (7.6)
DUP (weeks), median (range) 40.0 (1–1040)
Hospitalization (at inclusion), n (%) 30 (22.7)
Antipsychotic treatment
Continuous antipsychotic usec, n (%) 100 (76)
Intermittent antipsychotic used, n (%) 32 (24)
Typical antipsychoticse, n (%) 16 (16)
Atypical antipsychotics, n (%) 116 (88)
Monotherapyf, n (%) 34 (26)
Polypharmacyg, n (%) 41 (31)
SD= standard deviation, n = number of subjects, % = percentage, AUDIT = Alcohol Use
Disorder Identification Test, DUP = duration of untreated psychosis.
a Diet was dichotomized into “similar or poorer diet” (including patients who did not
change their diet habits from inclusion to 12 months, as well as patients who reported a
poorer diet at 12months) and “better diet” (consisting of patients who reported a benefi-
cial change in diet).
b Exercisewas dichotomized into “similar or reduced exercise” (including patients who
did not change their exercise habits from inclusion to 12 months, as well as patients who
reported a reduced exercise at 12months) and “increased exercise” (consisting of patients
who reported increased exercise at 12 months).
c Continuous antipsychotic use was defined as use of any type of antipsychotic agent
throughout the study period.
d Intermittent antipsychotic use was defined as use of any type of antipsychotic agent,
either at baseline or at 12 months.
e All typical antipsychotic agents were used in combination with atypical agents.
f Monotherapy with the same antipsychotic agent at baseline and at 12 months, n:
olanzapine 15, aripiprazole 7, quetiapine 4, risperidone (tablet or injection) 3, ziprasidon
3, and paliperidone 1.
g Polypharmacy was defined as using multiple antipsychotic agents either (or both) at
baseline and at 12 months.
Table 2
Paired t-tests examining the change in clinical characteristics from baseline to 12 months.
n Baseline 12 months Δ t (df) p-value
mean (SD) mean (SD) mean (SD)
Psychotic symptoms
Total PANSS scores 129 63.2 (13.9) 55.2 (14.7) −8.1 (14.0) −6.6 (128) b0.001
PANSS positive subscores 131 2.6 (1.0) 2.1 (1.0) −0.5 (1.1) −5.3 (130) b0.001
PANSS negative subscores 132 2.2 (1.0) 2.0 (0.9) −0.2 (0.9) −2.2 (130) 0.03
Metabolic parameters
Total cholesterol 99 4.90 (0.97) 4.92 (0.96) 0.02 (0.72) 0.29 (98) 0.77
HDL (mmol/L) 90 1.39 (0.40) 1.32 (0.37) −0.07 (0.27) −2.39 (89) 0.02
LDL (mmol/L) 86 2.99 (0.82) 3.08 (1.27) 0.16 (1.06) 1.44 (85) 0.15
Ln TG (mmol/L) 89 0.15 (0.55) 0.20 (0.52) 0.07 (0.55) 1.15 (88) 0.25
BMI (kg/m2) 112 24.9 (4.3) 26.3 (4.7) 1.4 (2.5) 5.83 (111) b0.001
n = total number of subjects with both baseline and 12 months data, PANSS = Positive and Negative Syndrome Scale, HDL = high-density lipoprotein cholesterol, LDL = low-density
lipoprotein cholesterol, Ln TG= ln of triglycerides, BMI=bodymass index, SD= standard deviation,Δ=change from baseline to one year follow-up, t= t-test, df=degrees of freedom.
P-values are obtained from paired t-tests.
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0.22, p= 0.04). Ln TG levels were correlated with changes in HDL (r=
−0.28, p = 0.01) and LDL (r = 0.33, p = 0.002) levels.
3.3. Relationship between serum lipid levels, BMI and psychotic symptoms
At baseline, multivariate linear regression analyses showed a nega-
tive association between HDL level and PANSS negative subscores
when controlling for age, gender and continuous vs. intermittent anti-
psychotic use (B = −0.67, p = 0.02) (Supplementary Table 5). At
12months, therewere no significant associations between serum lipids,
BMI, and PANSS positive and negative subscores (Supplementary Table
5).
The mixed effects model demonstrated a significant association be-
tween an increase in HDL and a decrease in PANSS negative subscores
after one year (B =−0.48, p = 0.03) when controlling for age, gender
and continuous vs. intermittent antipsychotic use (Table 3). Similar re-
sults were found when we analyzed with complete lipid dataset (B:
−0.62, p = 0.01). Furthermore, the association between change in
HDL and change in negative symptoms remained significant after con-
trolling for BMI change (B=−0.54, p=0.02) (Table 4). No significant
associations were found between total cholesterol, LDL, ln TG, BMI and
PANSS positive and negative subscores (Table 3).
3.4. Post hoc analyses examining the negative association betweenHDL and
PANSS negative subscores
Group comparison between patients with an increase in HDL levels
(n=41, 46%) versus thosewith a decrease (n=49, 54%) during the fol-
low-up period displayed no significant differences in sociodemographic
or illness-related factors except that the HDL increase group had higher
mean PANSS negative subscore at baseline, 2.5 (SD= 1.1) vs. 2.0 (SD=
1.0) (p=0.04) and a highermeanAUDIT score at 12months, 8.8 (SD=
7.0) vs. 5.1 (SD = 5.2) (p = 0.01), respectively (Supplementary Table
6).
Post hoc mixed model analyses showed that neither illness (includ-
ing diagnosis subgroup, DUP, hospitalization, concurrent changes in
PANSS positive subscores and CDSS scores) nor lifestyle-related factors
(including smoking, alcohol use, changes in diet and changes in exer-
cise) significantly influenced the relationship between HDL and PANSS
negative subscores (Supplementary Table 7).
4. Discussion
The main finding of the present one year follow-up study of FEP pa-
tients was that increase in HDL levels during one year of antipsychotic
treatmentwas significantly associatedwith a reduction in negative psy-
chotic symptoms (i.e. PANSS negative subscores), an association that
remained significant after controlling for potential confounders, includ-
ing demographic variables, lifestyle factors, and BMI.
The important role of cholesterol (total, HDL, and LDL) for human
health has been known for decades. Patients with schizophrenia have
markedly increased prevalence of metabolic abnormalities including
dyslipidemia, and several meta-analyses have demonstrated hypertri-
glyceridemia and low HDL-cholesterol in chronic schizophrenia
(Mitchell et al., 2013; Vancampfort et al., 2013). More recently, such
low HDL levels have also been reported in FEP, including antipsychotic
drug-naïve patients (Enez Darcin et al., 2014; Fleischhacker et al.,
2013; Misiak et al., 2016; Wu et al., 2013; Zhai et al., 2017) and even
subjects with prodromal symptoms only, i.e. at high risk of developing
psychosis (Cordes et al., 2016). Thesefindings suggest that a suboptimal
level of HDL cholesterol serves as an unfavorable lipid marker in early
psychosis.
It is, therefore, interesting that we demonstrate a significant associ-
ation between an increase in HDL level and a reduction in PANSS nega-
tive subscores during one year of antipsychotic treatment in FEP
patients. Usually, the lipid disturbances in schizophrenia tend toworsen
with time, and multi-episode patients with schizophrenia have signifi-
cantly higher prevalence of abnormally low HDL cholesterol as com-
pared to FEP and antipsychotic naïve patients (Vancampfort et al.,
2013). We found on a group level that the mean HDL level decreased
following one year of antipsychotic treatment, which is in accordance
with the literature on medicated FEP (Correll et al., 2014; Wu et al.,
2013). Still, almost half of the FEP patients in our study experienced
an increase in HDL level. The reasons for this beneficial change in HDL
are uncertain, but they may be related to treatment effects (including
antipsychotic drugs) and changes in lifestyle and diet. As the different
antipsychotic agents have different effects on serum lipid levels, it
would have been interesting to examine the subgroups of antipsy-
chotics (e.g., olanzapine) that have previously been shown to have a
high tendency to cause dyslipidemia. However, due to the low number
of subjects treated with each of the antipsychotic agent throughout the
study period, we could not look specifically at the subgroups of drugs.
Our data do not prove any causal relationship between the increase
in HDL and decrease in negative symptoms in FEP patients. An interest-
ing but speculative theory is to consider HDL in serum as an indirect
proxy for cholesterol in the brain, where improved supply could play a
positive role in myelination. It has previously been indicated that pa-
tients with schizophrenia have reduced myelination in the CNS
(Bernstein et al., 2015; Davis et al., 2016; Mighdoll et al., 2015), and in
vivo MRI and animal studies have demonstrated pro-myelinating ef-
fects of antipsychotic drugs (Bartzokis et al., 2012, 2007; Ebdrup et al.,
2016; Xu et al., 2010) that in part could be related to their lipid-stimu-
lating effects (Cai et al., 2015; Steen et al., 2017). It is also possible that
genetic factors per se could influence lipid metabolism as a risk factor
for schizophrenia (Andreassen et al., 2013; Solberg et al., 2016). On
the other hand, the observed link between HDL and PANSS negative
subscores could represent an indirect effect of successful treatment
that reduces the negative symptoms, leading to subsequent changes in
lifestyle and diet improving HDL levels. The fact that the patients who
experienced an increase in HDL had lower HDL levels at baseline and
more pronounced negative symptoms could to some degree support
this. Nevertheless, it is worth mentioning that we found a similar link
between higher HDL levels and lower negative psychotic symptoms
also at baseline. Additionally, the patients who increased in HDL levels
Table 3
Mixed models examining the association between change in metabolic parameters and PANSS positive and negative subscores trajectories from baseline to 12 months.
PANSS positive subscores PANSS negative subscores
Coefficient 95% CI p-value Coefficient 95% CI p-value
Total cholesterol 0.10 (−0.05, 0.25) 0.19 0.01 (−0.14, 0.16) 0.90
HDL 0.33 (−0.09, 0.75) 0.13 −0.48 (−0.90, −0.06) 0.03
LDL 0.09 (−0.04, 0.23) 0.17 0.03 (−0.10, 0.16) 0.68
Ln TG 0.07 (−0.18, 0.33) 0.56 0.15 (−0.10, 0.40) 0.23
BMI −0.01 (−0.04, 0.02) 0.45 −0.01 (−0.04, 0.03) 0.73
PANSS = Positive and Negative Syndrome Scale, HDL = high-density lipoprotein cholesterol, LDL = low-density lipoprotein cholesterol, Ln TG = ln of triglycerides, BMI = body mass
index, CI = confidence interval. Analyzed with mixed effects model and adjusted for covariates age, gender, and antipsychotic use. Antipsychotic use was dichotomized into continuous
antipsychotic use (use of any type of antipsychotic agent throughout the study period) vs. intermittent antipsychotic use (use of any type of antipsychotic agent, either at baseline or at 12
months).
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did not differ from those who decreased with respect to
sociodemographic, lifestyle- or illness-related factors, except for
reporting higher alcohol consumption at 12 months. Still, there was
no increase in alcohol use during the follow-up period as these patients
had similar levels of alcohol consumption at baseline. In addition, it is
unlikely that higher alcohol consumption could explain why these pa-
tients improved in negative psychotic symptoms as high alcohol con-
sumption is often related to more psychotic symptoms (Addington et
al., 2014).
Prior studies that have investigated the potential relationship be-
tween lipid changes and improvement of psychotic symptoms during
antipsychotic treatment have predominantly reported an association
between increase in serum TG levels and reduction in overall psychotic
symptoms and in positive symptoms (Atmaca et al., 2003; Lally et al.,
2013; Pande et al., 2002; Procyshyn et al., 2007) leading us to hypothe-
size that a similar relationship could also be found in our sample of FEP
patients. However, we did not observe such a relationship. One possible
explanation for this difference may be that the patients in prior studies
were often treated with clozapine, a drug reserved for patients with
treatment-resistant psychosis and recognized for its dyslipidemic po-
tential (Mitchell et al., 2013). In our sample (with only three clozapine
users), TG levels were not significantly altered during the follow-up pe-
riod. This may have impeded a potential relationship between TG levels
and psychotic symptoms.
Many studies have reported an association between treatment-re-
lated weight gain and improved clinical outcome in schizophrenia (Bai
et al., 2006; Basson et al., 2001; Bustillo et al., 1996; Czobor et al.,
2002; Hermes et al., 2011; Meltzer et al., 2003; Yang et al., 2014). We
did not observe such a link between increased bodyweight and reduced
psychotic symptoms, despite the fact that two thirds of our patients ex-
perienced an increase in BMI. Although BMI and serum lipids may be
correlated, we did not find a significant correlation between these two
metabolic variables. It should also be noted that these parameters may
be partly independent in patients treated with antipsychotic drugs
(Birkenaes et al., 2008; Kang and Lee, 2015; Lally et al., 2013;
Procyshyn et al., 2007).
The present study has limitations that require consideration. Be-
cause of the naturalistic study design there are many confounding fac-
tors, which cannot be controlled for. The dynamic nature of treatment
for schizophrenia with frequent changes in antipsychotic regimens dur-
ing the follow-up period is an important limitation. Furthermore, serum
lipids were missing for a number of patients, especially at 12 months.
We did, however, try to minimize the effect of these missing variables
by usingmixed effects models. Also, whenwe repeated the analyses in-
cluding only subjects with a complete dataset, similar results were
found. We did not provide structured assessments of intake of fish oil
and dietary seafood, or habitual amount of exercise, factors that may in-
fluence both the metabolic parameters and symptom levels. However,
we used self-report assessments of changes in diet and exercise habits
to partially control for these potential confounders in the mixed
model analyses. We also controlled for the effect of smoking, alcohol
use and education, which may be regarded as proxies for lifestyle
factors. It is nevertheless possible that other factors not accounted for
could have influenced the results. Patients were receiving standard
treatment from the University Hospital and followed recent guidelines,
thus, the clinical change was not due to different quality of treatment.
In conclusion,we found that an increase inHDL level during antipsy-
chotics treatment was related to improvement in negative symptoms,
independent of weight change. To further elaborate the clinical signifi-
cance of the effects of antipsychotic treatment on lipid metabolism, suf-
ficiently powered longitudinal studies in drug-naïve patients are
needed.
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Abstract
To investigate whether changes in serum lipids are associated with cognitive performance in first episode psychosis (FEP) 
patients during their first year of antipsychotic drug treatment. One hundred and thirty-two antipsychotic-treated FEP patients 
were included through the TOP study along with 83 age- and gender-matched healthy controls (HC). Information regarding 
cognitive performance, psychotic symptoms, lifestyle, body mass index, serum lipids [total cholesterol, high-density lipo-
protein (HDL) cholesterol, low-density lipoprotein cholesterol, and triglycerides] and antipsychotic treatment was obtained 
at baseline and after 1 year. The cognitive test battery is comprised of assessments for verbal learning, processing speed, 
working memory, verbal fluency, and inhibition. Mixed-effects models were used to study the relationship between changes 
over time in serum lipids and cognitive domains, controlling for potential confounders. There was a significant group by 
HDL interaction effect for verbal learning (F = 11.12, p = 0.001), where an increase in HDL levels was associated with 
improvement in verbal learning in FEP patients but not in HC. Practice effects, lifestyle, and psychotic symptoms did not 
significantly affect this relationship. Antipsychotic-treated FEP patients who increased in HDL levels during the first year of 
follow-up exhibited better verbal learning capacity. Further investigations are needed to clarify the underlying mechanisms.
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Introduction
More than 70% of patients with schizophrenia are esti-
mated to experience cognitive impairments [1]. For sev-
eral cognitive domains—including verbal learning and 
memory, attention, perception, and processing speed—the 
impairment may be as prominent as two standard devia-
tions below healthy controls [2] indicating a clinically rel-
evant decrease or deficits in cognitive functioning. These 
deficits can have a more substantial impact than positive 
psychotic symptoms in determining real-world functional 
outcome [3, 4], and may be present even after successful 
reduction in psychotic symptoms [5, 6]. Although consid-
erable efforts have been made to understand the neurobiol-
ogy of cognitive impairment in psychosis, the background 
is still mostly undetermined.
Lipids are essential for CNS development and function-
ing [7–10], including myelination and synapse communi-
cation. In schizophrenia and related psychotic disorders, 
both lipid disturbances as well as brain structural changes 
have been demonstrated. While several studies in the nor-
mal aging population, as well as in other neuropsychiatric 
disorders [11–17], characterized by compromised brain 
functioning have indicated a link between serum cho-
lesterol levels, in particular HDL cholesterol, and cog-
nition, few studies have examined the potential relation-
ship between serum lipids and cognition in patients with 
schizophrenia. In a cross-sectional study, Lancon et al. 
[18] found low HDL levels (along with hypertriglyceri-
demia, and abdominal obesity) to be related to impairment 
in verbal learning and memory. Another cross-sectional 
study [19] demonstrated that patients with schizophrenia 
and co-morbid metabolic syndrome exhibited impair-
ments in processing speed, attention/vigilance, working 
memory and problem solving, compared to those without 
metabolic syndrome. However, when the authors examined 
the different components of the metabolic syndrome, they 
found that the HDL level was positively associated with 
attention/vigilance. Also, studies in antipsychotic-treated 
patients have reported a link between serum lipids and 
cognitive performance. Krakowski and colleagues found 
that an increase in total cholesterol level and LDL level 
after a 12-week period of antipsychotic drug treatment was 
positively associated with improvements in global cogni-
tion [20] with verbal memory being the most prominent 
domain. Still, there are other studies in schizophrenia that 
have failed to show any associations between serum lipids 
and cognition [21, 22], and some have even found negative 
associations between serum lipids and cognitive perfor-
mance [23].
These discrepancies in prior studies may be due to the 
potential confounding effects of long-term medication, 
age-related neurodegeneration and disease risk-related 
environmental factors, as most previous studies have been 
focusing on chronic schizophrenia patients in a cross-sec-
tional study design. Another important limitation is a lack 
of age- and gender-matched healthy individuals to control 
for practice effects [24] and naturally occurring variations 
in serum lipid levels.
Aims of the study
The present longitudinal study of an FEP cohort was under-
taken to investigate potential associations between serum 
lipid levels and cognitive performance in the first year of 
antipsychotic treatment in a group of FEP patients with lim-
ited prior drug exposure, compared to a group of age- and 
gender-matched healthy controls (HC). We further investi-
gated the possible influence of lifestyle (smoking, alcohol, 
diet, and exercise), metabolic measures connected to serum 
lipids (body mass index), improvements in clinical symp-
tomatology secondary to antipsychotic drug treatment, and 
other illness-related factors (antipsychotic drug treatment, 
hospitalization, and depressive symptoms) on the relation-
ship between serum lipids and cognition in the patient group.
Methods and materials
Participants
The longitudinal FEP sample, recruited between 2003 and 
2013 through the Thematically Organized Psychosis (TOP) 
study (Oslo, Norway), was the same as used by Gjerde et al. 
[25]. The inclusion criteria for the TOP study were age 
between 18 and 65 years, and having a diagnosis within a 
broad schizophrenia spectrum psychosis according to the 
Diagnostic and Structural Manual of Mental Disorders, 
fourth version (DSM-IV, American Psychiatric Associa-
tion, 2000). Participants were recruited in a stable phase 
of their disorder. Exclusion criteria were current IQ under 
70, the presence of a neurological disorders or a history of 
head injuries. Additionally, for the longitudinal FEP study, 
patients who previously had received adequate antipsychotic 
drug treatment were not recruited [25]. Healthy controls 
(HC) were randomly selected and recruited from the same 
geographic catchment area as the patients, using national 
statistical records (2003–2011). They were matched for age 
and gender. To ensure a reliable HC sample, subjects were 
excluded if they or any of their first-degree relatives had 
a history of a severe psychiatric disorder as indicated by 
the Primary Care Evaluation of Mental Disorders [26]. The 
final sample consisted of 132 first episode psychosis (FEP) 
patients and 83 HC. Participants were tested at baseline 
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and after 1 year. None of the participants used medication 
against thyroid problems, diabetes, hypertension or choles-
terol-lowering medications (statins or fibrates).
All participants gave written informed consent prior to 
their inclusion in the study, and the Regional Ethics Com-
mittee and The Norwegian Data Inspectorate approved the 
study.
Clinical assessments
Demographic and clinical data (including antipsychotic drug 
treatment) were obtained through structured interviews and 
from hospital medical records. The diagnosis was estab-
lished by use of the Structural Clinical Interview for DSM-
IV (SCID) [27]. Psychotic symptoms were assessed with 
the Positive and Negative Syndrome Scale (PANSS) [28] 
and depressive symptoms with the Calgary Depression Scale 
for Schizophrenia (CDSS) [29]. Remission was defined as 
at least 1 week with no score of ≥ 4 on any of the following 
five PANSS items: P1, P3, P5, P6, or G9. Alcohol use was 
measured with the Alcohol Use Disorders Identification Test 
(AUDIT) [30]. Information on diet and exercise habits for 
the FEP patients was obtained by self-assessment at baseline 
and follow-up. Patients were asked to describe their eating 
habits as healthy, moderately healthy or unhealthy, while 
exercise was initially assessed as light, moderate or hard. 
Diet was then dichotomized into “similar or poorer diet” 
(including patients who did not change their diet habits from 
inclusion to 12 months, as well as patients who reported 
a poorer diet at 12 months) and “better diet” (consisting 
of patients who reported a beneficial change in diet). Exer-
cise was likewise dichotomized into “similar or reduced 
exercise” and “increased exercise” at 12 months (for more 
details, see [25]).
Antipsychotic drug treatment in the FEP group
As we did not have sufficient statistical power to create sepa-
rate subgroups for the different antipsychotic agents (see 
supplementary Tables 1, 2 and 3 for antipsychotic use), we 
Table 1  Demographic, metabolic, and cognitive characteristics of the FEP and HC sample
p values are obtained from T tests and chi-square test
p values in bold indicate numbers that are significant on the 95% confidence limit
FEP first episode psychosis, HC healthy controls, SD standard deviation, n number of subjects, % percentage, AUDIT Alcohol Use Disorder 
Identification Test, DUP duration of untreated psychosis, PANSS Positive and Negative Syndrome Scale, CDSS Calgary Depression Scale for 
Schizophrenia
a Diet was divided into “similar or poorer” and “better” compared to diet habits at baseline
b Exercise was divided into “similar or reduced” and “increased” compared to exercise habits at baseline
c “Continuous antipsychotic drug use” refers to the continuous use of any antipsychotic agent during the study period
d “Intermittent antipsychotic drug use” refers to the use of any antipsychotic agent, either at baseline or 12 months
FEP (n) HC (n) FEP, mean (SD) HC, mean (SD) t p value
Age (years) 132 83 26.7 (7.6) 29.0 (6.8) − 2.6 0.01
Education (years) 132 83 12.9 (2.8) 14.2 (2.0) − 4.43 < 0.001
Alcohol use (AUDIT scores) 120 71 7.3 (7.4) 5.9 (3.0) 1.89 0.06
DUP (weeks), median (range) 132 40.0 (1–1040)
Total PANSS scores 132 63.2 (13.9)
PANSS-positive subscores 132 2.6 (1.0)
PANSS-negative subscores 132 2.2 (1.0)
Depressive symptoms (CDSS scores) 128 6.2 (4.5)
FEP (n) HC (n) FEP, n (%) HC, n (%) X2 p value
Gender (male) 132 83 85 (64.4) 80 (59.7) 0.62 0.45
Ethnicity (Caucasian) 132 83 87 (65.9) 132 (98.3) 52.32 < 0.001
Smoking (daily) 132 86 60 (45.5) 17 (19.8) 15.04 < 0.001
Hospitalization at inclusion 132 30 (22.7)
Change in diet (“better diet”)a 132 20 (15.2)
Change in exercise (“increased exercise “)b 129 21 (15.9)
Continuous antipsychotic drug  usec 132 100 (76)
Intermittent antipsychotic drug  used 132 32 (24)
Antipsychotic monotherapy 132 91 (69)
Antipsychotic polypharmacy 132 41 (31)
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organized data on antipsychotic medication as “continuous 
antipsychotic drug use” versus “intermittent antipsychotic 
drug use” [25]. Continuous use was defined as using any 
antipsychotic agent at baseline and at 12 months (not nec-
essarily the same agent at both time points), while inter-
mittent use was defined as using any antipsychotic agent at 
either baseline or at 12 months. In addition, we differenti-
ated between antipsychotic monotherapy (using only one 
antipsychotic at the specific time point) and polypharmacy 
(using two or more antipsychotic agents at the same time 
point). All patients who used first-generation drugs also used 
second-generation drugs, and due to insufficient information 
regarding switches and duration of antipsychotic treatments 
during the follow-up period, it was not possible to calculate 
cumulative drug exposure.
Table 2  Mixed models 
examining serum lipids, BMI 
and cognitive performance at 
baseline in FEP and HC
p values in bold indicate numbers that are significant on the 95% confidence limit
Verbal learning was measured with California Verbal Learning Test, processing speed with Digit Symbol 
Test, working memory with Letter number span, verbal fluency with Verbal Fluency Test, and inhibition 
with Color-Word Interference Test. Analyzed with mixed-effects models while controlling for age, gender, 
education, and group (FEP vs. HC). The HC were defined as the reference group
FEP first episode psychosis, HC healthy controls, SD standard deviation, F F value, B regression coef-
ficient, SE standard error of the regression coefficient, HDL high-density lipoprotein cholesterol, LDL low-
density lipoprotein cholesterol, Ln TG Ln of triglycerides, BMI body mass index
FEP, mean (SD) HC, mean (SD) Group Group
F p value B SE (B)
Total cholesterol (mmol/L) 4.97 (1.00) 4.59 (0.90) 8.94 0.003 0.39 0.13
HDL (mmol/L) 1.39 (0.40) 1.44 (0.43) 0.08 0.79
LDL (mmol/L) 2.99 (0.82) 2.59 (0.81) 11.54 0.001 0.38 0.11
Ln TG (mmol/L) 0.81 (0.31) 0.77 (0.26) 0.82 0.37
BMI (kg/m2) 24.9 (4.3) 24.1 (3.7) 1.57 0.21
Verbal learning (total scores) 49.31 (11.80) 59.22 (8.54) 35.25 < 0.001 − 8.82 1.48
Processing speed (total scores) 60.40 (16.82) 79.55 (13.32) 65.19 < 0.001 − 16.77 2.08
Working memory (total scores) 9.21 (2.61) 11.89 (2.40) 48.33 < 0.001 − 2.50 0.36
Verbal fluency (total scores) 35.58 (14.54) 45.39 (9.98) 18.27 < 0.001 − 7.65 1.79
Inhibition (total scores) 66.07 (24.14) 49.52 (10.83) 27.75 < 0.001 15.08 2.86
Table 3  Mixed models 
examining serum lipid, BMI 
and cognitive trajectories over 
1 year in FEP and HC
p values in bold indicate numbers that are significant on the 95% confidence limit
Verbal learning was measured with California Verbal Learning Test, processing speed with Digit Symbol 
Test, working memory with Letter number span, verbal fluency with Verbal Fluency Test, and inhibition 
with Color-Word Interference Test. Analyzed with mixed-effects models examining a time × group interac-
tion while controlling for age, gender, education, time, and group (FEP vs. HC). The HC were defined as 
the reference group
FEP first episode psychosis, HC healthy controls, F f value, B regression coefficient, SE standard error of 
the regression coefficient, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein choles-
terol, Ln TG ln of triglycerides, BMI body mass index
Time Group × time Group × time
F p value F p value B SE (B)
Total cholesterol (mmol/L) 0.005 0.94 0.003 0.96
HDL (mmol/L) 2.77 0.10 2.24 0.14
LDL (mmol/L) 0.32 0.57 1.48 0.23
Ln TG (mmol/L) 0.05 8.39 0.05 0.82
BMI (kg/m2) 23.84 < 0.001 6.99 0.01 0.95 0.36
Verbal learning (total scores) 17.60 < 0.001 6.86 0.01 3.54 1.35
Processing speed (total scores) 0.05 0.003 2.27 0.13
Working memory (total scores) 0.10 0.75 0.10 0.75
Verbal fluency (total scores) 0.21 0.65 6.38 0.01 − 3.15 1.25
Inhibition (total scores) 0.60 0.02 0.37 0.54
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Cognitive tests
The cognitive test battery is comprised of five cognitive 
domains (verbal learning, processing speed, working mem-
ory, verbal fluency, and inhibition) based on previous find-
ings related to cognitive dysfunction in FEP patients [31].
Psychologists trained in standardized neuropsychologi-
cal testing carried out the cognitive assessment. Current IQ 
was estimated from the Wechsler Adult Intelligence Scale 
(WASI); subscale similarities and block design. Verbal 
learning was measured with the California Verbal Learning 
Test (CVLT-II) [32], verbal learning sub-score. Processing 
speed was measured with the Digit Symbol Test [33]. Work-
ing memory was measured with the Letter number sequenc-
ing test [33]. Verbal fluency was measured with the Verbal 
Fluency Test, phonetic sub-score from the Delis–Kaplan 
Executive Functioning System (D-KEFS) [34]. Finally, inhi-
bition was measured with the Color-Word Interference Test 
from the D-KEFS [34], inhibition sub-score. Raw scores 
were reported for all tests to be able to calibrate the cogni-
tive performance of the FEP patients compared to a repre-
sentative age- and gender-matched HC group from the same 
catchment area as the patients. Higher scores indicated better 
performance on all tests except for the inhibition sub-test 
where higher scores indicated poorer performance. All par-
ticipants showed an adequate neuropsychological test effort 
indicated by two errors or less on the forced recognition 
trial of the California Verbal Learning Task (CVLT-II) [32].
Serum lipids and BMI
Blood was drawn from the antecubital vein in the morning 
after overnight fasting at baseline and 12 months, on the 
same day as the neuropsychological testing took place (time 
period: 2003–2013). The Department of Clinical Chemis-
try at Oslo University Hospital, using standard enzymatic 
methods from Roche Diagnostics Norge AS (Oslo, Norway), 
analyzed cholesterol (total, HDL, LDL) and triglycerides 
(TG). All blood samples were sent immediately after collec-
tion and analyzed continuously as routine samples. Digital 
weights were used to weight all the participants and body 
mass index (BMI) calculated accordingly: BMI = weight (in 
kilograms) divided by height (in meters squared) (kg/m2).
Statistical analyses
The data were analyzed with SPSS version 23 (SPSS Inc., 
Chicago, IL, USA/IBM, New York, USA). The level of sta-
tistical significance was preset to p < 0.05 (two tailed). For 
the comparison of demographic characteristics, chi-square 
tests and t tests were used as appropriate.
For the main analyses, we employed linear mixed models 
with unstructured covariance matrix to examine longitudinal 
changes and between-group effects of lipid measures on 
cognitive measures. Preliminary analyses were conducted 
to ensure assumptions of normality, linearity, multicollin-
earity, and homoscedasticity. Serum TG values were ln-
transformed after inspection of residuals. Due to issues with 
multicollinearity, we did not enter all the lipids in the same 
mixed model analysis. There were no problems with linear-
ity or homoscedasticity.
In separate mixed models, we first examined any baseline 
differences in metabolic and cognitive measures controlling 
for age, gender, and education. Then, we explored the 1-year 
changes in serum lipids, BMI, and cognitive performance. 
In the latter longitudinal models, we also included time and 
a group (FEP and HC) × time interaction.
Our approach to the interpretation of statistical results 
obtained from the cognitive models was that a main effect 
of time would indicate cognitive changes due to drug treat-
ment or other causes (i.e., practice effects). To disambiguate 
the latter two possibilities, we would compare the cognitive 
performance of the patient group with that of the HC group. 
Group × time interactions that favored steeper improvement 
in the FEP group would be viewed as an indication of a 
possible treatment effect, reflecting cognitive enhancement. 
A main effect for time in the absence of such an interaction 
could be regarded as representing practice effects.
The mixed models that displayed a significant 
group × time interaction were subsequently examined for 
a potential relationship with serum lipids. The rationale for 
this was that group-specific changes to cognition might be 
related to alterations in serum lipids due to antipsychotic 
drug treatment. In these mixed models, the scores from the 
specific cognitive tests were defined as dependent variables, 
while time (baseline and 12 months), age, gender, years of 
education, group affiliation (FEP or HC), and serum lipids 
were entered as independent variables. To investigate if there 
was a group-dependent effect of lipids on cognition, we also 
included a group × lipid interaction.
In post hoc analyses, using similar mixed models as 
in our main analyses, we further examined if any group-
specific lipid effects on cognition could be explained by 
ethnicity, lifestyle-related factors (smoking, alcohol, diet, 
and exercise), concomitant changes in BMI, be secondary 
to antipsychotic treatment effects on positive and negative 
symptoms, remission status at 12 months, or be explained 
by other illness-related factors (hospitalization and depres-
sive symptoms).
Missing data
Preliminary analyses indicated a random distribution of 
the missing variables and that there were no significant dif-
ferences in sociodemographic characteristics or cognitive 
test scores between the subjects with a complete dataset on 
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serum lipids compared to the ones with missing data (Lit-
tle’s MCAR test: chi-square = 1912.51, df = 1865, p = 0.22). 
Forty-seven (36%) of the FEP patients lacked cognitive 
data at follow-up. These FEP patients were included in the 
main analyses because they had baseline data and a mixed 
linear model approach using all available information was 
employed. As a precaution, we also checked the validity of 
our results by repeating the analyses excluding participants 
with an incomplete dataset.
Results
For a detailed description of demographic characteristics 
and group comparison of FEP with HC, see Table 1. In sum-
mary, the FEP patients had significantly shorter education, 
more non-Caucasian ethnicity and a higher percentage of 
daily smokers, compared to the HC.
Group differences in serum lipids at baseline 
and after 1 year of follow‑up
As described in Table 2, the FEP patients had significantly 
higher levels of total cholesterol and LDL compared to 
the HC at baseline, (F = 8.94, p = 0.003) and (F = 11.54, 
p = 0.001), respectively. During the follow-up, there were 
no significant changes in mean levels of serum lipids among 
the FEP patients when compared to the HC at the group level 
(Table 3). Still, there were individual differences, and at the 
individual level the serum lipid changes for the FEP were the 
following: 47 participants (47%) experienced a decrease and 
52 participants (53%) an increase in their total cholesterol 
levels; 49 participants (54%) experienced a decrease and 
41 participants (46%) an increase in their HDL levels; 43 
participants (50%) experienced a decrease and 43 partici-
pants (50%) an increase in their LDL levels; 40 participants 
(45%) experienced a decrease and 49 participants (55%) an 
increase in their TG levels.
Group differences in cognition at baseline 
and after 1 year of follow‑up
The FEP patients demonstrated marked impairments in cog-
nitive functioning across all domains at baseline (p < 0.001) 
(Table 2). During the 1-year follow-up, there was a main 
effect of time (F = 17.60, p < 0.001) (indicating signifi-
cant changes in cognitive performance from baseline to 
12 months) as well as a group by time interaction for ver-
bal learning (F = 6.86, p = 0.01), with a steeper change in 
FEP compared to HC (B = 3.54, p = 0.01), indicating that 
practice effects alone cannot explain the relatively higher 
improvement in patients compared to HC. The mixed model 
analyses also showed a group by time interaction for verbal 
fluency (F = 6.38, p = 0.01); here, the FEP group exhibited a 
deterioration in comparison with the HC group, (B = − 3.15, 
p = 0.01), respectively.
Association between serum lipids and cognition
When examining the two cognitive domains that showed a 
group by time interaction (verbal learning and verbal flu-
ency) for associations with serum lipid levels, we found that 
there was a significant group by HDL interaction effect for 
verbal learning (F = 11.12, p = 0.001), where an increase 
in HDL level was related to improvement in verbal learn-
ing among FEP patients compared to the HC (B = 10.32, 
p = 0.001). Verbal fluency, in contrast, did not evidence any 
significant group by lipid interactions. Follow-up analyses 
excluding patients with incomplete cognitive datasets pro-
duced comparable results (data not shown).
Because the FEP patients, in contrast to HC, included 
several subjects with their primary education outside Nor-
way, which could influence the cognitive test scores, we also 
reran the analyses without these patients and obtained simi-
lar results as in our main analyses (data not shown).
Post hoc analyses exploring the significant 
associations found between serum lipids 
and cognition
The post hoc mixed models controlling for antipsychotic 
usage (i.e., continuous use vs. intermittent use), and positive 
and negative symptoms indicated that the group (i.e., FEP)-
specific link between HDL and verbal learning remained 
highly significant (F = 7.45, p = 0.007). A significant main 
effect of positive symptoms (F = 4.67, p = 0.03) and nega-
tive symptoms (F = 11.77, p = 0.001), but not for antipsy-
chotic drug use (F = 1.03, p = 0.31), was also exhibited. As 
the magnitude of the effect is reflected in the standardized 
regression coefficients, we examined these coefficients to 
discern whether HDL cholesterol had a stronger impact 
than negative and positive symptoms on verbal learning. 
Our results indicated that HDL (B = 3.13, p = 0.007) was 
a stronger predictor for verbal learning than were negative 
(B = − 2.20, p = 0.001) and positive symptoms (B = − 1.76, 
p = 0.03). Likewise, controlling for remission status did not 
significantly impact the observed link between serum HDL 
and verbal learning in the FEP group (B = 8.42, p = 0.002).
We further investigated the influence of antipsychotic 
drug treatment (continuous use vs. intermittent use, and 
antipsychotic monotherapy vs. polypharmacy) on the rela-
tionship between HDL levels and verbal learning. The 
group (FEP)-specific HDL-link remained highly significant, 
(F = 10.76, p = 0.001) and (F = 10.54, p = 0.001), whereas 
the main effect of antipsychotic drug treatment was absent, 
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inferring limited value to differential treatment effects on the 
observed link between HDL and verbal learning.
Furthermore, though there was a main effect of BMI on 
verbal learning (F = 4.88, p = 0.03), the group by HDL inter-
action remained significant (F = 9.86, p = 0.002) indicating 
that the link between HDL and verbal learning was inde-
pendent of BMI. Of note, ethnicity, hospitalization, depres-
sive symptoms, smoking habits, diet, exercise, and alcohol 
use demonstrated no attenuation of results for the observed 
link between HDL and verbal learning (data not shown).
Discussion
The current study of antipsychotic-treated FEP patients 
showed that during the first year of follow-up, an increase 
in serum HDL was associated with better verbal learning 
capacity. This relationship was independent of practice effect 
(as controlled by a group of age- and gender-matched HC), 
lifestyle, concurrent changes in BMI, and improvements in 
clinical symptomatology. Having in mind that cognitive per-
formance is an important predictor of longitudinal clinical 
and functional outcomes in patients with psychotic disor-
ders, our findings may be of clinical relevance.
Consistent with prior literature [35], the FEP patients per-
formed poorer on all cognitive tests compared to the HC. 
During the follow-up, there was a group-specific improve-
ment in verbal learning, which subsequent analyses showed 
was associated with an increase in HDL levels among the 
FEP patients but not amongst HC. Our findings are in line 
with Lancon and colleagues [18] finding a positive asso-
ciation between HDL and verbal learning and memory in 
a cross-sectional sample of chronic schizophrenia patients. 
The present study is, however, the first to report such an 
association in a cohort of FEP patients with age- and gender-
matched healthy controls.
The observed link between HDL and cognition is also 
consistent with the mechanisms that relate lipids to the brain 
while also agreeing with evidence of impaired lipid metabo-
lism (including cholesterol) in psychotic patients [36–40]. 
Lipids are not only essential for myelination; synaptic 
growth and regeneration also depend greatly on the avail-
ability of brain cholesterol [41, 42]. Depletion of cholesterol 
in tissue cultures has, for example, been shown to inhibit 
synaptogenesis and causes neurodegenerative changes [42]. 
Brain structures such as the hippocampus express high 
transcript levels of lipid-biosynthesizing enzymes [42], are 
densely populated by synapses, and play a prominent role in 
verbal learning and memory [43, 44]. Several studies have 
found a positive link between performances on verbal learn-
ing and hippocampal volumes [45–47], as well as on distinct 
subfield volumes [48]. More importantly, a growing num-
ber of evidence in the normal aging population and patients 
with neuropsychiatric disorders, points to high serum HDL 
levels, in particular, being protective against hippocampal 
atrophy [49]. This dependency of the hippocampus on intact 
cholesterol metabolism may at least in parts explain our find-
ing of a distinct link between HDL cholesterol and the hip-
pocampus-based task of verbal learning. While studies are 
reporting a correlation between different cognitive domains 
within an individual [50–55], there are several investigators 
that have emphasized a cognitive architecture best described 
by relatively independent cognitive domains [2, 56–58], 
and verbal learning is recognized as one such independent 
cognitive dimension. In further support of distinguishable 
cognitive dimensions is the fact that pharmacological inter-
ventions, including antipsychotic drug treatment, have been 
shown to cause changes in specific cognitive domains [59], 
indicating a pharmacological dissociation of certain groups 
of cognitive processes.
For decades, the traditional view has been that the cho-
lesterol in the brain is synthesized de novo; newer evidence, 
however, suggests that excessive cholesterol synthesis may 
be regulated by intricate efflux mechanisms linking central 
and peripheral cholesterol levels [60–63]. Indeed, serum 
HDL has been found to be highly correlated with HDL in 
cerebrospinal fluid [64]. Still, the nature of this relationship, 
between serum lipids and lipids in the CNS, is not fully elu-
cidated. It is, however, likely that long-term lipid status may 
have a different impact on brain structure and functioning 
than the short-term impacts observed in treatment studies 
[19, 20, 65], and that these changes in brain structure and 
functioning may be more pronounced in the developmental 
lifespan [66]. While we included a relatively young FEP 
population (with a mean age of 25 years), future studies may 
consider including high-risk patients, as well as having a 
longer study period with frequent observation points.
We recently demonstrated that an increase in HDL during 
antipsychotic drug treatment was related to an improvement 
in negative symptoms in the same FEP cohort [25]. Other 
studies have shown a relationship between negative symp-
toms and verbal learning [67]. As we now find HDL levels 
being associated with specific cognitive domains, it is plau-
sible that improvements in cognitive functioning over time 
were more related to clinical symptom improvement, reflect-
ing “pseudospecificity” [68]. Additionally, lack of motiva-
tion and motor retardation inherent in the negative syndrome 
could also have disturbed test performance in patients with 
prominent negative symptoms. We attempted to disentangle 
these phenomena by controlling for secondary changes in 
negative (and positive) symptoms during antipsychotic drug 
treatment, obtaining similar results as in our main analy-
ses. Intriguingly, the standardized regression coefficients 
revealed that the HDL level was more profoundly related to 
working memory than positive and negative symptoms were, 
adding support to the growing literature on the role of lipids 
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in psychotic disorders. Also, other factors that are known to 
influence cholesterol metabolism as well as cognitive func-
tion such as lifestyle and behavioral factors [69–73] were 
controlled for in the post hoc analyses, achieving similar 
results as in our main analyses.
The present study has some additional limitations that 
need to be addressed. The constitution of the HC group 
was different from the FEP group since the latter included 
subjects with their primary education from outside Norway, 
which could influence cognitive performance especially for 
verbal tests. We tried to minimize the effect of this limitation 
by controlling for education in the mixed model analyses. 
Also, we reran the analyses excluding the patients without a 
Norwegian education, generating similar results. Information 
on diet and exercise habits was only available for FEP but not 
for HC. Additionally, self-assessment about diet and exercise 
may be problematic as it may be linked to high social desira-
bility; on the other hand, achieving truly reliable data on these 
parameters may be difficult outside the confinement of an 
institution. Due to power issues, we were not able to examine 
specifically and compare different antipsychotic agents and 
how this may influence our results. Still, our main objective 
was to examine the effect of serum lipids per se on cognition 
in FEP patients, and for this particular aim, differentiating 
the antipsychotic agents might be less prudent. We further 
recognize that other factors then practice can explain a main 
effect of time: the controls are healthy, and could in theory 
be susceptible to a ceiling effect in the amount of change 
that can be achieved; leading to potential differences in the 
learning potential in the two groups. While an untreated con-
trol group may have been ideal to address this matter, it is 
not ethically feasible. Finally, as our study is naturalistic in 
design, temporality cannot be established, and studies with a 
randomized controlled design, which include treatment tar-
geted explicitly at elevating HDL levels and measurements of 
change in cognitive performance, are necessary.
In conclusion, the present study of antipsychotic-treated 
FEP patients showed that during the first year of follow-up, 
an increase in serum HDL was associated with better cog-
nitive performance. Further research, implementing clini-
cal data with for instance myelin-focused brain imaging 
techniques, is warranted. As cognitive deficits dramatically 
impact social and occupational functioning, our findings 
of a link between HDL and cognition could potentially 
contribute to the development of new treatment strategies, 
with functional improvements achieved by increasing HDL 
levels as an add-on treatment for cognitive remediation 
that has shown to be effective in patients with psychosis.
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Cortical gray/white matter contrast
Cortical myelin
Serum cholesterol
A B S T R A C T
Altered cortical brain morphology is observed in psychotic disorders. Despite the importance of lipid home-
ostasis for healthy brain functioning, knowledge about its role in cortical alterations in psychosis is limited. In a
sample of patients with psychotic disorders, we investigated the relationship between treatment with olanzapine
(OLZ), and cortical thickness and gray/white matter intensity contrast, and the association between these
measures and serum lipid levels. We included 33 OLZ users, 19 unmedicated psychotic patients and 76 healthy
controls (HC). Data on serum lipids and cortical measures based on MR brain images processed with FreeSurfer
were analyzed with General Linear Models. We found that intensity contrast was similar in OLZ users as com-
pared to HC and that the cortex (frontal, orbitofrontal, medial temporal) was thinner in OLZ users (p < 0.05,
Bonferroni corrected). An OLZ-specific HDL interaction effect was further found for the pericentral cortical
thickness measure (p < 0.05, Bonferroni corrected). Additionally, nominally significant findings indicated si-
milar OLZ-specific interaction effects for cortical thickness in several regions, and an OLZ-specific interaction
with LDL for occipital lobe contrast (p < 0.05, uncorrected). Our findings may suggest a drug-related lipid-effect
on brain myelination. Experimental studies and replications in different study samples are needed to clarify these
complex relationships further.
1. Introduction
Altered cortical morphology is a replicated brain structural finding
in psychotic disorders (Crespo-Facorro et al., 2011; Jung et al., 2011;
Narr et al., 2005; Rimol et al., 2012; Schultz et al., 2010; Uranova et al.,
2001; Weinberger and Lipska, 1995), and it is widely held that un-
derstanding these alterations are key to understanding the pathophy-
siology of psychosis (Bartzokis, 2012; Lewis and Lieberman, 2000;
Murray and Lewis, 1987; Uranova et al., 2001). In schizophrenia, cor-
tical volume has been shown to be reduced primarily in frontal and
temporal regions (Haijma et al., 2013; Walterfang et al., 2006). The
reductions are mainly due to cortical thinning, rather than surface area
reductions (Rimol et al., 2012). Using structural magnetic resonance
imaging (MRI), other properties of the cerebral cortex have been shown
to be abnormal in schizophrenia. In a recent study from our group,
increased gray/white matter intensity contrast along the cortical sur-
face was observed in primary sensory and motor regions of schizo-
phrenia patients (Jørgensen et al., 2016), known to be highly myeli-
nated areas of the human cerebral cortex (Glasser et al., 2014; Glasser
and Van Essen, 2011).
Despite the importance of lipid homeostasis for brain function in
health (Orth and Bellosta, 2012; Schmitt et al., 2015), and the mounting
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evidence of altered lipid metabolism in psychotic disorders (Andreassen
et al., 2013; De Hert et al., 2006; Fleischhacker et al., 2013; Kaddurah-
Daouk et al., 2012; Misiak et al., 2016; Saari et al., 2004; Thakore,
2004; Verma et al., 2009; Wu et al., 2013; Zhai et al., 2017); research
on the role of lipid metabolism for cortical thickness or contrast var-
iations observed in psychosis patients is scarce. It is, however, estab-
lished that impaired lipid metabolism can affect brain myelination
(Chrast et al., 2011; Mauch et al., 2001; O'Brien and Sampson, 1965). In
vivo MR studies as well as post-mortem brain research findings have
indicated that abnormal myelination is involved in the pathophysiology
of schizophrenia (Davis et al., 2003; Kubicki et al., 2007; Vikhreva
et al., 2016). While white matter myelination is the most studied, the
cerebral cortex is also myelinated, and cortical myelin is critical for the
optimization of brain function (Bartzokis, 2011). In vivo MRI and
postmortem studies of brains of schizophrenia patients have demon-
strated alterations of cortical myelin (Bartzokis, 2012; Bartzokis and
Altshuler, 2005; Tishler et al., 2017; Uranova et al., 2011). Hence, it
may be hypothesized that altered lipid metabolism can cause altera-
tions of cortical myelination which may be reflected in altered macro-
structural properties of the cerebral cortex and detected using MRI. In
particular, changes in lipid metabolism are seen during treatment with
several of the antipsychotic drugs (Allison et al., 1999; Young et al.,
2015), especially olanzapine and clozapine (Newcomer, 2005). Anti-
psychotic-related increase in lipid levels has furthermore been asso-
ciated with symptom improvement (Gjerde et al., 2017; Lally et al.,
2013; Spivak et al., 1999), and one proposed mechanism is increased
myelination (Bartzokis, 2012).
Cortical thickness and cortical gray/white matter intensity contrast
are both measures with indirect and partly undetermined relationships
with cortical myelin content. For cortical thickness, it is known that the
inner layers of the cortex are heavily myelinated (Braitenberg, 1962),
and that they constitute a significant fraction of its overall thickness
(Rowley et al., 2015). Therefore, increased cortical myelin content is
expected to result in increased cortical thickness. The gray/white
matter intensity contrast has previously been investigated in normal
aging (Salat et al., 2009; Vidal-Pineiro et al., 2016) and illness states
including Alzheimer's disease (Salat et al., 2011) and psychiatric dis-
orders (Jørgensen et al., 2016; Kong et al., 2015, 2012). While the
biological interpretation of this measure is not fully clarified, it is in-
fluenced by genetic variation independent from cortical thickness
(Panizzon et al., 2012). The T1 signal itself shows a strong positive
relationship with tissue myelin content (Koenig et al., 1991), but given
that the gray/white matter contrast is computed as a ratio between
values from gray and white matter, increased cortical myelin content is
expected to lead to a decrease of the gray/white matter intensity con-
trast. Therefore, hypotheses with different directionality are needed for
these measures.
The present study aimed to determine how treatment with a me-
tabolically potent antipsychotic agent, olanzapine (OLZ), relates to
cortical thickness and gray/white matter intensity contrast in patients
with non-affective psychotic disorder, and to study the relationship
between these cortical measures and serum lipid levels. To distinguish
between the effect of illness and antipsychotic treatment on brain
structure, we included a group of unmedicated non-affective psychosis
patients and a group of healthy control (HC) subjects for comparison.
We hypothesized that the OLZ users, in contrast to the unmedicated
patients, would be similar to HC in cortical thickness and contrast
measures, but show higher cortical thickness and lower gray/white
matter contrast compared to unmedicated patients, owing to a putative
positive effect of OLZ on cortical myelination. These effects were ex-
pected to be widespread, but we also investigated the possibility of
region-specific effects. We further hypothesized that serum lipid levels
are associated with cortical thickness and contrast measures, with most
distinct effects among OLZ users compared to unmedicated patients and
HC.
2. Methods
2.1. Study design and sample
For the present cross-sectional study, a total of 52 patients with non-
affective psychosis and 76 healthy controls were selected from the
ongoing Thematically Organized Psychosis (TOP) study, conducted at
the Norwegian Centre for Mental Disorders Research (NORMENT),
Oslo, Norway. Inclusion criteria for the main TOP study are a diagnosis
of psychotic disorder, age between 18 and 65 years, no history of
neurological disorder or severe head injury, and IQ > 70 (for a more
detailed description of the TOP study see Engh et al., 2010). The HC
were drawn from the Norwegian national population registry and se-
lected from the same catchment area as the patients and excluded if
they had current or previous psychiatric illnesses, family history of
severe mental disorders, or met criteria for alcohol or substance de-
pendency. There was no age- or gender matching.
Patients were excluded if the time interval between MRI scan and
blood sample exceeded 90 days (mean interval = 38.8 days,
SD = 28.6). We selected a subsample of patients with non-affective
psychotic disorders who were either on stable OLZ monotherapy
(n = 33) or unmedicated (n=19). Stable monotherapy was defined as
using the same daily dose of OLZ (minimum 5 mg) at the time of blood
sampling and on the day of MRI. Being unmedicated was defined as the
absence of any antipsychotic medication at the time of blood sampling
and at the time of MRI scanning. None of participants were using
cholesterol-lowering medication (statins or fibrates), or medications
against hypertension, diabetes or thyroid disorders.
The distribution of DSM-IV diagnoses in the OLZ group was: schi-
zophrenia, N = 12 (36%); schizophreniform disorder, N=5 (15%);
schizoaffective, N=4 (12 %); and other psychotic disorders (psychosis
NOS), N=12 (36%). For the unmedicated group the diagnoses were:
schizophrenia, N=9 (47%); schizophreniform disorder N=1 (5 %);
other psychotic disorder (psychosis NOS) N=9 (48 %).
The Regional Committee for Medical Research Ethics and the
Norwegian Data Inspectorate approved the study.
2.2. Current and prior medication use in the OLZ group
Information about medication use on the day of MRI scanning was
obtained by clinical interview, and supplemented by chart review and
information from the clinical assessment. Median OLZ dose was 10 mg
(range: 2.5–25 mg) and median duration from the start of OLZ treat-
ment to study time was 3.5 months (range: 0.03 – 132 months).
Compliance was assured by measuring antipsychotic drug levels in
serum samples.
Of the 33 OLZ users, nine had received previous treatment with
other antipsychotic agents; one had received previous treatment with
OLZ during two separate time periods while ten had not received any
antipsychotic medication before initiating OLZ treatment. Information
about previous medication was missing for 13 participants in this
group.
2.3. Prior medication use in the unmedicated patient group
Of the 19 unmedicated patients, six where antipsychotic-naïve
while ten patients had used antipsychotics previously. Information
about previous medication was missing for three participants in this
group. Among the ten patients who had received antipsychotic treat-
ment earlier, the average time since last treatment with any anti-
psychotic medication was 18 months (SD: 16 months, range 3–47
months, data was missing for one patient). Six of these subjects had
previously used OLZ (mean dosage 10 mg, SD: 6.1 mg, data missing for
one patient). The duration of OLZ treatment was short (<6 months),
except for one patient who had undergone 5 years of OLZ treatment
(data missing for two subjects). Average time passed since last
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olanzapine treatment was 21 months (SD: 22 months, range 5–53
months, data missing for two patients). For details of the unmedicated
group see Table 1.
2.4. Clinical assessment
Trained psychiatrists or clinical psychologists interviewed the pa-
tients. Sociodemographic history (age, gender, ethnicity, education
level), current smoking, alcohol consumption, substance use, duration
of untreated psychosis (DUP), illness duration, global functioning,
psychiatric symptoms, previous or current psychiatric hospitalization
and antipsychotic medication were recorded from interviews and
medical records.
All patients were diagnosed using the Structural Clinical Interview
for DSM-IV (SCID) (First et al. 1996). Psychotic symptoms were rated
using the Positive and Negative Syndrome Scale (PANSS) (Kay et al.,
1987). DUP was defined as the number of weeks from the first occur-
rence of a psychotic symptom above clinical threshold to the first
adequate treatment (for details see Bratlien et al., 2013). Global func-
tioning was assessed using the Global Assessment of Functioning (GAF)
split version (with separate scales for symptoms (GAF-S) and func-
tioning (GAF-F)) (Pedersen et al., 2007). Alcohol and substance use was
measured with the Alcohol Use Disorders Identification Test (AUDIT)
(Saunders et al., 1993) and the Drug Use Disorders Identification Test
(DUDIT) (Berman et al., 2005). In patients’ interviews, information
regarding diet (classified as healthy, moderately healthy or unhealthy)
and exercise habits (classified as light, moderate or frequent) was ob-
tained, these data were however not available for the HC.
2.5. Serum lipid measurements
Blood was sampled in the morning after overnight fasting.
Cholesterols (total, HDL, LDL) and triglycerides (TG) were analyzed at
the Department of Clinical Chemistry at Oslo University Hospital with
standard enzymatic methods (Roche Diagnostics Norge AS, Oslo,
Norway). Sampling was conducted between the years 2004–2011.
2.6. MRI acquisition
Subjects were scanned at Oslo University Hospital, Ullevål, using a
Siemens Magnetom Sonata 1.5T system (Siemens Medical Solutions,
Erlangen, Germany) equipped with a standard eight-channel head coil.
Two sagittal T1-weighted images (MPRAGE) were acquired using the
tfl3d1_ns pulse sequence, with the following parameters: Echo
time = 3.93 ms, repetition time= 2730 ms, inversion time=1000 ms,
flip angle= 7°, field of view=24 cm, voxel
Table 1
Sociodemographic and clinical characteristics among olanzapine-treated (OLZ) and unmedicated patients and healthy controls.
1. OLZ 2. Unmedicated 3. Healthy controls p-values Post-hoc tests
N = 33 N = 19 N = 76
Age (years), mean (SD) 31.0 (11.2) 33.1 (11.1) 31.9 (9.6) NS
Gender (male), n (%) 18 (55) 14 (74) 45 (59) NS
Ethnicity (Caucasian), n (%) 28 (85) 14 (74) 74 (97) X2 (8, N = 128) = 18.09, p = 0.02 2 vs. 3
Education (years), mean (SD) 13.2 (3.2) 12.2 (2.4) 14.2 (2.4) F (2,115) = 3.54, p= 0.03 2 vs. 3
Handedness (right), n (%) 25 (96) 13 (81) 65 (86) NS
Smoking (daily), n (%) 20 (62.5) 8 (47.1) 12 (22) NS
Diet, n (%) H: 23 (71.9) H: 10 (58.8) NA NS
MH: 8 (25.0) MH: 7 (41.2) NA
UH: 1 (3.1) UH: 0 NA
Exercise, n (%) L: 21 (70) L: 6 (46.2) NA NS
M: 7 (23.3) M: 5 (38.5) NA
F: 2 (6.7) F: 2 (15.4) NA
Alcohol use (AUDIT), mean (SD) 8.0 (8.9) 9.8 (8.4) NA NS
Substance use (DUDIT), mean (SD) 5.7 (10.3) 6.5 (8.1) NA NS
Diagnosis, n (%) SZ= 12 (36), SZ= 9 (47), NA NS
SF=5 (15), SF= 1 (5),
SA= 4 (12), SA=0 (0),
NOS=12 (36) NOS=9 (48)
DUP (weeks), median (range) 16.5 (1–468) 104.0 (1–1040) NA U= 104.5, Z=−2.64, p= 0.01 1 vs. 2
Duration of illness (years), mean (SD) 2.9 (4.0) 7.6 (7.2) NA t(34)=−2.53, p=0.02
Currently hospitalized, n (%) 6 (18.2) 1 (5.3) NA NS
Previous admissions due to psychosis, mean (SD) 1.3 (1.0) 0.7 (1.1) NA NS
OLZ dosage (mg/day), mean (SD) 11.82 (4.98) NA NA NA
OLZ treatment duration (months), mean (SD) 19.2(33.3) NA NA NA
Total PANSS, mean (SD) 54.6 (15.0) 57.1 (10.2) NA NS
Positive PANSS subscores, mean (SD) 11.9 (4.1) 15.3 (4.7) NA t(50)=−2.67, p= 0.01 1 vs. 2
Negative PANSS subscores, mean (SD) 14.5 (7.4) 11.2 (3.3) NA NS
Global functioning, function (GAF-F), mean (SD) 47 .4 (12.1) 47.5 (12.6) NA NS
Global functioning, symptoms (GAF-S), mean (SD) 47.8 (12.2) 44.0 (11.6) NA NS
Total cholesterol (mmol/L), mean (SD) 5.10 (0.10) 5.06 (1.15) 4.99 (0.89) NS
HDL (mmol/L), mean (SD) 0.82 (0.18) 0.88 (0.18) 0.91 (0.18) F (2,125)= 3.28, p= 0.04 1 vs. 3
LDL (mmol/L), mean (SD) 3.25 (0.91) 3.14 (0.94) 2.82 (0.72) F (2,122)= 3.51, p= 0.03 1 vs. 3
TG (mmol/L), mean (SD) 0.76 (0.23) 0.70 (0.17) 0.83 (0.33) NS
BMI (kg/m2), mean (SD) 25.4 (3.5) 23.7 (2.1) 24.7 (3.5) NS
Groups: 1=Olanzapine-treated patients (OLZ), 2= unmedicated patients, 3=healthy controls. Diet was classified as H= healthy, MH= moderately healthy, and
UH=unhealthy. Exercise was classified as L= little, M=moderate, and F= frequent. AUDIT=Alcohol Use Disorder Identification Test, DUDIT= Drug Use
Disorder Identification Test, DUP= duration of untreated psychosis, was defined as the number of weeks from the first occurrence of a psychotic symptom above
clinical threshold to the first adequate treatment. PANSS=Positive and Negative Syndrome Scale, GAF-F= Global Assessment of Functioning- functions, GAF-S=
Global Assessment of Functioning-symptoms, HDL= high-density lipoprotein cholesterol (Ln of HDL values are reported in the table), LDL= low-density lipo-
protein cholesterol, TG= triglycerides (Ln of TG values are reported in the table), BMI=body mass index, SZ= schizophrenia, SF= schizophreniform,
SA= schizoaffective, NOS=psychosis not otherwise specified, N=number of subjects, NA=not applicable, SD= standard deviation, F=F-test, T= t-test,
df= degrees of freedom. P-values are obtained from one-way ANOVA, T-tests, Chi-square test and Mann-Whitney U test. Post-hoc tests (t-tests) were performed for
the F-tests that were significant and we only report the significant group differences.
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size= 1.33 × 0.94 × 1 mm, number of partitions= 160. Acquisition
parameters were optimized for increased cortical contrast. A neuror-
adiologist evaluated all scans for brain pathology.
2.7. MRI processing and calculation of cortical thickness
Three-dimensional models of the cortical surfaces were created
using FreeSurfer 5.3.0 (http://surfer.nmr.mgh.harvard.edu/). Detailed
description of the FreeSurfer processing steps can be found in Fischl
(2012). All surfaces were inspected, and manual editing was performed
according to standard FreeSurfer quality control procedures. From the
reconstructed surfaces, cortical thickness was measured as the shortest
distance from the white to the pial surface at each vertex. For the main
analyses, we extracted average cortical thickness for each label in the
Desikan-Killiany atlas (34 regions) (Desikan et al., 2006) and merged
33 of these labels (all except the insular cortex) into eight bilateral lobar
regions, as shown in Fig. 1. Average cortical thickness across the cor-
tical surface was also extracted. Additionally, vertex-wise analyses
using the GLM function in FreeSurfer were performed to probe more
region-specific effects. Correction for multiple comparisons was applied
using FDR set at 5%. We further explored group differences using a
more lenient threshold of p < 0.01, uncorrected (Supplementary
Fig. 1).
2.8. Calculation of cortical contrast
The cortical contrast was defined as the normalized difference be-
tween signal intensity values at each side of the gray/white matter
boundary. Specifically, intensity values were sampled from the non-
uniform intensity normalized volume (nu.mgz) along the reconstructed
gray/white matter boundary using mri_vol2surf. In GM, an average of
intensity values sampled from 0–60% into the cortical ribbon was ob-
tained at each vertex. In the white matter, intensity values sampled
from 0–1.5 mm into the subcortical white matter were obtained at each
vertex. The percentage difference between gray matter and white
matter intensity values was then calculated at each vertex, as the dif-
ference between the two divided by their mean * 100 (for details see
Jørgensen et al., 2016). Average percentage contrast was then calcu-
lated for each of the eight lobar regions described above, and for the
whole cortical surface. In our previous study (Jørgensen et al., 2016)
we observed low to moderate and region-specific correlations between
cortical thickness and cortical gray/white matter intensity contrast. In
the present study, cortical thickness and contrast were also correlated in
all regions except for cingulate and pericentral cortex (Supplementary
Table 1).
2.9. Statistical analyses
Statistical analyses were performed using SPSS version 23 (SPSS Inc,
Chicago, IL, USA / IBM, New York, USA). For comparison of demo-
graphic and clinical characteristics, one-way ANOVA, Student's t-test,
Mann -Whitney U test and χ2 statistics were used. Two-sided tests were
used for all analyses, and the significance level was set at p ≤ 0.05.
For the main analyses, a set of General Linear Models (GLM) was
applied covarying for age and sex. Group (OLZ-treated patients, un-
medicated patients or HC) was entered as a factor. Cortical intensity
contrast and cortical thickness were investigated as dependent variables
in separate models along with each metabolic parameter (total cho-
lesterol, HDL, LDL, TG) as the independent variable. OLZ users and
unmedicated patients were compared with HC, and with each other. We
also tested a group × lipid interaction with HC as a reference group.
Serum HDL and TG were ln-transformed to obtain a normal distribu-
tion.
A sequential Bonferroni correction procedure was applied for mul-
tiple testing. First, we corrected the F-tests, where eight regions of in-
terest gave a corrected p-value of 0.05 / 8 = 0.00625. Bonferroni post-
hoc tests were applied subsequently for each test. For the regression
analyses with serum lipids, a corrected p-value of 0.00625 was used.
Additional post-hoc analyses were performed to investigate poten-
tial confounding. Variables that were significantly different between
the groups (ethnicity, education, DUP, illness duration and positive
symptoms, see Table 1) were treated as potential confounders. By
adding these variables to each of the group comparisons described
above, using separate models to examine the contribution of each po-
tential confounder, we examined if our variable of interest (group) re-
mained significant also in these models. In addition, as previous studies
have indicated that BMI change may be related to brain volume change
(Jørgensen et al., 2017) and serum HDL levels to negative symptoms
(Gjerde et al., 2017), we also controlled for these factors in separate
models.
Clinical correlates (i.e. positive and negative symptoms) of our lipid
findings were further examined with partial correlations controlling for
Fig. 1. Overview of the eight lobar regions that were used in the analyses.
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age and gender within the OLZ group. Similar partial correlations were
used to examine the influence of OLZ dose and duration on serum lipid
levels.
Finally, we conducted post-hoc power analyses using the statistical
package G*Power (3.1.9.3 for Mac).
3. Results
Demographic and clinical characteristics are shown in Table 1. In
summary, the HC group had a higher percentage of Caucasians com-
pared to OLZ users and unmedicated patients, and higher HDL and
lower LDL levels compared to OLZ users. Moreover, OLZ users had
shorter DUP, shorter duration of illness, and less positive symptoms
compared to the unmedicated patients. There were no significant dif-
ferences in diagnostic distribution, hospitalization status, global func-
tioning, smoking, alcohol use, illicit drug use, diet, exercise, serum lipid
values or BMI between the two patient groups.
3.1. Group comparisons of intensity contrast
The OLZ users had similar cortical gray/white matter intensity
contrast measures as the HC (p < 0.05, Bonferroni corrected) (Table 2).
Although the unmedicated patients had higher nominally intensity
contrast compared to HC (frontal, cingulate, lateral temporal, and
medial temporal regions) (p < 0.05, uncorrected), they did not remain
significant after correction for multiple comparisons (p > 0.05, Bon-
ferroni corrected)
3.2. Group comparisons of cortical thickness
OLZ users had significantly thinner cortices compared to HC in
frontal, orbitofrontal, and medial temporal regions (p < 0.05,
Bonferroni corrected) (Table 2), while there were no significant dif-
ferences in cortical thickness between unmedicated patients and HC
(Table 2).
3.3. Examining group difference in vertex-wise analyses
In the vertex-wise analyses, no significant group differences were
found in cortical thickness or contrast after FDR correction. For com-
pleteness, regions showing significant group differences using a
threshold of p < 0.01 (uncorrected) are shown in the Supplementary
Fig. 1.
3.4. Group specific interactions with lipid levels for cortical thickness and
intensity contrast
There was a group specific interaction with HDL cholesterol where
OLZ treated patients with higher HDL levels had thicker cortices in
mean, frontal, orbitofrontal, cingulate, occipital, and pericentral re-
gions (p < 0.05, uncorrected). However, only the pericentral region
remained significant after correcting for multiple comparisons
(p < 0.05, Bonferroni corrected) (Supplementary Table 2). No inter-
actions were found between HDL levels and thickness measures among
unmedicated patients or HC. Also, there were no significant interactions
between group and total cholesterol/TG/LDL levels for cortical thick-
ness.
For the gray/white matter intensity contrast, a group-specific in-
teraction with LDL cholesterol for occipital lobe contrast was observed
where higher LDL levels were associated with higher intensity contrast
in OLZ users specifically (p < 0.05, uncorrected) (Supplementary
Table 2). However, this interaction did not remain significant after
corrections for multiple comparisons were applied (p > 0.05, Bonfer-
roni corrected).
Table 2







F-test Post-hoc tests, 1 vs. 3, 2 vs. 3
and 2 vs. 1
Cortical thickness (mm)
Mean thickness 2.29 (0.02) 2.36 (0.02) 2.35 (0.01) F(2,123)= 4.50, p=0.01
Frontal 2.40 (0.02) 2.48 (0.03) 2.49 (0.01) F (2,123)= 5.97, p=0.003 1 vs. 3 p= 0.003, 2 vs. 3
p=NS, 2 vs. 1 p=NS
Orbitofrontal 2.40 (0.02) 2.47 (0.03) 2.48 (0.01) F (2,123)= 5.60, p=0.005 1 vs. 3 p= 0.004, 2 vs. 3
p=NS, 2 vs. 1 p=NS
Cingulate 2.50 (0.02) 2.53 (0.03) 2.53 (0.01) F (2,123)= 0.91, p=0.41
Lateral temporal 2.67 (0.02) 2.75 (0.03) 2.75 (0.02) F (2,123)= 4.63, p=0.01
Medial temporal 2.64 (0.02) 2.73 (0.03) 2.73 (0.02) F (2,123)= 6.08, p=0.003 1 vs. 3 p= 0.003, 2 vs. 3
p=NS, 2 vs. 1 p=NS
Parietal 2.10 (0.02) 2.17 (0.03) 2.14 (0.01) F (2,123)= 2.46, p=0.09
Occipital 1.86 (0.02) 1.87 (0.02) 1.86 (0.01) F (2,123)= 0.12, p=0.89
Pericentral 2.06 (0.02) 2.13 (0.03) 2.10 (0.01) F (2,123)= 2.56, p=0.08
Cortical gray/white matter
intensity contrast
Total mean contrast 27.39 (0.24) 28.30 (0.32) 27.68 (0.16) F (2,123)= 2.62, p=0.08
Frontal 28.36 (0.28) 29.91 (0.19) 29.63 (0.38) F (2,123)= 3.71, p=0.03
Orbitofrontal 29.01 (0.28) 30.15 (0.38) 29.50 (0.19) F (2,123)= 2.95, p=0.06
Cingulate 29.58 (0.26) 30.66 (0.35) 29.95 (0.17) F (2,123)= 3.07, p=0.05
Lateral temporal 29.31 (0.27) 30.43 (0.36) 29.74 (0.18) F (2,123)= 3.12, p=0.05
Medial temporal 28.77 (0.27) 29.92 (0.37) 29.19 (0.18) F (2,123)= 3.16, p=0.05
Parietal 27.37 (0.24) 28.13 (0.32) 27.58 (0.16) F (2,123)= 1.87, p=0.16
Occipital 24.56 (0.23) 24.97 (0.31) 24.42 (0.15) F (2,123)= 1.33, p=0.27
Pericentral 24.28 (0.21) 24.87 (0.28) 24.36 (0.14) F (2,123)= 1.59, p=0.21
The uncorrected p-values for group 2 (unmedicated) vs. group 3 (HC) were between 0.07-0.09.
Groups: 1=Olanzapine-treated patients (OLZ), 2=unmedicated patients, 3= healthy controls. NS= not significant, p= p-values. Analyzed with GLM adjusted
for age, gender and group. Specific hypothesis testing if OLZ users (1) were more alike HC (3), and if unmedicated patients (2) were different from HC (3). Only the
post-hoc tests that remained significant after sequential Bonferroni procedure are reported.
Of note, for the cortical gray/white matter intensity contrast, the uncorrected p-values were significant for group 2 (unmedicated) vs. group 1 (OLZ) comparisons for
frontal, cingulate, lateral temporal, and medial temporal regions (p < 0.05, uncorrected).
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3.5. Post hoc analyses
3.5.1. Examining the influence of demography and illness on the observed
group and lipid specific relationships
In general, the group effects found in the main analyses remained
significant when controlling for potential confounders, including eth-
nicity, education, DUP, illness duration, and positive symptoms
(p < 0.05, uncorrected) (for details see Supplementary Tables 3a and
3b). Moreover, the significant interactions demonstrated in the main
analyses (HDL × group for cortical thicknesses and LDL × group for
intensity contrast), remained significant when controlling for BMI and
negative symptoms (p < 0.05, uncorrected). Of note, neither BMI nor
negative symptoms were significantly related to cortical thickness or
contrast (data not shown).
3.5.2. Post hoc analyses examining the clinical relevance of the serum lipid
levels
Partial correlations controlling for age and gender, demonstrated no
significant correlations between serum HDL (or LDL) levels and severity
of positive and negative symptoms (data not shown).
3.5.3. Serum lipid levels in relation to dose and duration of OLZ treatment
Partial correlation analyses controlling for age and gender showed
no significant correlations between HDL and LDL levels, and OLZ dose
and duration (data not shown).
3.5.4. Post-hoc power analyses
Post-hoc power analyses showed that the statistical power in our
study was between 0.5–0.7 for intensity contrast measures, 0.5–0.9 for
the thickness measures, and 0.5–0.7 for the interaction term group x
HDL; thus, medium-strong power.
4. Discussion
The main findings of the present study were that the gray/white
matter intensity contrast in OLZ users was comparable to the HC, but
increased in the unmedicated patients. This is consistent with the hy-
pothesized “normalizing” effect of OLZ treatment on contrast measures.
Furthermore, although a general thinning of the cortex was found in
OLZ users, a moderating effect of serum HDL cholesterol was also ob-
served; an effect possibly explained by increased access to lipids during
antipsychotic drug treatment with implications on lipids related cor-
tical measures.
Coherent with our hypothesis, the cortical gray/white matter in-
tensity contrast was comparable in OLZ users and HC. The unmedicated
patients, on the other hand, displayed nominally higher intensity con-
trasts. While increased gray/white matter contrast in unmedicated pa-
tients theoretically could be caused by both lower gray matter intensity
values (i.e. lower cortical myelin content) or higher white matter in-
tensity values (or a combination of the two), they overlap with heavily
myelinated regions based on MRI-based myelin mapping and post-
mortem studies (Glasser et al., 2014; Glasser and Van Essen, 2011).
Thus, reduced tissue contrast could reflect higher gray-matter signal
intensity, reflecting increased cortical myelin content coherent with our
hypothesis (Jørgensen et al., 2016). Still, it is important to acknowledge
that the unmedicated group did not consist of solely drug-naïve pa-
tients. We can therefore not rule out that prior antipsychotic exposure
and illness chronicity could have influenced our findings.
Contrary to our initial hypothesis, we found that the OLZ group had
reduced cortical thickness in frontal, orbitofrontal, and medial temporal
cortex compared to HC, while the unmedicated patients did not differ
significantly from the HC. Indices related to illness severity including
symptom load (Ho et al., 2011; Lieberman et al., 2005), hospitalizations
(Lieberman et al., 2001) and poorer social functioning
(Lieberman et al., 2001) have previously been associated with reduced
brain volumes and cortical thinning. In our study, the DUP and illness
duration were longer, and the severity of positive symptoms was
greater among the unmedicated patients, who also had a trend towards
fewer hospital admissions. Thus, the data did not unequivocally in-
dicate that the OLZ treated patients were a more severely affected
group. Our findings converge to some degree with a recently published
systematic review examining the relationship between long-term anti-
psychotic drug treatment (>2 years) and changes in brain structure,
reporting that higher drug exposure was associated with parietal vo-
lume decrease, and trend-wise with decreases in frontal, temporal, and
occipital lobe (Huhtaniska et al., 2017). Our findings further agree with
a study published in JAMA Psychiatry (Lesh et al., 2015) demonstrating
thinner cortices in antipsychotic treated patients compared to a group
of unmedicated patients. Intriguingly, in the latter study, the authors
found no evidence of detrimental effects of atypical antipsychotics on
cognition or brain activity, underscoring the complexity of the re-
lationship between medications induced effects on brain structures and
their clinical relevance.
Our findings further show that in the OLZ group but not in the
unmedicated or in the HC group, there was a positive association be-
tween serum HDL levels and cortical thickness. To our knowledge, this
has not previously been reported. While the cross-sectional design does
not allow for inference of causal relationships, there is substantial
evidence from in vivo MRI and animal studies indicating lipogenic and
pro-myelinating effects of atypical antipsychotic drugs (Bartzokis et al.,
2012, 2009, 2007; Ebdrup et al., 2016; Ersland et al., 2017; Fernø et al.,
2009, 2006, 2005; Steen et al., 2017; Vik-Mo et al., 2008; Vita et al.,
2015; Xu et al., 2010; Zhang et al., 2012). Therefore, a potential ex-
planation for the increased cortical thickness in the subgroup of OLZ
patients with higher HDL levels may be a cholesterol-dependent effect
on myelin. Indeed, HDL in serum may serve as a proxy for cholesterol
supply in the brain (Fagan et al., 2000), where improved supply could
have a positive effect on myelin. Antipsychotic drugs also upregulate
the expression of cholesterol transport proteins (Vik-Mo et al., 2009)
and changes in body cholesterol balances have been shown to alter
myelin integrity (Dietschy and Turley, 2001). In fact, the specific as-
sociation between HDL and cortical thickness could perhaps be ex-
plained by the fact that HDL can cross the blood-brain barrier (Di Paolo
and Kim, 2011; Ferretti and Bacchetti, 2011; Roheim et al., 1979). In-
creased availability of cholesterols, especially HDL, has further been
shown to impact synaptic plasticity and vesicle formation (Koudinov
and Koudinova, 2001; Mauch et al., 2001).
A growing number of studies in various neuropsychiatric disorders
links higher levels of HDL with less cognitive impairments (Merched
et al., 2000; van Exel et al., 2002). Moreover, a recent study of first
episode psychosis patients demonstrated that an increase in serum HDL
levels during antipsychotic drug treatment was associated with im-
provement in negative symptoms (Gjerde et al., 2017). Controlling for
negative symptoms and education in the present study, no significant
changes of the results were found. The specific areas that displayed
significant HDL × group interaction with a thicker cortex in OLZ users
(uncorrected) correspond with areas implicated in cognitive deficits,
negative symptoms, hallucinations and self-disturbance, which are all
core phenomenological features of schizophrenia (Kaufmann et al.,
2015; Morch-Johnsen et al., 2015; Shergill et al., 2014).
In the present study, higher levels of LDL were related to higher
cortical contrast in OLZ users as compared to the other two groups.
However, this interaction did not remain significant after Bonferroni
correction. Our findings coincide to some degree with data from a
longitudinal study by Szeszko et al. (2014) of first episode psychosis
patients treated with atypical antipsychotic drugs (risperidone or ar-
ipiprazole) where a significant association was found between increase
of LDL levels and reduction in fractional anisotropy as measured by
diffusion tensor imaging. Though, a direct effect of LDL on myelin
cannot be proven based on the present data, LDL is a risk factor for
cardiovascular disease and may indirectly affect thickness through he-
modynamic changes (Alosco et al., 2014).
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The present study has some limitations that need to be addressed.
The naturalistic and cross-sectional study design is a constraint, as
causality cannot be determined. Moreover, we did not have enough
statistical power to detect small differences in cortical measures.
Although we controlled for several potential confounders, including
BMI (Jørgensen et al., 2017), we cannot rule out that the medicated and
unmedicated groups might differ in other respects as a result of selec-
tion by treatment status. Likewise, the HC were screened for mental
disorders and cannabis use during the last 3 months; this could have
contributed to a more healthy comparison group compared to e.g. the
use of unselected population-based control samples. We also lacked
data on alcohol, diet, and exercise habits for the HC. Regarding anti-
psychotic drug treatment, the time interval for OLZ treatment effect on
brain structures has not been well clarified. In our sample the duration
of OLZ treatment varied (median duration was 3.5 months, range:
0.03–132 months). Longitudinal studies with prolonged monotherapy
treatments are needed to address this issue in greater details. Many of
the patients in the unmedicated group had prior antipsychotic drug
exposure; ideally to clarify the differential effect of illness and anti-
psychotic drug treatment, investigations in previously drug-naïve pa-
tients are preferred. Moreover, while myelin strongly contributes to T1
signal intensity (Koenig et al., 1991), the signal is also influenced by
tissue properties including water and iron content, and distinguishing
which of these properties contribute to relative differences is not
straightforward. To examine potential drug-related pro-myelinating
effects directly, cortical myelin mapping using the T1/T2 ratio (Glasser
and Van Essen, 2011; Lutti et al., 2014) and field maps during scan
acquisitions should be obtained to allow for optimal correction.
To conclude, the cortical gray/white matter intensity contrast was
found to be similar among users of the atypical antipsychotic OLZ and
HC, suggesting comparable cortical myelin content. Despite the general
thinning of the cortex in the OLZ users, there was a moderating effect of
HDL on cortical thickness, which may indicate increased cortical
myelin among the OLZ users. While the current findings may inform
about the neurobiology of antipsychotic drug treatment, experimental
studies are needed to determine the mechanisms involved.
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